

Legend: **New Text** ~~Removed Text~~ Unchanged Text **Moved Text Section**

The following is a summary of the principal risks that could adversely affect our business, operations, and financial results. **Risks Related to Our Business** • We are an early-stage technology company with a limited history of generating revenue, have a history of operating losses, and we may never achieve or maintain profitability. • We may be unable to continue as a going concern if we do not successfully raise additional capital on favorable terms, or at all, or if we fail to generate sufficient revenue from operations. • Our efforts may never demonstrate the feasibility of our proposed CGM and blood pressure monitoring solution. • We face competition from other technology companies and our operating results will suffer if we fail to compete effectively. • If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. • We are subject to risks associated with our utilization of consultants. • We will need to grow the size of our organization, and we may experience difficulties in managing this growth. • We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions. • Our business is affected by macroeconomic conditions. • Our business and operations are subject to risks related to climate change. • The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate. • Our business could be negatively impacted by corporate social responsibility and sustainability matters. **Risks Related to Product Development, Manufacturing and Commercialization** • We are highly dependent on the success of our initial products, the Evie Ring and the EvieMED Ring, and cannot give any assurance that they will be successfully commercialized. • If we do not successfully manage the launch and marketing of new products or services, our financial results could be adversely affected. • We depend on third parties to design, manufacture, market and distribute our products. If any third party fails to successfully design, manufacture, market or distribute any of our products, our business will be materially harmed. • Our business and operations would suffer in the event of information technology system failures, including cyber-attacks. • The use of artificial intelligence presents new risks and challenges to our business. **Risks Related to Intellectual Property and Other Legal Matters** • It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. • If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected. • We may in the future be a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to develop our products. • We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property. • We could become subject to product liability claims, product recalls and warranty claims that could be expensive, divert management's attention and harm our business. • Increased use of social media could create or amplify the effects of negative publicity and adversely affect sales and operating results. **Risks Related to Regulation** • FDA clearance of the pulse oximetry feature of our EvieMED Ring does not ensure commercial success of the product. • We expect to seek FDA clearance with respect to additional EvieMED Ring monitoring capabilities and expect to seek FDA clearance or approval for our planned CGM and blood pressure monitoring solution, which may be difficult to achieve, and existing laws or regulations or future legislative or regulatory changes may affect our business. • If any OEMs contracted to manufacture our products fail to comply with FDA's Quality System Regulations or other regulatory bodies' equivalent regulations, manufacturing operations could be delayed or shut down and the development of our products could suffer. • We expect our planned solution to be subject to certain Federal Communication Commission ("FCC") regulations. • Our current or future products may be subject to product recalls that could harm our reputation. • Healthcare reform measures could hinder or prevent our commercial success. • If we fail to comply with healthcare regulations with respect to our current or future products, we could face substantial penalties and our business, operations and financial condition could be adversely affected. • Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to our reputation and have a material adverse effect on our business. **Risks Related to Owning Our Securities and Our Financial Results** • Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result in decreases in the price of our securities. • Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. • The issuance of additional stock in connection with financings, acquisitions, our equity incentive plan, upon exercise of outstanding warrants or otherwise will dilute our existing stockholders. • Our stock price has fluctuated widely and is likely to continue to be volatile. • Our failure to meet the continued listing requirements of Nasdaq could result in a de-listing of our common stock. • Our Certificate of Incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us. • We have not paid dividends in the past and have no immediate plans to pay dividends. • Concentration of ownership among our existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions. • We are an "emerging growth company" under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors. • We are incurring significant costs as a public company that reports to the SEC and our management is required to devote substantial time to meet compliance obligations. • If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, the price of our common stock and trading volume could decline. • Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable. We operate in a rapidly changing environment that involves a number of risks that could materially affect our business, financial condition or future results, some of which are beyond our control. This discussion highlights some of the risks that may affect future operating results. These are the risks and uncertainties we believe are most important for you to consider. We cannot be certain that we will successfully address these risks. If we are unable to address these risks, our business may not grow, our stock price may suffer, and we may be unable to stay in business. Additional risks and uncertainties not presently known to us, which we currently deem immaterial or which are similar to those faced by other companies in our industry or business in general, may also impair our business operations. We are an early-stage technology company with a limited history of generating revenue, have a history of operating losses, and we may never achieve or maintain profitability. We are a technology company that was formed in January 2018. We have a limited operating history and have generated only limited revenue to date. We have largely focused our efforts and resources towards research and development activities relating to our development of the Evie Ring, EvieMED Ring and the SoC, the commercial launch of the Evie Ring and the FDA 510 (k) clearance for the pulse oximeter feature of the EvieMED Ring. The likelihood of success of our business plan must be considered in light of the challenges, substantial expenses, difficulties, complications and delays frequently encountered in connection with developing and expanding early-stage businesses and the regulatory and competitive environment in which we operate. Technology product development is a highly speculative undertaking, involves a substantial degree of risk and is a capital-intensive business. As of December 31, 2024, we had an accumulated deficit of approximately \$ 148.1 million. We expect that our losses will continue for the foreseeable future as we continue to invest significant additional resources toward the commercialization of our products and ongoing research and development. We have experienced these losses and accumulated deficit primarily due to the investments we have made in developing our proprietary technologies and products, building our team and manufacturing capabilities and the commercial launch and FDA clearance of our products. Without additional capital our existing cash and cash equivalents will be insufficient to fully fund our business plan. We expect to continue to incur losses for the foreseeable future. Our ability to achieve revenue-generating operations and, ultimately, achieve profitability will depend on whether we can obtain additional capital when we need it, complete the development of our technology, receive regulatory approvals of our technology, potentially find strategic collaborators that can incorporate our technology into applications which can be successfully commercialized and achieve market acceptance. There can be no assurance that we will ever generate substantial revenues or achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. We may be unable to continue as a going concern if we do not successfully raise additional capital on favorable terms, or at all, or if we fail to generate sufficient revenue from operations. Primarily as a result of our lack of revenue, history of losses to date and our lack of liquidity, there is substantial doubt as to our ability to continue as a going concern. As of December 31, 2024, we had total assets of approximately \$ 11.3 million and total liabilities of approximately \$ 4.0 million. We believe that our cash and cash equivalents as of December 31, 2024 will not be sufficient to fund our projected operating requirements beyond the second quarter of 2025. We expect to continue to incur significant expenses and operating losses for at least the next several years. Our forecast of the period through which our financial resources will be adequate to support our operations is a forward-looking statement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this "Risk Factors" section. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. We do not have any prospective arrangements or credit facilities as a source of future funds, and there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, or at all. If we are unable to raise additional capital or if we are unable to generate sufficient revenue from our operations, we may not stay in business. We may seek additional capital through a combination of private and public equity

offerings, debt financings and strategic collaborations. If we raise additional funds through the issuance of equity or convertible debt securities, the percentage ownership of our existing stockholders could be significantly diluted and these newly issued securities may have rights, preferences or privileges senior to those of holders of the common stock offered hereby. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, which could increase our expenses and require that our assets secure such debt. Moreover, any debt we incur must be repaid regardless of our operating results. However, we do not own any significant assets that we expect could serve as acceptable collateral for a bank or other commercial lender. The above circumstances may discourage some investors from purchasing our stock, lending us money or from providing alternative forms of financing. In addition, the current economic instability in the world's equity and credit markets may materially adversely affect our ability to sell additional securities and / or borrow cash. There can be no assurance that we will be able to raise additional working capital on acceptable terms or at all. If we are unable to raise additional capital when needed, we may be required to curtail the development of our technology or materially curtail or reduce our operations. We could be forced to sell or dispose of our rights or assets. Any inability to raise adequate funds on commercially reasonable terms would have a material adverse effect on our business, results of operation and financial condition, including the possibility that a lack of funds could cause our business to fail and liquidate with little or no return to investors. Even if we take these actions, they may be insufficient, particularly if our costs are higher than projected or unforeseen expenses arise. Additionally, if we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or products or to grant licenses on terms that may not be favorable to us. If we choose to expand more rapidly than we presently anticipate, we may also need to raise additional capital sooner than expected. Our efforts may never demonstrate the feasibility of our proposed CGM and blood pressure monitoring solution. We have developed a working prototype of our proposed solution that is capable of generating data we believe will be able to be used to measure various health vital signs and measurements, including heart rate, HRV, sleep, respiration, temperature, blood oxygen, steps, calories, blood glucose and blood pressure levels, but significant additional research and development activity will be required before we achieve a commercial product. We have conducted limited studies to compare the data our prototype device generates to measurements from conventional blood glucose and blood pressure measuring tools, and we are using the data generated in those studies to refine our product design and to develop the algorithms our product in development will utilize. However, we have not yet conducted any studies that demonstrate that our planned product is able to measure blood glucose or blood pressure levels at any particular accuracy level and we may never be able to complete any clinical studies that demonstrate accuracy levels that would be necessary for a commercial product. Our research and development efforts remain subject to all of the risks associated with the development of new products based on emerging technologies, including unanticipated technical or other problems and the possible insufficiency of funds needed in order to complete development of these products and enable us to execute our business plan. Any such problems may result in delays and cause us to incur additional expenses that would increase our losses. If we cannot complete, or if we experience significant delays in, developing our technology and products and services based on such technology for use in potential commercial applications, particularly after incurring significant expenditures, our business may fail. To our knowledge, the technological concepts we are applying to develop commercial applications have not previously been successfully applied by anyone else. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies in the early stages of development, especially technology companies such as ours. Potential investors should carefully consider the risks and uncertainties that a company with a limited operating history typically faces. In particular, potential investors should consider that we cannot assure you that we will be able to:

- successfully implement or execute our current business plan, or that our business plan is sound;
- successfully develop the technology necessary to develop our planned solution having the functionality and characteristics we discuss herein;
- successfully develop a practical, efficient or economical commercial version of one or more products;
- obtain any additional issued patents;
- successfully develop proprietary technology and trade secrets and secure market exclusivity and / or adequate intellectual property protection for our products by way of patent protection or otherwise;
- successfully protect any such proprietary technology and trade secrets from competitors and third parties claiming infringement or misappropriation;
- attract and retain an experienced management and advisory team; and
- raise sufficient funds in the capital markets to effectuate our business plan, including for the development and commercialization of our products.

If we cannot successfully execute any one of the foregoing, our business may not succeed, and your investment will be adversely affected. We face competition from other technology companies and our operating results will suffer if we fail to compete effectively. The technology industry, generally, and the general wellness, continuous glucose and blood pressure monitoring markets, in particular, are intensely competitive, subject to rapid change, and significantly affected by new product introductions and other market activities by industry participants. To compete successfully, we will need to demonstrate the advantages of our products and technologies over well-established alternative solutions, products and technologies, as well as newer ones, and convince consumers and enterprises of the advantages of our products and technologies. With respect to our Evie Ring and other planned solutions, we face or will face direct and indirect competition from a number of competitors who have developed or are developing products for general wellness and continuous or periodic monitoring of glucose and blood pressure levels, and we anticipate that other companies will develop additional competitive products in the future. Traditional glucometers and blood pressure monitors remain an inexpensive alternative to our proposed solution. We have existing competitors and potential new competitors, many of which have or will have substantially greater name recognition, financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals, and sales and marketing of approved products than we have. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Established competitors may invest heavily to quickly discover and develop novel technologies that could make obsolete or uneconomical the technology or the products that we plan to develop. Other small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Any new product that we develop that competes with a competitor's existing or future product may need to demonstrate compelling advantages in cost, convenience, quality, and safety to be commercially successful. In addition, new products developed by others could emerge as competitors to our proposed product development candidates. If our technology under development or our future products are not competitive based on these or other factors, our business would be harmed, and our financial condition and operations will suffer. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy. Our ability to implement our business plan depends in large part upon our ability to attract and retain highly qualified managerial and engineering personnel. We will need to hire additional personnel as we further develop our products. Competition for skilled personnel in our market is intense and competition for experienced engineers may limit our ability to hire and retain highly qualified personnel on acceptable terms. Despite our efforts to retain valuable employees, members of our management and engineering teams may terminate their employment with us on short notice. The loss of the services of any of our executive officers or other key employees could potentially harm our business, operating results or financial condition. Currently, we do not maintain key man insurance policies with respect to any of our executive officers or employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior engineering personnel. Other technology companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories than we have. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize products would be limited. We are subject to risks associated with our utilization of consultants. To improve productivity and accelerate our development efforts while we build out our own engineering team, we use experienced consultants to assist in selected business functions, including the development of our integrated circuits. We take steps to monitor and regulate the performance of these independent third parties. However, arrangements with third party service providers may make our operations vulnerable if these consultants fail to satisfy their obligations to us as a result of their performance, changes in their own operations, financial condition or other matters outside of our control. Effective management of our consultants is important to our business and strategy. The failure of our consultants to perform as anticipated could result in substantial costs, divert management's attention from other strategic activities or create other operational or financial problems for us. Terminating or transitioning arrangements with key consultants could result in additional costs and a risk of operational delays, potential errors and possible control issues as a result of the termination or during the transition. We will need to grow the size of our organization, and we may experience difficulties in managing this growth. As we expand our activities, there will be additional demands on our financial, technical, operational and management resources. To manage our anticipated future growth, we must continue to implement and improve our financial, technical, operational and management systems and continue to recruit and train additional qualified personnel. Due to our limited financial resources and operating history, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions. We may acquire additional businesses or products, form strategic alliances or create joint ventures with third

parties that we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following any such acquisition, we will achieve the expected synergies to justify the transaction. Our business is affected by macroeconomic conditions. Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and foreign currency exchange rates and overall economic conditions and uncertainties, including those resulting from the current and future conditions in the global financial markets. Cost inflation, including increases in raw material prices, labor rates, and transportation costs may impact our profitability. Global financial markets and the banking sector can experience extreme volatility, disruption and credit contraction, which adversely affect global economic conditions. The volatility of the capital markets could also affect the value of our investments and our ability to liquidate our investments or access our cash and cash equivalents in order to fund our operations. Our ongoing cash management strategy is to maintain diversity in our deposit accounts at multiple financial institutions, but there can be no assurance that this strategy will be successful. If our banking partners are negatively impacted by financial conditions affecting the banking system and financial markets, then our ability to access our cash and cash equivalents may be threatened which could have a material adverse effect on our business and financial condition. Increasing interest rates, reduced access to capital markets and bank failures could also adversely affect the ability of our suppliers, OEMs, VARs, distributors, licensors, collaborators and other strategic partners to remain effective business partners or to remain in business. The loss of a strategic partner, or a failure to perform by a strategic partner, could have a disruptive effect on our business and could adversely affect our results of operations. Our business and operations are subject to risks related to climate change. The effects of global climate change present risks to our business. Natural disasters, extreme weather and other conditions caused by or related to climate change could adversely impact our supply chain, the availability and cost of raw materials and components, energy supply, transportation, or other inputs necessary for the operation of our business. Climate change and natural disasters could also result in physical damage to our facilities as well as those of our suppliers, and strategic partners, which could cause disruption in our business and operations. Our facilities and our equipment would be costly to replace and could require substantial lead time to repair or replace. Although we believe we possess adequate insurance for the disruption of our business related to climate change, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. The sizes of the markets for our current and future products have not been established with precision and may be smaller than we estimate. Our estimates of the annual total addressable markets for our current products and products under development are based on a number of internal and third-party estimates, including, without limitation, the size of customer populations and the assumed prices at which we can sell our products. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our current or future products may prove to be incorrect. If the actual number of customers who would benefit from our products, the price at which we can sell our products, or the annual total addressable market for our products is smaller than we have estimated, it may impair our sales growth and have an adverse impact on our business. Our business could be negatively impacted by corporate social responsibility and sustainability matters. There has been an increased focus from investors, customers, employees and other stakeholders concerning corporate social responsibility and sustainability matters, which may result in increases in our costs to operate our business or restrict certain aspects of our activities. The standards by which corporate social responsibility and sustainability efforts and related matters are measured are developing and evolving, and certain areas are subject to assumptions that could change over time. We could be criticized for the scope of such initiatives or goals or perceived as not acting responsibly in connection with these matters. In addition, we could experience reputational harm if we are targeted by groups or influential individuals who disagree with our positions on social or environmental issues. Additionally, lawsuits or regulatory actions based on allegations that certain public statements regarding corporate social responsibility and sustainability matters by companies are false and misleading “greenwashing” campaigns could significantly impact our operations and could have an adverse impact on our financial condition. Any such matters could have a material adverse impact on our future results of operations, financial position and cash flows. We are highly dependent on the success of our initial products, the Evie Ring and the EvieMED Ring, and cannot give any assurance that they will be successfully commercialized. We are highly dependent on the success of our initial products, the Evie Ring and the EvieMED Ring. There is no guarantee that we will be successful in the commercialization of these or any other future product. While we commercially launched the Evie Ring without FDA clearance, we recently received FDA clearance for the pulse oximeter feature of the EvieMED Ring and expect to commercially launch this product in the second quarter of 2025. We intend to seek FDA clearance for additional features of the EvieMED Ring, which will require substantial additional clinical development, extensive preclinical testing and clinical trials. We cannot give any assurance that our products will be successfully commercialized or that we will receive regulatory clearances or approvals for additional features. Any failure to achieve commercial success or obtain additional regulatory clearances or approvals would have a material adverse effect on our business. If we do not successfully manage the launch and marketing of new products or services, our financial results could be adversely affected. We face risks associated with launching new products and pre-announcing products and services when the products or services have not been fully developed or tested. In addition, we may experience difficulty in managing or forecasting customer reactions, purchasing decisions, transition requirements, or programs with respect to newly launched products (or products in development). If our products and services are not able to deliver the performance or results expected by our target markets or are not delivered on a timely basis, our reputation and credibility may suffer. If we encounter development challenges or discover errors in our products late in our development cycle, we may delay the product launch date. The expenses or losses associated with unsuccessful product development or launch activities, or a lack of market acceptance of our new products, could adversely affect our business, financial condition, or results of operations. We depend on third parties to design, manufacture, market and distribute our products. If any third party fails to successfully design, manufacture, market or distribute any of our products, our business will be materially harmed. We depend and expect to continue to depend on strategic partners such as third-party OEMs, VARs and other distributors to complete the design, manufacture, market and distribute the Evie Ring, EvieMED Ring and other future products. If these strategic partners fail to successfully design, manufacture, market or distribute our current or future products, our business will be materially harmed. We have limited control over the efforts and resources that any third-party OEMs, VARs and other distributors devote to designing, manufacturing, marketing or distributing our products under development. An OEM may not be able to successfully design and manufacture our products and such failure by an OEM could substantially harm the value of our business. Similarly, the OEMs, VARs or other distributors we engage with to market and sell our product under development may not be successful at marketing and selling such product. If we cannot find suitable strategic partners or our strategic partners do not perform as expected, our potential for revenue may be dramatically reduced and our business could be harmed. Our business and operations would suffer in the event of information technology system failures, including cyber-attacks. Our information technology computer systems, as well as those of our contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including fires and earthquakes), terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. In the ordinary course of our business, we collect and store sensitive data, including intellectual property, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, on our networks. The secure processing, maintenance and transmission of this information is critical to our operations. High-profile security breaches at other companies and in government agencies have increased in recent years, and security industry experts and government officials have warned about the risks of hackers and cyber-attacks targeting businesses such as ours. Cyber-attacks are becoming more sophisticated and frequent, and in some cases have caused significant harm. Computer hackers and others routinely attempt to breach the security of technology products, services and systems, and to fraudulently induce employees, customers, or others to disclose information or unwittingly provide access to systems or data. While we devote significant resources to security measures to protect our systems and data, these measures cannot provide absolute security, and our information technology and infrastructure may be vulnerable to attacks by hackers or internal bad actors, or breached due to employee error, a technical vulnerability, malfeasance or other disruptions. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information and significant regulatory penalties, and such an event could disrupt our operations, damage our reputation and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our development of our products. The use of artificial intelligence presents new risks related and challenges to our business. Artificial intelligence (“AI”) is increasingly being used across the global business landscape, including in the industry in which we operate. We have already employed certain AI technologies into our business to enhance our operations, products, technology, and services and expect our use of AI to increase as the technology rapidly evolves and improves. However, AI innovation presents risks and challenges that could impact our business. AI algorithms may be flawed. Datasets may be insufficient or contain biased information. Ineffective AI development and deployment practices by us or our commercial partners could result in

violations of our confidentiality and privacy obligations or applicable laws and regulations, jeopardize our Intellectual Property rights, cause or contribute to unlawful discrimination, result in the misuse of personally identifiable information, including PHI, or give rise to significant cyber security risks, any of which could have a material adverse effect on our business, results of operations, and financial condition. We may also face increased competition from other companies that are employing AI and related technologies, some of whom may develop more effective methods than we and any of our commercial partners have, which could have a material adverse effect on our business, results of operations, or financial condition. In addition, uncertainties regarding developing legal and regulatory requirements and standards may require significant resources to modify and maintain business practices to comply with U. S. and foreign laws concerning the use of AI and related technologies, the nature of which cannot be determined at this time.

It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection. Our success depends significantly on our ability to obtain, maintain and protect our proprietary rights to the technologies used in our products. Patents and other proprietary rights provide uncertain protections, and we may be unable to protect our intellectual property. As of December 31, 2023-2024, we own, jointly own, or have exclusive rights to 28-32 issued and in-force patents (that cover one or more of our products or product candidates for method, system and device development). Furthermore, as of December 31, 2023-2024, we own, jointly own, or have exclusive rights to 18-5 pending U. S. patent applications, 4-one pending foreign patent applications, and one pending PCT International patent application. While we plan to file additional patent applications, we may never develop any invention that results in any additional issued patents. Even if we obtain patents, we may be unsuccessful in defending our patents (and other proprietary rights) against third party challenges. Although we expect to attempt to obtain patent coverage for our technology where available and where we believe appropriate, there may be aspects of the technology for which patent coverage may never be sought or received. We may not possess the resources to or may not choose to pursue patent protection outside the United States or any other country other than the United States where we may eventually decide to sell our future products. Our ability to prevent others from making or selling duplicate or similar technologies will be impaired in those countries in which we have no patent protection. Any patent applications we have filed or may file in the future may never result in issued patents, or patents issued based upon such applications may issue only with limited coverage or may issue and be subsequently successfully challenged by others and held invalid or unenforceable. There may exist prior art that may prevent our patent applications from resulting in issued patents, and there may be other inventors who file patent applications on inventions that are the same or similar to ours or that otherwise may be found to anticipate our inventions before we file patent applications of our own on our inventions, which may result in the issue of patents on our inventions or similar or anticipatory inventions to those other inventors. Even if patents issue based on our current or any future applications, any issued patents may not provide us with any competitive advantages. Competitors may be able to design around our patents or develop products that provide outcomes comparable or superior to ours. Our patents may be held invalid or unenforceable as a result of legal challenges by third parties, and others may challenge the inventorship or ownership of our patents and pending patent applications. In addition, if we choose to and are able to secure protection in countries outside the United States, the laws of some foreign countries may not protect our intellectual property rights to the same extent as do the laws of the United States. In the event a competitor infringes upon our patents or other intellectual property rights, enforcing those rights may be difficult, expensive and time consuming and we may elect not to enforce our patents or other intellectual property rights based on the facts and circumstances known to us at the time. Even if successful, litigation to enforce our intellectual property rights or to defend our patents against challenge could be expensive and time consuming and could divert our management's attention. We may not have sufficient resources to enforce our intellectual property rights or to defend our patents against a challenge. If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be adversely affected. In addition to our patent activities, we rely upon, among other things, unpatented proprietary technology, processes, trade secrets and know-how. Any involuntary disclosure to or misappropriation by third parties of our confidential or proprietary information could enable competitors to duplicate or surpass our technological achievements, potentially eroding our competitive position in our market. While we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information and technology to enter into confidentiality agreements, we cannot be certain that this know-how, information and technology will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. These agreements may be terminated or breached, and we may not have adequate remedies for any such termination or breach. Furthermore, these agreements may not be enforceable or provide meaningful protection for our trade secrets and know-how in the event of unauthorized use or disclosure. The disclosure of trade secrets or other proprietary information would impair our competitive position and may materially harm our business. We may in the future be a party to intellectual property litigation or administrative proceedings that could be costly and could interfere with our ability to develop our products. Because our industry is characterized by competing intellectual property, we may be sued for violating the intellectual property rights of others. Determining whether a product infringes a patent involves complex legal and factual issues, and the outcome of patent litigation actions is often uncertain. We have not conducted any significant search of patents issued to third parties, and no assurance can be given that third party patents containing claims covering our product under development, parts of our product under development, technology or methods do not exist, have not been filed, or could not be filed or issued. Because of the number of patents issued and patent applications filed in our technical areas or fields, our competitors or other third parties may assert that our products and the methods we plan to employ in the use of our products are covered by United States or foreign patents held by them. In addition, because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware, and which may result in issued patents that our product under development or other future products would infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. There could also be existing patents that one or more of our future products or parts may infringe and of which we are unaware. As the number of competitors in our market increases, and as the number of patents issued in this area grows, the possibility of patent infringement claims against us increases. Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations. In the event that we become subject to a patent infringement or other intellectual property lawsuit and if the relevant patents or other intellectual property were upheld as valid and enforceable and we were found to infringe or violate the terms of a license to which we are a party, we could be prevented from selling any infringing products of ours unless we could obtain a license or were able to redesign the product to avoid infringement. If we were unable to obtain a license or successfully redesign, we might be prevented from selling our product under development or other future products. If there is an allegation or determination that we have infringed the intellectual property rights of a competitor or other person, we may be required to pay damages, or a settlement or ongoing royalties. In these circumstances, we may be unable to sell our products at competitive prices or at all, and our business could be harmed. We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property. We do and may employ and contract with individuals who were previously employed by other technology companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and to not use the know-how or confidential information of their former employer or other third parties, we cannot guarantee that we have executed such agreements with all applicable parties. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees' former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable personnel or intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees. In addition, while it is our policy to require our employees, contractors and other third parties who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights under such agreements may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. We could become subject to product liability claims, product recalls and warranty claims that could be expensive, divert management's attention and harm our business. Our business exposes us to potential liability risks that are inherent in the manufacturing, marketing and sale of products used by consumers. We may be held liable if our product under development or other future products cause injury or death or are found otherwise unsuitable during usage. Our future products to be developed are expected to incorporate sophisticated components and computer software. Complex software can contain errors, particularly when first introduced. In addition, new products or enhancements may contain undetected errors or performance problems that, despite testing, are discovered only after installation. While we believe our technology will be safe, because our proposed solution is an RF-based technology that is being designed to be used in close proximity to users, users may allege or possibly prove defects, some of which could be alleged or proved to cause harm to users or others. A product liability claim, regardless of its merit or eventual outcome, could result in significant legal defense costs. We cannot guarantee that we will be able to obtain products liability insurance; if we do, however, the coverage limits of any insurance policies that we may choose to purchase to cover related risks may not be adequate

to cover future claims, and the cost of insurance, if obtainable, could be prohibitive. If sales of our products increase or we suffer future product liability claims, we may be unable to maintain product liability insurance in the future at satisfactory rates or with adequate amounts. A product liability claim, any product recalls or excessive warranty claims, whether arising from defects in design or manufacture or otherwise, could negatively affect our sales or require a change in the design or manufacturing process, any of which could harm our reputation and result in a decline in revenue, each of which would harm our business. In addition, if a product we designed or manufactured is defective, whether due to design or manufacturing defects, improper use of the product or other reasons, we may be required to notify regulatory authorities and / or to recall the product. A required notification to a regulatory authority or recall could result in an investigation by regulatory authorities of our products, which could in turn result in required recalls, restrictions on the sale of the products or other penalties. The adverse publicity resulting from any of these actions could adversely affect the perception of customers and potential customers. These investigations or recalls, especially if accompanied by unfavorable publicity, could result in our incurring substantial costs, losing revenues and damaging our reputation, each of which would harm our business. **Increased use of social media could create or amplify the effects of negative publicity and adversely affect sales and operating results. As part of our marketing efforts, we rely on search engine marketing and social media platforms to attract and retain customers. These efforts may not be successful, and pose a variety of other risks. Related, including the improper disclosure of proprietary or personally identifiable information, the posting of negative comments about our brand, fraud, use of out-of-date information or failure to comply with Regulation regulations regarding such practices. Negative or false commentary about us or our products or services may be posted on social media platforms and may harm our reputation or business and social media has also given users the ability to more effectively organize collective actions, such as boycotts, which could be taken against us or our products or services. Customers value readily available information and often act on such information without affording us an opportunity for redress or correction. The inappropriate use of social media vehicles, including a failure to abide by applicable laws and regulations, in the use of social media by us or our influencers, employees, contractors, suppliers, customers or other third parties associated or perceived to be associated with us could increase our costs, lead to litigation, fines or regulatory action or result in negative publicity that could damage our reputation. The occurrence of any such developments could have an adverse effect on our business results. In addition, any negative events reported in the media, including social media, whether or not accurate or involving us or our products or services, could create or amplify negative publicity for us or for the industry or market segments in which we operate. These and other types of social media risks could reduce demand for products and services offered by us and / or shift consumer preferences to competitors and could result in a decrease in customer demand for our products and services. FDA clearance of the pulse oximetry feature of our EvieMED Ring does not ensure commercial success of the product. In November 2024, we received 510 (k) clearance from the FDA for the pulse oximetry feature in our EvieMED Ring, making it a medical device. The EvieMED Ring clearance was the first medical device marketing authorization we have received. In order to market and distribute EvieMED Ring or other medical devices, we will need to modify certain of our internal business operations to ensure they comply with medical device requirements and to enable distribution of the product in accordance with the limitations of use described in our marketing authorizations. For example, for our EvieMED Ring product, the 510 (k) clearance limits distribution of this product to prescription use- only. In the direct-to- consumer model we utilize to distribute the Evie Ring, consumers purchase our products directly from us or one of our retailers, and we will not be able to utilize this model to distribute the EvieMED Ring in accordance with its prescription- required marketing authorization. Though we are currently exploring a number of new distribution channels, including working with durable medical equipment distributors, healthcare institutions, and other healthcare payor and provider channels, we may not be successful in identifying, or implementing with our current resources, an appropriate distribution channel. Further, even though we have received FDA clearance for EvieMED Ring, we will still need to demonstrate the business and clinical rationale and justifications of this product in order for healthcare institutions and providers to be convinced of the need to prescribe it, and we may not be successful in these efforts. We are seeking to seek FDA clearance with respect to additional EvieMED certain of the Evie Ring -s monitoring capabilities and expect to seek FDA clearance or approval for our planned CGM and blood pressure monitoring solution, which may be difficult to achieve, and existing laws or regulations or future legislative or regulatory changes may affect our business. While we commercialized our first iteration of the Evie Ring without FDA clearance, our EvieMED Ring is, and we expect subsequent iterations of the Evie Ring and our other future products will be subject to current and future regulation by the FDA and may be subject to regulation by other federal, state and local agencies. These agencies and regulations require manufacturers of medical devices to comply with applicable laws and regulations governing development, testing, manufacturing, labeling, marketing and distribution of medical devices. Devices are generally subject to varying levels of regulatory control, based on the risk level of the device. Governmental regulations specific to medical devices are wide- ranging and govern, among other things: • product design, development and manufacture; • laboratory, pre- clinical and clinical testing, labeling, packaging, storage and distribution; • premarketing clearance or approval; • record keeping; • product marketing, promotion and advertising, sales and distribution; and • post- marketing surveillance, including reporting of deaths, serious injuries and certain malfunctions, as well as corrections and removals (recalls). Before a new medical device or a new intended use for an existing product can be marketed in the United States, a company must first submit and receive either 510 (k) clearance or PMA from FDA, unless an exemption applies. The typical duration to receive a 510 (k) clearance is approximately nine to twelve months from the date of the initial 510 (k) submission and the typical duration to receive a PMA approval is approximately two years from the date of submission of the initial PMA application, although there is no guarantee that the timing will not be longer. Our end goal EvieMED Ring is to bring to market a solution that would be classified as a Class II medical device that will, which require required us to seek and receive a 510 (k) clearance for the pulse oximeter feature prior to marketing. We intend to seek a 510 (k) clearance with respect to additional monitoring capabilities. In some instances, the 510 (k) pathway for product marketing may be used with only proof of substantial equivalence in technology for a given indication with a lawfully marketed device (a “ predicate device ”). In other instances, FDA may require additional clinical work to prove efficacy in addition to technological equivalence and basic safety. Whether clinical data is provided or not, FDA may decide to reject the substantial equivalence argument we present. If that happens, our device would be automatically designated as a Class III device, and we would have to fulfill the more rigorous PMA requirements or request a “ de novo ” reclassification of the device into Class I or II. Thus, although at this time we do not anticipate that we will be required to do so, it is possible that one or more of our planned products or product features may require PMA approval de novo reclassification. We may not be able to obtain the necessary clearances or approvals or may be unduly delayed in doing so, which could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the product, which may limit the market for the product. Delays in obtaining clearance or approval could increase our costs and harm our revenues and growth. In addition, we are will be required to timely file various reports with FDA, including reports required by the medical device reporting regulations that require us to report to FDA if our devices may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur. If these reports are not filed timely, regulators may impose sanctions and sales of our products may suffer, and we may be subject to regulatory enforcement actions, all of which could harm our business. If we initiate a correction or removal for one of our devices to reduce a risk to health posed by the device, we would be required to submit a publicly available Correction and Removal report to FDA and, in many cases, similar reports to other regulatory agencies. This report could be classified by FDA as a device recall which could lead to increased scrutiny by FDA, other international regulatory agencies and our customers regarding the quality and safety of our devices. Furthermore, the submission of these reports has been and could be used by competitors against us in competitive situations and cause customers to delay purchase decisions or cancel orders and would harm our reputation. FDA and FTC also regulate the advertising and promotion of our products to ensure that the claims we make are consistent with our regulatory clearances, that there are adequate and reasonable data to substantiate the claims and that our promotional labeling and advertising is neither false nor misleading in any respect. If FDA or FTC determines that any of our advertising or promotional claims are misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions. FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by FDA or state agencies, which may include any of the following sanctions: • adverse publicity, warning letters, fines, injunctions, consent decrees and civil penalties; • repair, replacement, refunds, recall or seizure of our products; • operating restrictions, partial suspension or total shutdown of production; • refusing our requests for 510 (k) clearance or PMA of new products, new intended uses or modifications to existing products; • withdrawing 510 (k) clearance or PMAs that have already been granted; • refusal of importation or exportation; and • criminal prosecution and / or civil penalties. If any of these events were to occur, our business and financial condition would be harmed. The cost of compliance with new laws or regulations governing our technology or future products could adversely affect our financial results. New laws or regulations may impose restrictions or obligations on us that could force us to redesign our technology under development or other future products and may impose restrictions that are not possible or practicable to comply with, which could cause our business to fail. We cannot predict the impact on our business of any legislation or regulations related to our technology or future products that may be enacted or adopted in the future. If any OEMs contracted to manufacture our products fail to comply with FDA’s Quality System Regulations or other regulatory bodies’ equivalent regulations, manufacturing operations could be delayed or shut down and the development of our products could suffer. The manufacturing processes of third- party OEMs are required to comply with FDA’s Quality System Regulations and other regulatory bodies’ equivalent regulations, which cover the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of our planned non- invasive solution. They may also be subject to similar state requirements and licenses and engage in extensive recordkeeping and reporting and make available their manufacturing facilities and records for periodic unannounced**

inspections by governmental agencies, including FDA, state authorities and comparable agencies in other countries. If any OEM fails such an inspection, our operations could be disrupted and our manufacturing interrupted. Failure to take adequate corrective action in response to an adverse inspection could result in, among other things, a shut-down of our manufacturing operations, significant fines, suspension of marketing clearances and approvals, seizures or recalls of our products, operating restrictions and criminal prosecutions, any of which would cause our business to suffer. Furthermore, these OEMs may be engaged with other companies to supply and / or manufacture materials or products for such companies, which would expose our OEMs to regulatory risks for the production of such materials and products. As a result, failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a third-party manufacturer's facility. If FDA determines that any of the facilities that manufacture our proposed solution are not in compliance with applicable requirements, we may need to find alternative manufacturing facilities, which would impede or delay our ability to develop, obtain regulatory clearance or approval for, or market our products, if developed and approved. Additionally, our key component suppliers may not currently be or may not continue to be in compliance with applicable regulatory requirements, which may result in manufacturing delays for our product and cause our results of operations to suffer. We expect our planned solution to be subject to certain Federal Communication Commission ("FCC") regulations. Our RF-based technology involves the transmission of RF energy, and as such, will be subject to regulation by the FCC, including the FCC's equipment authorization regulations and its regulations governing human exposure to RF energy. In particular, we expect the planned solution to be regulated under Part 18 of the FCC's rules governing industrial, scientific, and medical (ISM) equipment, and to be classified as consumer ISM equipment under that rule part. Based on the expected frequency and power of operation, we expect that the product will comply with the Part 18 technical specifications for these types of devices, which we will be required to verify under FCC equipment authorization procedures. We also expect, based on the device's frequency and power of operation, that the product will comply with the FCC's requirements governing human exposure to RF energy. There is the risk that the product, as we expect it to be developed, may not comply with these requirements, which could significantly affect our development costs and delay commercialization of the product. There is also the risk that we will be unable to cost effectively develop and produce a solution using RF technology that complies with these FCC requirements. Our current or future products may be subject to product recalls that could harm our reputation. Regulatory agencies have the authority to require the recall of commercialized products in the event of material regulatory deficiencies or defects in design or manufacture. A government-mandated or voluntary recall by us could occur as a result of component failures, manufacturing errors or design or labeling defects. Recalls of our current or future products would divert management's attention, be expensive, harm our reputation with customers and harm our financial condition and results of operations. A recall announcement would also negatively affect the price of our securities. Healthcare reform measures could hinder or prevent our commercial success. There have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that could harm our future revenues and profitability and the future revenues and profitability of our potential customers. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. For example, one of the most significant healthcare reform measures in decades, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (the "Affordable Care Act"), was enacted in 2010. The Affordable Care Act contains a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which may impact existing government healthcare programs and result in the development of new programs. The Affordable Care Act imposed a 2.3 percent excise tax on sales of medical devices. The excise tax was suspended by statute twice before being repealed in December 2019. While this tax has been repealed, Congress could enact future legislation or further change the law related to the medical device excise tax in a manner that could negatively impact our operating results. The financial impact such future taxes could have on our business is unclear. Other significant measures contained in the Affordable Care Act include research on the comparative clinical effectiveness of different technologies and procedures, initiatives to revise Medicare payment methodologies, such as bundling of payments across the continuum of care by providers and physicians, and initiatives to promote quality indicators in payment methodologies. The Affordable Care Act also includes significant new fraud and abuse measures, including required disclosures of financial payments to and arrangements with physician customers, lower thresholds for violations and increasing potential penalties for such violations. Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act. It remains unclear whether changes will be made to the Affordable Care Act, or whether it will be repealed or materially modified. There likely will continue to be legislative and regulatory proposals at the federal and state levels directed at containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future or their full impact. The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may harm our ability to set a price that we believe is fair for our products, our ability to generate revenues and achieve or maintain profitability and the availability of capital. If we fail to comply with healthcare regulations with respect to our current or future products, we could face substantial penalties and our business, operations and financial condition could be adversely affected. Even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payers, certain federal and state healthcare laws and regulations pertaining to fraud and abuse and patients' rights will be applicable to our business. We could be subject to healthcare fraud and abuse and patient privacy regulation by both the federal government and the states in which we conduct our business. The regulations that will affect how we operate include: • the federal healthcare program Anti-Kickback Statute, which prohibits, among other things, any person from knowingly and willfully offering, soliciting, receiving or providing remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs, such as the Medicare and Medicaid programs; • the federal False Claims Act, which prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented, false claims, or knowingly using false statements, to obtain payment from the federal government; • federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters; • the federal Physician Payment Sunshine Act, created under the Affordable Care Act, and its implementing regulations, which require manufacturers of drugs, medical devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children's Health Insurance Program to report annually to the U. S. Department of Health and Human Services information related to payments or other transfers of value made to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; • the Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic and Clinical Health Act, which governs the conduct of certain electronic healthcare transactions and protects the security and privacy of protected health information; and • state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers. The Affordable Care Act, among other things, amends the intent requirement of the Federal Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the Federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal and similar foreign healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could harm our ability to operate our business and our results of operations. Failure to comply with privacy and security laws and regulations could result in fines, penalties and damage to our reputation and have a material adverse effect on our business. We are or may become subject to a number of federal and state laws and regulations protecting the use, disclosure, and confidentiality of certain patient health and personal information and restricting the use and disclosure of that protected information, including state breach notification laws, the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, and the California Consumer Privacy Act, among others. HIPAA extensively regulates the use and disclosure of individually identifiable health information, known as "protected health information," and require covered entities to implement administrative, physical and technical safeguards to protect the security of such information. Covered entities must report breaches of unsecured protected health information to affected individuals without unreasonable delay and notification must also be made to the U. S. Department of Health & Human Services, Office for Civil Rights (the "OCR") and, in certain situations involving large breaches, to the media. Various U. S. state laws and regulations may also require us to notify affected individuals and state agencies in the event of a data breach involving individually identifiable information. Compliance with HIPAA privacy regulations and security regulations is costly, and violations of the HIPAA privacy and security regulations may result in criminal and civil penalties. The OCR enforces the regulations and performs compliance audits. In addition to enforcement by OCR, state attorneys general are authorized to bring civil actions seeking either injunction or damages in response to violations that threaten the privacy of state residents. We also are or may become subject to state privacy-related laws, such as the CCPA, that are more restrictive than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties.

Risks Related to Owning Our Securities and Our Financial Results Our quarterly and annual results may fluctuate significantly, may not fully reflect the underlying performance of our business and may result in decreases in the price of our securities. Our financial condition and operating results may fluctuate significantly from quarter-to-quarter and year-to-year due to a variety of factors, some of which are beyond our control. Our operating results will be affected by

numerous factors such as: ● variations in the level of expenses related to our proposed products; ● status of our product development efforts; ● execution of collaborative, licensing or other arrangements, and the timing of payments received or made under those arrangements; ● intellectual property prosecution and any infringement lawsuits to which we may become a party; ● regulatory developments affecting our products or those of our competitors; ● our ability to obtain and maintain FCC clearance and / or FDA approval for our products, which have not yet been approved for marketing; ● our ability to successfully commercialize our products; ● market acceptance of our products; ● the timing and success of new products and feature introductions by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers or strategic partners; ● the amount and timing of costs and expenses related to the maintenance and expansion of our business and operations; ● general economic, industry and market conditions; ● the hiring, training and retention of key employees, including our ability to develop a sales team; ● litigation or other claims against us; ● our ability to obtain additional financing; ● the failure of our ability to meet maintain the minimum requirements for continued listing on the Nasdaq Capital Market; ● business interruptions caused by events such as pandemics and natural disasters; and ● advances and trends in new technologies and industry standards. Any or all of these factors could adversely affect our cash position requiring us to raise additional capital, which may be on unfavorable terms and result in substantial dilution. Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. We are subject to the periodic reporting requirements of the Exchange Act, and are required to maintain disclosure controls and procedures that are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the rules and forms of the SEC, and that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in those internal controls. Such internal controls are designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of a company's annual or interim financial statements will not be prevented or detected on a timely basis. We have identified a three material weaknesses in our internal control over financial reporting at December 31, 2023-2024 : (1) - The material weakness relates to the ineffective control environment, including an insufficient number of personnel with an appropriate level of knowledge and experience to create the proper environment for effective internal control over financial reporting, and did not maintain the other components of the COSO framework, including appropriate risk assessment, control activities, information and communication, and monitoring activities components, relating to (i) sufficiency of processes related to identifying and analyzing risks to the achievement of objectives, including technology, across the entity, (ii) developing general control activities over technology to support the achievement of objectives across the entity, (iii) sufficiency of selecting and developing control activities that contribute to the mitigation of risks to the achievement of objectives to acceptable levels and (iv) sufficiency of monitoring activities to ascertain whether the components of internal control are present and functioning; (2) effective information technology (IT) general controls for certain information systems supporting its key financial reporting processes. Specifically, the Company did not design and operation of our maintain (a) change management controls to ensure that program and data changes affecting financial close applications and reporting underlying accounting records are identified, tested, authorized and implemented appropriately, (b) access controls to ensure appropriate IT segregation of duties are maintained that adequately restrict and segregate privileged access between environments which support development and production, (c) controls to monitor on an on- going basis for the proper segregation of privileged access between environments which support development and production and (d) operations controls to ensure appropriate interfacing between systems; (3) ineffective process- level controls which affects substantially all financial statement account balances and disclosures within the Company. Although we are making efforts to remediate this these issue-issues, these efforts may not be sufficient to avoid similar material weaknesses in the future. Designing and implementing internal controls over financial reporting may be time consuming, costly and complicated as we are a small organization with limited management resources. If the material weakness in our internal controls is not fully remediated or if additional material weaknesses are identified, those material weaknesses could cause us to fail to meet our future reporting obligations, reduce the market's confidence in our consolidated financial statements, harm our stock price and subject us to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. In addition, our common stock may not be able to remain listed on Nasdaq or any other securities exchange. For as long as we are an " emerging growth company, " as defined in the JOBS Act, or a non- accelerated filer, as defined in Rule 12b- 2 under the Exchange Act, our auditors will not be required to attest as to our internal control over financial reporting. If we continue to identify material weaknesses in our internal control over financial reporting, are unable to comply with the requirements of Section 404 in a timely manner, are unable to assert that our internal control over financial reporting is effective or, once required, our independent registered public accounting firm is unable to attest that our internal control over financial reporting is effective, investors may lose confidence in the accuracy and completeness of our financial reports and the market price of our common stock could decrease. We could also become subject to stockholder or other third- party litigation as well as investigations by the securities exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial and management resources and could result in fines, trading suspensions or other remedies. Any control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. The issuance of additional stock in connection with financings, acquisitions, our equity incentive plan, upon exercise of outstanding warrants or otherwise will dilute our existing stockholders. If we issue additional equity securities, our existing stockholders' percentage ownership will be reduced, and these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences, and privileges senior to those of our common stock. Subject to compliance with applicable rules and regulations, we may issue our shares of common stock in connection with a financing, acquisition, our equity incentive plan, upon exercise of outstanding warrants or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and cause the trading price of our common stock to decline. Our stock price has fluctuated widely and is likely to continue to be volatile. The market price for our common stock varied between a high of \$ 2-12, 10-45 and a low of \$ 0-3, 58-01 in the twelve- month period ended December 31, 2023-2024, as adjusted for the 1- for- 15 reverse stock split effected October 29, 2024. Our stock price is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market and other factors, including those listed in this " Item 1A. Risk Factors " section and other, unknown factors. Among numerous other factors, our stock price also may be affected by: ● actual or anticipated fluctuations in our quarterly or annual operating results; ● changes in financial or operational estimates or projections; ● conditions in markets generally; ● changes in the economic performance or market valuations of companies similar to ours; and ● general economic or political conditions in the United States or elsewhere. In particular, the market prices of technology companies like ours have been highly volatile due to factors, including, but not limited to: ● any delay or failure to commercialize products acceptable to the market; ● developments or disputes concerning our product's intellectual property rights; ● our or our competitors' technological innovations; ● changes in market valuations of similar companies; ● announcements by us or our competitors of significant contracts, acquisitions, strategic partnerships, joint ventures, capital commitments, new technologies, or patents; and ● failure to complete significant transactions or collaborate with vendors in manufacturing our product. Any of these factors may result in large and sudden changes in the volume and trading price of our common stock. The stock market, generally, has from time to time experienced significant price and volume fluctuations that are not related to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of shares of our common stock. The daily trading volume of our common stock has historically been relatively low. If we are unable to develop and maintain a liquid market for our common stock, our shareholders may not be able to sell common stock at prices they consider to be fair or at times that are convenient, or at all. This situation may be attributable to a number of factors, including but not limited to the fact that we are a development an early- stage company that is relatively unknown to stock analysts, stockbrokers stock brokers, institutional investors, and others in the investor community. In addition, investors may be risk averse to investments in development-early- stage companies. The low trading volume is outside of our control and may not increase or, if it increases, may not be maintained. In addition, following periods of volatility in the market price of a company's securities, litigation has often been brought against that company, and we may become the target of litigation as a result of price volatility. Litigation could result in substantial costs and divert our management's attention and resources from our business. This could have a material adverse effect on our business, results of operations and financial condition. Our failure to meet the continued listing requirements of Nasdaq could result in a de- listing of our common stock. Our common stock is currently traded on the Nasdaq Stock Market (" Nasdaq "). On November 14, 2023, we were notified by Nasdaq that because the closing bid price for the Company's common stock listed on Nasdaq was below \$ 1. 00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550 (a) (2), requiring a minimum bid price of \$ 1. 00 per share (the " Minimum Bid Price Requirement "). On May 15, 2024, in accordance with Nasdaq Marketplace Rule 5810 (c) (3) (A), (1) we will have a period of 180 calendar days from to regain compliance with Bid Price Requirement expiring November 11-14-2023, or until May 13, 2024. On October 29, 2024, the Company completed a 1- for- 15 reverse stock split of its issued and outstanding common stock. On November 12, 2024, the Company was notified by Nasdaq that it had regained compliance with the Minimum Bid Price Requirement. Even though the Company is now in compliance with continued listing requirements of Nasdaq, (2) if at any future failure time prior to May 13, 2024, the bid price of the Company to satisfy such requirements could result in Nasdaq taking steps to delist the Company's common stock closes at or above \$ 1. Such 00 per share for a

minimum delisting would likely have a negative effect on the price of 10 consecutive business days, Nasdaq will provide written notification that the Company has achieved its common stock and would impair shareholders' ability to sell or purchase the Company's common stock. In the event of a delisting, the Company would take actions to restore its compliance with the Minimum Bid Price Nasdaq's listing Requirement requirements, but and (2) in the event the Company does not provide not - no regain assurance that any such action taken by the Company would allow its common stock to become listed again, stabilize the market price or improve the liquidity of the Company's common stock, prevent the Company's common stock from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq's listing requirements. On January 17, 2025, Nasdaq announced the Minimum effectiveness of new listing rules that will complicate regaining compliance with the Bid Price Requirement by removing May 13, 2024, the Company will be eligible stay period during an appeal of a delisting determination to a hearings panel and reducing the availability of further compliance periods for an additional 180-day period to issuers that implement multiple reverse stock splits. Any perception that we may not regain compliance for future with the Minimum Bid Price Requirement as long as it meets all other continued listing requirements, with the exception of the Minimum Bid Price Requirement. However, there can be no assurance that we will be afforded additional time to regain compliance noncompliance with the minimum bid price requirement following the initial 180-day period or that we will regain compliance with the Minimum Bid Price Requirement. If we are unable to regain compliance with Nasdaq Marketplace Rule 5550-(a)(2) in a timely manner, Nasdaq will commence suspension and delisting of procedures. If Nasdaq delists our common stock by Nasdaq from trading on its exchange, among other things, it could lead adversely affect our ability to attract new investors a number of negative implications, including reduced decrease the liquidity in of the outstanding shares of our common stock, reduce the price at which such shares trade loss of federal preemption of state securities laws, fewer business development opportunities and greater difficulty increase the transaction costs inherent in obtaining financing trading such shares with overall negative effects for our stockholders. Our Certificate of Incorporation designates specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders' ability to obtain a favorable judicial forum for disputes with us. Our Third Amended and Restated Certificate of Incorporation specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving claims brought against us by stockholders; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Securities Act, the Exchange Act, the rules and regulations thereunder or any other claim for which the federal courts have exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting in the State of Delaware. Our Certificate of Incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our Certificate of Incorporation described above. We believe these provisions benefit us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes and in the application of the Securities Act by federal judges, as applicable, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provisions may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder's ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. The enforceability of similar choice of forum provisions in other companies' certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provisions contained in our Certificate of Incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations. We have not paid dividends in the past and have no immediate plans to pay dividends. We plan to reinvest all of our earnings, to the extent we have earnings, in order to further develop our technology and potential products and to cover operating costs. We do not plan to pay any cash dividends with respect to our securities in the foreseeable future. We may never generate sufficient surplus cash that would be available for distribution to the holders of our common stock as a dividend. Therefore, our shareholders should not expect to receive cash dividends on the common stock. Concentration of ownership among our existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions. All decisions with respect to the management of the Company will be made by our board of directors and our officers, who beneficially own approximately 40.13, 5.1% of our common stock, as calculated in accordance with Rule 13d-3 promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). In addition, Peter Appel, Leabman Holdings LLC and Emily Fairbairn beneficially own approximately 9.9%, 7.2% and 5% and 6.18%, respectively, as calculated in accordance with Rule 13d-3 promulgated under the Exchange Act. As a result, these stockholders will be able to exercise a significant level of control over all matters requiring stockholder approval, including the election of directors, amendment of our Certificate of Incorporation and approval of significant corporate transactions. This control could have the effect of delaying or preventing a change of control of the Company or changes in management, in each case, which other stockholders might find favorable, and will make the approval of certain transactions difficult or impossible without the support of these significant stockholders. We are an "emerging growth company" under the JOBS Act and we cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make our common stock less attractive to investors. We are an "emerging growth company," as defined in the JOBS Act, and we expect to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not "emerging growth companies" including, but not limited to, (i) being required to present only two years of audited financial statements and related financial disclosure, (ii) not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, (iii) extended transition periods for complying with new or revised accounting standards, (iv) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and (v) exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. We have taken, and in the future may take, advantage of these exemptions until such time that we are no longer an "emerging growth company." We cannot predict if investors will find our common stock less attractive because we rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and the price of our common stock may be more volatile. We will remain an "emerging growth company" through December 31, 2026, although we will lose that status sooner if our annual revenues exceed \$ 1.07 billion, if we issue more than \$ 1 billion in non-convertible debt in a three-year period, or if the market value of our common stock that is held by non-affiliates exceeds \$ 700 million as of any June 30. **If we remain an emerging growth company through December 31, 2026, we will have to consider any consequences that might apply from the change in status when we prepare the financial statements and related disclosures as of and for the year ended December 31, 2026.** We are incurring significant costs as a public company that reports to the SEC and our management is required to devote substantial time to meet compliance obligations. As a public company listed in the United States, we incur significant legal, accounting and other expenses that we did not incur as a private company. We are subject to reporting requirements of the Exchange Act and the Sarbanes-Oxley Act, as well as rules subsequently implemented by the SEC and Nasdaq that impose significant requirements on public companies, including requiring the establishment and maintenance of effective disclosure and financial controls and changes in corporate governance practices. In addition, the Dodd-Frank Wall Street Reform and Protection Act includes significant corporate governance and executive compensation-related provisions that have and will continue to increase our legal and financial compliance costs, make some activities more difficult, time-consuming or costly and may also place undue strain on our personnel, systems and resources. Our management and other personnel must devote a substantial amount of time to these compliance initiatives. In addition, these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be more difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers. If securities or industry analysts do not publish research reports about our business, or if they issue an adverse opinion about our business, the price of our common stock and trading volume could decline. The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by securities and industry analysts. If no or few analysts commence research coverage of us, or one or more of the analysts who cover us issues an adverse opinion about our company, the price of our common stock would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the price of our common stock or trading volume to decline. Our charter documents and Delaware law may inhibit a takeover that stockholders consider favorable. Our Certificate of Incorporation and bylaws and applicable provisions of Delaware law may delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. The provisions in our Certificate of Incorporation and bylaws: • authorize our board of directors to issue preferred stock without stockholder approval and to designate the rights, preferences and privileges of each class; if issued, such preferred stock would increase the number of outstanding shares of our common stock and could include terms that may deter an acquisition of us; • classifies our board of directors into three classes, with members of each class serving staggered three-year terms; • limit who may call stockholder meetings; • do not provide for cumulative voting rights; • provide that all vacancies may be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; • provide that

stockholders must comply with advance notice procedures with respect to stockholder proposals and the nomination of candidates for director; ● provide that stockholders may only amend our Certificate of Incorporation and Bylaws upon a supermajority vote of stockholders; and ● provide that the Court of Chancery of the State of Delaware will be the exclusive forum for certain legal claims. In addition, section 203 of the Delaware General Corporation Law may limit our ability to engage in any business combination with a person who beneficially owns 15 % or more of our outstanding voting stock unless certain conditions are satisfied. This restriction lasts for a period of three years following the share acquisition. These provisions may have the effect of entrenching our management team and may deprive our shareholders of the opportunity to sell shares to potential acquirers at a premium over prevailing prices. This potential inability to obtain a control premium could reduce the price of our common stock. **Item 1B. Unresolved Staff Comments Not applicable. Item 1C. Cybersecurity Risk Management and Strategy** We operate in the technology and general wellness, continuous glucose and blood pressure monitoring sectors, which are subject to various cybersecurity risks that could adversely affect our business, financial condition, and results of operations, including intellectual property theft; fraud; extortion; harm to employees or customers; violation of privacy laws and other litigation and legal risk; and reputational risk. We have implemented a risk-based approach to identify and assess the cybersecurity threats that could affect our business and information systems. Our processes also include assessing cybersecurity threat risks associated with our use of third-party services providers in normal course of business use. Third-party risks are included within our cybersecurity risk management processes discussed above. In addition, we assess cybersecurity considerations in the selection and oversight of our third-party services providers, including due diligence on the third parties that have access to our systems and facilities that house systems and data. Our business depends on the availability, reliability, and security of our information systems, networks, data, and intellectual property. Any disruption, compromise, or breach of our systems or data due to a cybersecurity threat or incident could adversely affect our operations, customer service, product development, and competitive position. They may also result in a breach of our contractual obligations or legal duties to protect the privacy and confidentiality of our stakeholders. Such a breach could expose us to business interruption, lost revenue, ransom payments, remediation costs, liabilities to affected parties, cybersecurity protection costs, lost assets, litigation, regulatory scrutiny and actions, reputational harm, customer dissatisfaction, or harm to our vendor relationships. **Cybersecurity Governance and Oversight** Our board of directors addresses our cybersecurity risk management as part of its general oversight function. We maintain security controls that are continuously reviewed to protect against emerging cyber threats. Our IT Department monitors these security controls and risks and regularly reports to senior management and the board of directors on material developments. To manage our material risks from cybersecurity threats and to protect against, detect, and prepare to respond to cybersecurity incidents, we undertake the below listed activities: ● Monitor emerging data protection laws in conjunction with our advisors and implement changes to our processes to comply; ● Maintain firewall and virus protection software; and ● Maintain a cybersecurity insurance policy. Our cybersecurity incident response processes are designed to escalate certain cybersecurity incidents to designated employees and other members of management depending on the circumstances, including in some cases to our executive team. The board of directors receives regular reports from management concerning our cybersecurity risk management program. The board also receives various summaries and/or presentations related to cybersecurity threats, risks and mitigation. As of the date of this Annual Report on Form 10-K, we are not aware of any cybersecurity threats that have materially affected, or are reasonably likely to materially affect, our business strategy, results of operations or financial position. **Item 2. Properties** Our principal office is located at 6800 Koll Center Parkway, Pleasanton, California; and is comprised of office and laboratory space that we occupy pursuant to a lease. See Note 10 Commitments and Contingencies of our consolidated financial statements for further discussion of this lease facility. **Item 3. Legal Proceedings** We are not currently a party to any pending legal proceedings that we believe will have a material adverse effect on our business or financial conditions. We may, however, be subject to various claims and legal actions arising in the ordinary course of business from time to time. **Item 4. Mine Safety Disclosures PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Market Information** Our shares of common stock have been listed on the Nasdaq Capital Market under the symbol "MOVE" since March 23, 2021. Prior to that date, there was no public trading market for our common stock. As of April 10, 2024, there were 215 holders of record of our common stock. **Dividend Policy** We have never paid cash dividends on our securities, and we do not anticipate paying any cash dividends on our shares of common stock in the foreseeable future. We intend to retain any future earnings for reinvestment in our business. Any future determination to pay cash dividends will be at the discretion of our board of directors, and will be dependent upon our financial condition, results of operations, capital requirements and such other factors as our board of directors deems relevant. **Recent Sales of Unregistered Securities Item 6. Reserved Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations** The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this Annual Report. This discussion and analysis contains forward-looking statements that are based on our management's current beliefs and assumptions, which statements are subject to substantial risks and uncertainties. Our actual results may differ materially from those expressed or implied by these forward-looking statements as a result of many factors, including those discussed in "Risk Factors" in Item 1A of this Annual Report. Please also see "Cautionary Note Regarding Forward-Looking Statements" at the beginning of this Annual Report. **Overview** Movano Inc., dba Movano Health, a Delaware corporation, is developing a platform to deliver purpose-driven healthcare solutions to bring medical-grade, high-quality data to the forefront of consumer health devices. Our initial commercial product in development is the Evic Ring, a wearable designed specifically for women that was launched in November 2023. The Evic Ring combines health and wellness metrics to give a full picture of one's health, which include resting heart rate, HRV, SpO2, respiration rate, skin temperature variability, period and ovulation tracking, menstrual symptom tracking, activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. In addition to the Evic Ring, we are developing one of the smallest patented and proprietary SoC designed specifically for blood pressure or CGM systems. Movano Health built the integrated sensor from the ground up with multiple antennas and a variety of frequencies to achieve an unprecedented level of precision in health monitoring. We are currently conducting clinical trials with the SoC and developing algorithms that, if successful, will enable us to develop wearables that can monitor glucose non-invasively and blood pressure without a cuff. Our end goal is to bring a Class II FDA-cleared device to the market that includes CGM and cuffless blood pressure monitoring capabilities. Over time, our technology could also enable the measurement and continuous monitoring of other health data. On April 28, 2021, the Company established Movano Ireland Limited, organized under the laws of Ireland, as a wholly owned subsidiary of the Company. **Financial Operations Overview** We are an early-stage technology company with a limited operating history. To date, we have invested substantially all of our efforts and financial resources into (i) the research and development of the products we are developing, including conducting clinical studies and related sales, general and administrative costs, and (ii) the commercialization of our first commercial product, the Evic Ring. To date, we have funded our operations primarily from the sale of our equity securities. We have incurred net losses in each year since inception. Our losses were \$ 29.3 million and \$ 30.3 million for the years ended December 31, 2023 and 2022, respectively. Substantially all our net losses have resulted from costs incurred in connection with our research and development programs and from sales, general and administrative costs associated with our operations. As of December 31, 2023, we had \$ 6.1 million in available cash and cash equivalents. **Adoption of New Accounting Pronouncement—Leases** In February 2016, the FASB issued ASU 2016-02, Leases (ASC 842) which requires lessees to recognize leases on the balance sheet by recording a right-of-use asset and lease liability. We adopted this new guidance as of January 1, 2022 and applied the modified retrospective approach, whereby prior comparative periods will not be retrospectively presented in the consolidated financial statements. We elected the package of practical expedients not to reassess prior conclusions related to contracts containing leases and lease classification and the lessee practical expedient to combine lease and non-lease components for all asset classes. We made a policy election to not recognize right-of-use assets and lease liabilities for short-term leases for all asset classes. See Note 10 Commitments and Contingencies of our consolidated financial statements for further details. Upon adoption on January 1, 2022, we recognized right-of-use assets and lease liabilities for operating leases of \$ 380,000 and \$ 429,000, respectively. The difference between the right-of-use asset and lease liability primarily represents the net book value of deferred rent recognized as of December 31, 2021, which was adjusted against the right-of-use asset upon adoption. **Adoption of New Accounting Pronouncement—Debt** In August 2020, the FASB issued Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being recognized separately from their host contracts. The pronouncement also revises the derivatives scope exception for contracts in an entity's own equity and improves the consistency of earnings per share calculations as that relates to convertible instruments. We early-adopted this pronouncement as of January 1, 2022 using the modified retrospective method of transition. The adoption did not have any impact on our consolidated financials. **Adoption of New Accounting Pronouncement—Income Taxes** On December 14, 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2024. Entities are permitted to early adopt the standard for annual financial statements that have not yet been issued or made available for issuance. Adoption is either prospectively or retrospectively; we will adopt this ASU on a prospective basis. We are currently evaluating the impact of the ASU but do not expect any material impacts upon adoption. **Critical Accounting Estimates** The discussion and analysis of our consolidated financial condition and results of operations are based on our consolidated financial statements, which we have prepared in accordance with U. S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements as well as the

reported expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. While our significant accounting policies are described in Note 2 “Significant Accounting Policies” to the consolidated financial statements in Part II, Item 8 of this Annual Report on Form 10-K, we believe that the following accounting estimates are most critical to a full understanding and evaluation of our consolidated reported financial results.

Common Stock Warrants During the normal course of business, from time to time, we issue warrants to purchase common stock as part of a debt or equity financing or to vendors as consideration to perform services. We assess each warrant to determine if it meets the characteristics of a liability or a derivative, and if the warrant does meet the characteristics of a liability or a derivative, we classify the warrant as a liability measured at fair value. The derivative liabilities are remeasured at each period end, on a recurring basis, to the estimated fair value with the changes in fair value reflected as current period income or loss until the warrant is exercised, extinguished, or expires. If the warrant does not meet the characteristics of a liability or a derivative, we classify the warrant as equity, and record the warrant at its fair value on the date of issuance. The fair value of our warrants is estimated using appropriate pricing models based on the nature and characteristics of the underlying warrants and such models contain estimates and assumptions that require careful consideration and judgment. To date, we have not experienced changes in these estimates and have not had to modify our assumptions.

Stock-Based Compensation We measure equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires us to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of our common stock, and an assumed risk-free interest rate. As a result, if we revise our assumptions and estimates, our stock-based compensation expense could change. These assumptions include:

- Dividend Rate**—The expected dividend rate was assumed to be zero, as we have not previously paid dividends on common stock and have no current plans to do so.
- Expected Volatility**—The expected volatility was derived from the historical stock volatilities of several public companies within our industry that we consider to be comparable to our business over a period equivalent to the expected term of the stock option grants.
- Risk-Free Interest Rate**—The risk-free interest rate is based on the interest yield in effect at the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the option’s expected term.
- Expected Term**—The expected term represents the period that our stock options are expected to be outstanding. The expected term of option grants that are considered to be “plain vanilla” are determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options. For other option grants not considered to be “plain vanilla,” we determined the expected term to be the contractual life of the options.
- Forfeitures**—We made the one-time policy election to recognize forfeitures when they occur.

We account for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. We account for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. We establish a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. We record an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on our tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.

Years Ended December 31, 2023 and 2022 Our consolidated statements of operations for the years ended December 31, 2023 and 2022 as discussed herein are presented below. Year Ended December 31, Change 2023-2022 \$ % (in thousands, except share and per share data)

OPERATING EXPENSES: Research and development \$ 16,893 \$ 18,994 \$ (2,101) -11 % Sales, general and administrative 12,797 11,468 1,329 12 % Total operating expenses 29,690 30,462 (772) -3 % Loss from operations (29,690) (30,462) 772 3 % Other income (expense), net: Interest and other income, net 407 133 274 206 % Other income (expense), net 407 133 274 206 % Net loss \$ (29,283) \$ (30,329) \$ 1,046 3 % Research and Development Research and development expenses totaled \$ 16.9 million and \$ 19.0 million for the years ended December 31, 2023 and 2022, respectively. This decrease of \$ 2.1 million was due primarily to a reduction in design costs and activity. Research and development expenses for the year ended December 31, 2023 included expenses related to employee compensation of \$ 5.6 million, other professional fees of \$ 5.7 million, tools and equipment expenses of \$ 4.4 million, rent of \$ 0.2 million, depreciation and amortization of \$ 0.1 million, and other expenses of \$ 0.9 million. Research and development expenses for the year ended December 31, 2022 included expenses related to employee compensation of \$ 9.4 million, other professional fees of \$ 6.7 million, tools and equipment expenses of \$ 2.0 million, rent of \$ 0.2 million, depreciation and amortization of \$ 0.1 million, and other expenses of \$ 0.6 million. Sales, General and Administrative Sales, general and administrative expenses totaled \$ 12.8 million and \$ 11.5 million for the years ended December 31, 2023 and 2022, respectively. This increase of \$ 1.3 million was due primarily to the growth of the Company and in preparation for the Evie Ring product launch. Sales, general and administrative expenses for the year ended December 31, 2023 included expenses related to employee and board of director compensation of \$ 5.9 million, professional and consulting fees of \$ 2.6 million, rent of \$ 0.1 million, insurance of \$ 0.8 million, and other expenses of \$ 3.4 million. Sales, general and administrative expenses for the year ended December 31, 2022 included expenses related to employee and board of director compensation of \$ 6.1 million, professional and consulting fees of \$ 2.5 million, rent of \$ 0.1 million, insurance of \$ 1.3 million, and other expenses of \$ 1.5 million. Loss from Operations Loss from operations was \$ 29.7 million for the year ended December 31, 2023, as compared to \$ 30.5 million for the year ended December 31, 2022. Other Income (Expense), Net Other income (expense), net for the year ended December 31, 2023 was a net other income of \$ 0.4 million as compared to a net other income of \$ 0.1 million for the year ended December 31, 2022. The increase of \$ 0.3 million was primarily attributable to additional interest income on cash and cash equivalent due to higher prevailing interest rates. Net Loss As a result of the foregoing, net loss was \$ 29.3 million for the year ended December 31, 2023, as compared to \$ 30.3 million for the year ended December 31, 2022. Liquidity and Capital Resources At December 31, 2023, we had cash and cash equivalents of \$ 6.1 million. During the year ended December 31, 2023, we used \$ 26.2 million of cash in our operating activities. Our cash and cash equivalents are not expected to be sufficient to fund our operations for the next twelve months after the date these consolidated financial statements are issued. In August 2022, we entered into an at-the-market issuance (“ATM”) agreement with B. Riley Securities Inc., or B. Riley, to sell shares of our common stock for aggregate gross proceeds of up to \$ 50.0 million, from time to time, through an ATM equity offering program under which B. Riley acts as sales agent. During the years ended December 31, 2023 and 2022, the Company sold an aggregate of 2,531,757 and 810,400 shares of common stock, respectively, through the ATM program for proceeds of approximately \$ 3.2 million and \$ 2.2 million, net of commissions paid, respectively. Approximately \$ 44.4 million remains available on the ATM equity offering program at December 31, 2023. We expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We anticipate that our expenses will increase substantially as we: ● advance the engineering design and further development of the Evie Ring and other potential products; ● prepare applications required for marketing approval of the Evie Ring in the United States; ● continue to expand our plans for manufacturing, distributing and marketing the Evie Ring and other potential products; and ● add operational, financial and management information systems and personnel, including personnel to support our product development, commercialization efforts and our operation as a public company. On April 2, 2024, the Company entered into a securities purchase agreement for the private placement of an aggregate of 45,252,517 units with each unit consisting of (1) one share of the Company’s common stock or at the election of the purchaser a pre-funded warrant, and (2) one warrant to purchase one share of common stock. The purchase price paid for each unit was \$ 0.533. Certain directors and officers participated and purchased 287,500 units at an offering price of \$ 0.565 per share. Each pre-funded warrant has an exercise price of \$ 0.001 per share, was immediately exercisable on the date of issuance and does not expire. Each warrant has an exercise price equal to \$ 0.4071 per share, was exercisable immediately and expires on the fifth anniversary of the initial exercise date of the warrant. The warrants being issued to the Company’s officers and directors have an exercise price equal to \$ 0.44. The gross proceeds were approximately \$ 24.1 million, before deducting offering fees and expenses of approximately \$ 1.4 million. The offering closed on April 5, 2024. Until we can generate a sufficient amount of revenue from our products, if ever, we expect to finance future cash needs through public or private equity offerings, debt financings or corporate collaborations and licensing arrangements. Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available, we may be required to delay, reduce the scope of or eliminate one or more of our research or development programs or our commercialization efforts or it may become impossible for us to remain in operation. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to our technologies or applications or grant licenses on terms that may not be favorable to us. We may seek to access the public or private capital markets whenever conditions are favorable, even if we do not have an immediate need for additional capital at that time. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Our consolidated financial statements do not include adjustments to the amounts and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern. Our ability to continue as a going concern depends on our ability to raise additional capital through the sale of equity or debt securities to

support our future operations. The following table summarizes our cash flows for the periods indicated (in thousands):

Year Ended December 31, 2023	2022	Net cash used in operating activities
2023	2022	Net cash used in operating activities
26,177	24,902	Net cash provided by / (used in) investing activities
(64)	15,724	Net cash provided by financing activities
21,600	2,262	Net decrease in cash and cash equivalents
(4,641)	(6,916)	Operating Activities

During the year ended December 31, 2023, we used cash of \$ 26.2 million in operating activities, as compared to \$ 24.9 million used in operating activities during the year ended December 31, 2022. The \$ 26.2 million used in operating activities during the year ended December 31, 2023 was primarily attributable to our net loss of \$ 29.3 million and changes in our operating assets and liabilities totaling \$ 0.3 million. These items were offset by non-cash items, including stock-based compensation of \$ 3.0 million, non-cash lease expense of \$ 0.2 million, and depreciation and amortization of \$ 0.2 million. The \$ 24.9 million used in operating activities during the year ended December 31, 2022 was primarily attributable to our net loss of \$ 30.3 million and changes in our operating assets and liabilities totaling \$ 2.1 million. These items were offset by non-cash items, including stock-based compensation of \$ 3.1 million, depreciation of \$ 0.1 million and accretion of discount on short-term investments of \$ 0.1 million.

Investing Activities During the year ended December 31, 2023 we used cash of \$ 64,000 in investing activities, consisting of purchases of property and equipment. During the year ended December 31, 2022 we were provided cash of \$ 15.7 million in investing activities, consisting of \$ 15.8 million in maturities of short-term investments and offset by \$ 0.1 million for the purchase of office and laboratory equipment.

Financing Activities During the year ended December 31, 2023, we were provided cash of \$ 21.6 million which included net proceeds of \$ 6.7 million, \$ 8.1 million and \$ 3.6 million from the issuance of equity securities in public offerings in February 2023, June 2023 and November 2023, respectively, net proceeds of \$ 3.2 million from the issuance of common stock through the ATM equity offering program. During the year ended December 31, 2022, we were provided cash of \$ 2.3 million from financing activities, comprised of \$ 2.3 million from the issuance of common stock.

Funding Requirements We anticipate that, excluding non-recurring items, we will continue to generate annual losses for the foreseeable future as we continue the commercialization and further development of our Evic Ring and other products in development. We will require additional capital to fund our operations, to complete our ongoing and planned clinical studies, to commercialize our products, to continue investing in and to further develop our general infrastructure, and such funding may not be available to us on acceptable terms or at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may be required to delay, limit, reduce the scope of, or terminate one or more of our clinical studies, research and development programs, or our future commercialization efforts. Our future funding requirements will depend on many factors, including the following:

- the success of our commercialization of the Evic Ring;
- the scope, rate of progress, results and cost of our product development and clinical testing;
- the cost of manufacturing our products in development and any products that we may develop in the future;
- the number and characteristics of the potential products that we pursue;
- the cost, timing, and outcomes of regulatory approvals; and
- the potential that our common stock will be delisted by Nasdaq in the event we fail to regain compliance in a timely manner with the minimum bid price requirement.

We expect to satisfy future cash needs through existing capital balances, through some combination of public or private equity offerings, debt financings, licensing arrangements, and other marketing and distribution arrangements. Please see "Risk Factors—Risks Related to Our Business." Contractual Obligations Material contractual obligations arising in the normal course of business primarily consist of operating leases and financing leases. See Note 10 to the consolidated financial statements for amounts outstanding for operating leases and financing leases on December 31, 2023. Off-Balance Sheet Transactions At December 31, 2023, We did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements. Non-cancelable Obligations We did not have any non-cancelable contractual commitments as of December 31, 2023. Item 7A. Quantitative and Qualitative Disclosures About Market Risk Item 8. Financial Statements and Supplementary Data. INDEX TO CONSOLIDATED FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm (Moss Adams LLP, San Francisco, California, PCAOB ID: 659) F-2 Consolidated Balance Sheets at December 31, 2023 and 2022 F-3 Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2023 and 2022 F-4 Consolidated Statements of Stockholders' Equity for the years ended December 31, 2023 and 2022 F-5 Consolidated Statements of Cash Flows for the years ended December 31, 2023 and 2022 F-6 Notes to the Consolidated Financial Statements F-7 F-1 Report of Independent Registered Public Accounting Firm To the Shareholders and the Board of Directors of Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Movano Inc. (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023 and 2022, and the consolidated results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Basis for Opinion These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U. S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures to respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. /s/ Moss Adams LLP April 16, 2024 We have served as the Company's auditor since 2019. Movano Inc. Year Ended December 31, 2023 2022 ASSETS Current assets: Cash and cash equivalents \$ 6,118 \$ 10,759 Payroll tax credit, current portion 450 379 Vendor deposits 399 103 Inventory 1,114 — Prepaid expenses and other current assets 442 405 Total current assets 8,523 11,646 Property and equipment, net 342 443 Payroll tax credit, noncurrent portion 169 667 Other assets 387 487 Total assets \$ 9,421 \$ 13,243 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable \$ 3,118 \$ 557 Deferred revenue 1,252 — Other current liabilities 1,529 4,421 Total current liabilities 5,899 4,978 Noncurrent liabilities: Early exercised stock option liability 23 136 Other noncurrent liabilities 50 214 Total noncurrent liabilities 73 350 Total liabilities 5,972 5,328 Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, \$ 0.0001 par value, 5,000,000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 — Common stock, \$ 0.0001 par value, 150,000,000 shares authorized at December 31, 2023 and 75,000,000 at December 31, 2022; 55,848,272 and 33,659,460 shares issued and outstanding at December 31, 2023 and 2022, respectively 6 3 Additional paid-in capital 127,823 103,009 Accumulated deficit (124,380) (95,097) Total stockholders' equity 3,449 7,915 Total liabilities and stockholders' equity \$ 9,421 \$ 13,243 See accompanying notes to consolidated financial statements. Year Ended December 31, 2023 2022 OPERATING EXPENSES: Research and development \$ 16,893 \$ 18,994 Sales, general and administrative 12,797 11,468 Total operating expenses 29,690 30,462 Loss from operations (29,690) (30,462) Other income (expense), net: Interest and other income, net 407 133 Other income (expense), net 407 133 Net loss and comprehensive loss \$ (29,283) \$ (30,329) Net loss per share, basic and diluted \$ (0.63) \$ (0.92) Weighted average shares used in computing net loss per share, basic and diluted 46,195,403 33,025,721 (In thousands, except share data) Additional Accumulated Other Total Common Stock Paid-In Comprehensive Accumulated Stockholders' Shares Amount Capital Loss Deficit Equity Balance at December 31, 2021 32,772,060 \$ 3,97,506 \$ (11) \$ (64,768) \$ 32,730 Stock-based compensation 3,096 — 3,096 Issuance of common stock, net of issuance costs 810,400 — 2,231 — 2,231 Issuance of common stock upon exercise of options 77,000 — 31 — 31 Vesting of early exercised stock options — 145 — 145 Other comprehensive loss — 11 — 11 Net loss — (30,329) (30,329) Balance at December 31, 2022 33,659,460 \$ 3,103,009 \$ — \$ (95,097) \$ 7,915 Stock-based compensation — 2,980 — 2,980 Issuance of common stock upon February 2023 public offering, net of issuance costs 5,340,600 15,179 — 5,180 Issuance of warrants upon February 2023 public offering — 1,473 — 1,473 Issuance of common stock upon June 2023 public offering, net of issuance costs 9,200,000 18,065 — 8,066 Issuance of common stock upon November 2023 public offering, net of issuance costs 4,870,600 13,568 — 3,569 Issuance of common stock 2,531,757 — 3,203 — 3,203 Issuance of common stock upon exercise of options 245,855 — 109 — 109 Issuance of common stock warrant — 124 — 124 Vesting of early exercised stock options — 113 — 113 Net loss — (29,283) (29,283) Balance at December 31, 2023 55,848,272 \$ 6,127,823 \$ — \$ (124,380) \$ 3,449 Year Ended December 31, 2023 2022 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss \$ (29,283) \$ (30,329) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 158 147 Stock-based compensation 2,980 3,096 Noncash lease expense 224 (13) Accretion of discount on short-term investments — 103 Loss on disposal of property and equipment 13 44 Changes in operating assets and liabilities: Payroll tax credit 427 (250) Inventory (1,114) — Prepaid expenses, vendor deposits and other current assets (209) 788 Other assets (41) (50) Accounts payable 2,555 246 Deferred revenue 1,252 — Other current and noncurrent liabilities (3,139) 1,316 Net cash used in operating activities (26,177) (24,902) CASH FLOWS FROM

INVESTING ACTIVITIES: Purchases of property and equipment (64) (105) Maturities of short-term investments — 15, 829 Net cash provided by (used in) investing activities (64) 15, 724 CASH FLOWS FROM FINANCING ACTIVITIES: Issuance of common stock and warrants upon February 2023 public offering, net of issuance costs 6, 653 — Issuance of common stock upon June 2023 public offering, net of issuance costs 8, 066 — Issuance of common stock upon November 2023 public offering, net of issuance costs 3, 569 — Issuance of common stock, net of issuance costs 3, 203 2, 231 Issuance of common stock upon exercise of stock options 109 31 Net cash provided by financing activities 21, 600 2, 262 Net decrease in cash and cash equivalents (4, 641) (6, 916) Cash and cash equivalents at beginning of period 10, 759 17, 675 Cash and cash equivalents at end of period \$ 6, 118 \$ 10, 759 NONCASH INVESTING AND FINANCING ACTIVITIES: Vesting of common stock issued upon early exercise \$ 113 \$ 145 Warrants issued upon February 2023 public offering \$ 1, 473 \$ — Issuance of common stock warrant \$ 124 \$ — Property and equipment purchases in other current liabilities \$ — \$ 19 Right of use asset recorded for equipment finance lease \$ 50 \$ — Notes to Consolidated Financial Statements Note 1 — Business Organization, Nature of Operations Movano Inc., dba Movano Health (the “Company”, “Movano”, “Movano Health”, “we”, “us” or “our”), was incorporated in Delaware on January 30, 2018 as Maestro Sensors Inc. and changed its name to Movano Inc. on August 3, 2018. The Company is in the development stage and is developing a platform to deliver purpose-driven healthcare solutions at the intersection of medical and consumer devices. Movano is on a mission to make medical grade data more accessible and actionable for all. The Company’s solutions are being developed to provide vital health information, including heart rate, heart rate variability (“HRV”), sleep, respiration rate, temperature, SpO2, steps, and calories as well as glucose and blood pressure data, in a variety of form factors to meet individual style needs and give users actionable feedback to improve their quality of life. On April 28, 2021, the Company established Movano Ireland Limited, organized under the laws of Ireland, as a wholly owned subsidiary of the Company. Operations and activity at the wholly owned subsidiary were not significant for the years ended December 31, 2023 and 2022, respectively. Since inception, the Company has engaged in only limited research and development of product candidates and underlying technology and the commercialization of the Company’s first proposed commercial product, the Evie Ring. As of December 31, 2023, the Company had not yet completed the development of its product and had not yet recorded any revenues. On February 6, 2023, the Company completed a \$ 7.5 million underwritten public offering of 5,340,600 shares of its common stock and warrants to purchase up to 2,670,300 shares of common stock, including the full exercise of the underwriter’s overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of \$ 1.57. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock and accompanying warrant was \$ 1.40. The net proceeds from the offering were approximately \$ 6.7 million (See Note 7). On June 15, 2023, the Company completed a \$ 9.2 million underwritten public offering of 9,200,000 shares of its common stock, including the full exercise of the underwriter’s overallotment option. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock was \$ 1.00. The net proceeds from the offering were approximately \$ 8.1 million (See Note 7). On November 17, 2023, the Company completed a \$ 4.1 million underwritten public offering of 4,870,600 shares of its common stock, including the full exercise of the underwriter’s overallotment option. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock was \$ 0.85. The net proceeds from the offering were approximately \$ 3.6 million. (See Note 7). The Company has incurred losses from operations and has generated negative cash flows from operating activities since inception. The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Through December 31, 2023, the Company has relied primarily on the proceeds from equity offerings to finance its operations. Through December 31, 2023, the Company has received gross proceeds of approximately \$ 5.6 million from an at-the-market issuance program, and an aggregate offering price amount of approximately \$ 44.4 million remains available to be issued. (See Note 7.) The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products. The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has an accumulated deficit of \$ 124.4 million as of December 31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. The Company’s existence is dependent upon management’s ability to obtain additional funding sources. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its product or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. Note 2 — Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying consolidated financial statements in accordance with GAAP. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include the fair value of stock options and warrants and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the Chief Executive Officer. Cash, Cash Equivalents and Short-term Investments The Company invests its excess cash primarily in money market funds, commercial paper and short-term debt securities. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. As of December 31, 2023 and 2022, the Company did not hold any short-term investments. Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. Substantially all cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts and institutional money market funds. The amounts deposited in the money market accounts exceed federally insured limits. Further, the Company has amounts in excess of federally insured limits as of December 31, 2023 at one financial institution that totaled approximately \$ 2.5 million. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials. The Company has no financial instruments with off-balance sheet risk of loss. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were primarily comprised of prepaid expenses and other current receivables. Inventory, which consists of raw materials, is stated at the lower of cost or net-realizable value. Cost comprises purchase price and incidental expenses incurred in bringing the inventory to its present location and condition. Cost is computed using the weighted-average cost method. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimate net realized value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. F-8 Software Development Costs Costs related to software development are included in research and development expense until the point that technological feasibility is reached, which, for the Company’s product, will be shortly before the product is released to manufacturing. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated lives of the product. During the years ended December 31, 2023 and 2022, no development costs were capitalized. Impairment of Long-Lived Assets The Company reviews the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. Revenue The Company generates revenue from the sale of Evie Rings, portable chargers and charging cables, ring sizers, and mobile applications. As part of the purchase, customers also receive customer support and future unspecified software updates. These items are collectively referred to as the Evie Ring Elements. During the year ended December 31, 2023 the Company began taking pre-orders for the Evie Ring Elements but did not deliver any Evie Rings as of December 31, 2023. The Company recognizes revenue when control is transferred to the customer in an amount that reflects the net consideration to which the Company expects to be entitled. In determining how revenue should be recognized, a five-step process is used which includes identifying the contract, identifying the distinct performance obligations, determining the transaction price, allocating the transaction price to each distinct performance obligation, and determining the timing of revenue recognition for each distinct performance obligation. For each contract, the Company considers the obligation to transfer the Evie Ring Elements, each of which are distinct, to be separate performance obligations. Transaction price for the Evie Ring Elements reflects the net consideration to which the Company expects to be entitled. Transaction price is based on the sales price. The Company includes an estimate of variable consideration in the calculation of the transaction price at the time of sale. Variable consideration primarily includes product return provisions. The Company classifies the product return provisions as liabilities in the consolidated balance sheet. The adequacy of the estimates for the variable consideration is reviewed at each reporting date. If the actual amount of consideration differs from the estimates, the Company would adjust

the estimates, impacting revenue in the period that such variances become known. If any of the judgments were to change, this change could cause a material increase or decrease in the amount of revenue reported in a particular period. The Company allocates the transaction price to each performance obligation using the relative standalone selling price ("SSP") for each distinct good or service in the contract. The Company offers limited rights of return for a 30-day right of return, whereby customers may return the Evie Ring Elements. The Company records revenue from the sales of the Evie Ring Elements upon transfer of control of the distinct Evie Ring Elements to the customer. The Company typically determines transfer of control for the Evie Ring Elements based on when the product is delivered, or when our customer has obtained the significant risks and reward of ownership. The future unspecified software updates and customer support that the Company offers are separate performance obligations, and revenue is recognized over time on a ratable basis. F-9 The sales of the Evie Ring Elements include an assurance warranty. Contract balances represent amounts presented in the consolidated balance sheets when the Company has transferred goods or services to the customer, or the customer has paid consideration to the Company under the contract. Payment is made by the customer upon the purchase of the Evie Ring Elements, and the Company has no accounts receivable at December 31, 2023, 2022, or 2021, respectively. The Company records deferred revenue when cash payments from customers are received prior to the transfer of control or satisfaction of the related performance obligations. A contract asset is recorded when inventory has shipped but control has not yet transferred to the customer. Deferred revenue at December 31, 2023 was \$ 1.3 million and is included in current liabilities on the consolidated balance sheets. There was no deferred revenue at December 31, 2022 or 2021, respectively. There were no contract assets at December 31, 2023, 2022, or 2021, respectively. The Company collects sales taxes at the point of sale and remits the taxes to the proper state authorities. Sales tax is excluded from the measurement of the transaction price. Shipping and handling costs are incurred as part of fulfillment activities with customers and are included as a component of cost of revenue. Advertising Costs The Company expenses advertising costs as they are incurred. Advertising expenses were \$ 1.35 million for the year ending December 31, 2023 and were not significant for the year ended December 31, 2022. These costs are included in "Sales, general and administrative expenses" in the accompanying consolidated statements of operations and comprehensive loss. Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities on the Company's behalf. The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company's common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur. F-10 The Company assesses each warrant to determine if it meets the characteristics of a liability or a derivative, and if the warrant does meet the characteristics of a liability or a derivative, the warrant is measured at fair value. The derivative liabilities are remeasured at each period end, on a recurring basis, to the estimated fair value with the changes in fair value reflected as current period income or loss until the warrant is exercised, extinguished, or expires. If the warrant does not meet the characteristics of a liability or a derivative, the warrant is classified as equity and recorded at its fair value on the date of issuance. The fair value of warrants is estimated using appropriate pricing models based on the nature and characteristics of the underlying warrants. Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company's repurchase right lapses. Leases The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition, and if the lease is classified as an operating lease or finance lease in accordance with Accounting Standards Codification 842, Leases ("ASC 842"). Operating and finance leases are included in right-of-use ("ROU") assets and lease liabilities in the Company's consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. For leases which do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considers relevant banking rates and the Company's costs incurred for underwriting discounts and financing costs in its previous equity financings. The ROU assets also include any lease payments made and exclude lease incentives. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately. Short-term leases of twelve months or less, if any, are expensed as incurred which approximates the straight-line basis due to the short-term nature of the leases. The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the years ended December 31, 2023 and 2022. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company's tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share since the effects of potentially dilutive securities are antidilutive. F-11 Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being recognized separately from their host contracts. The pronouncement also revises the derivatives scope exception for contracts in an entity's own equity and improves the consistency of earnings per share calculations as that relates to convertible instruments. The Company has early-adopted this pronouncement as of January 1, 2023 using the modified retrospective method of transition. The adoption did not have any impact on the Company's consolidated financials. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2024. Adoption of the provisions should be on a prospective basis. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption. Note 3—FAIR VALUE MEASUREMENTS Financial assets and liabilities are recorded at fair value. The Company uses a three-level hierarchy, which prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those financial instruments. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3—Significant unobservable inputs that cannot be corroborated by market data. The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company's Level 1 financial assets are money market funds whose fair values are based on quoted market prices. The carrying amounts of prepaid expenses and other current assets, payroll tax credit, vendor deposits, inventory, accounts payable, deferred revenue, and other current liabilities approximate fair value due to the short-term nature of these instruments. F-12 The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in thousands). December 31, 2023 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds \$ 4,393 \$ 4,393 \$ — \$ — Total cash equivalents \$ 4,393 \$ 4,393 \$ — \$ — December 31, 2022 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds \$ 8,171 \$ 8,171 \$ — \$ — Total cash equivalents \$ 8,171 \$ 8,171 \$ — \$ — Note 4—CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of the following (in thousands): December 31, 2023 2022 Cash and cash equivalents: Cash \$ 1,725 \$ 2,588 Money market funds \$ 4,393 \$ 8,171 Total cash and cash equivalents \$ 6,118 \$ 10,759 Note 5—Property and Equipment Property and equipment, net, as of December 31, 2023 and 2022, consisted of the

following (in thousands): December 31, 2023-2022 Office equipment and furniture \$ 266 \$ 263 Software 144 131 Test equipment 310 277 Total property and equipment 720 671 Less: accumulated depreciation (378) (228) Total property and equipment, net \$ 342 \$ 443 Total depreciation and amortization expense related to property and equipment for the years ended December 31, 2023 and 2022 was approximately \$ 158, 000 and \$ 147, 000, respectively. F-13 Note 6—Other Current Liabilities Other current liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands): December 31, 2023-2022 Accrued compensation \$ 299 \$ 2, 708 Accrued research and development 461 536 Accrued vacation 246 243 Accrued severance payment 5 517 Lease liabilities, current portion 217 212 Other 301 205 Total other current liabilities \$ 1, 529 \$ 4, 421 Note 7—Common Stock As of December 31, 2023 and 2022, the Company was authorized to issue 150, 000, 000 and 75, 000, 000 shares of common stock, respectively, with a par value of \$ 0. 0001 per share. As of December 31, 2023 and 2022, 55, 848, 272 and 33, 659, 460 shares were outstanding, respectively. January and February 2023 Issuance of Common Stock On February 6, 2023, the Company completed a \$ 7. 5 million underwritten public offering of 5, 340, 600 shares of its common stock and warrants to purchase up to 2, 670, 300 shares of common stock, including the full exercise of the underwriter’s overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of \$ 1. 57 (See Note 8). The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock and accompanying warrant was \$ 1. 40. The Company used the relative fair value method to allocate the gross proceeds of approximately \$ 7. 5 million between the common stock and the warrants. The net proceeds from the offering were approximately \$ 6. 7 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately \$ 0. 8 million. The Company recorded the fair value of the warrants of \$ 1. 5 million as additional costs of issuance, thus reducing the net proceeds of \$ 6. 7 million to \$ 5. 2 million as presented in the accompanying consolidated statements of stockholders’ equity. June 2023 Issuance of Common Stock On June 15, 2023, the Company completed a \$ 9. 2 million underwritten public offering of 9, 200, 000 shares of its common stock, including the full exercise of the underwriter’s overallotment option. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock was \$ 1. 00. The net proceeds from the offering were approximately \$ 8. 1 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately \$ 1. 1 million. November 2023 Issuance of Common Stock On November 17, 2023, the Company completed a \$ 4. 1 million underwritten public offering of 4, 870, 600 shares of its common stock, including the full exercise of the underwriter’s overallotment option. The public offering price per share, before the underwriters’ discount and commissions, for each share of common stock was \$ 0. 85. The net proceeds from the offering were approximately \$ 3. 6 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately \$ 0. 5 million. F-14 At the Market Issuance of Common Stock On August 15, 2022, the Company entered into an At-the-Market Issuance Agreement (the “Issuance Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”). Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company’s common stock having an aggregate offering price of up to \$ 50, 000, 000 (the “Shares”). Sales of Shares, if any, may be made by means of transactions that are deemed to be “at the market” as defined in Rule 415 under the Securities Act, including block trades, ordinary brokers’ transactions on the Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices or by any other method permitted by law. Under the terms of the Issuance Agreement, the Company may also sell Shares to the Sales Agent as principal for its own accounts at a price to be agreed upon at the time of sale. Any sale of Shares to the Sales Agent as principal would be pursuant to the terms of a separate terms agreement between the Company and the Sales Agent. The Company has no obligation to sell any of the Shares under the Issuance Agreement and may at any time suspend solicitation and offers under the Issuance Agreement. During the year ended December 31, 2023, the Company issued and sold an aggregate of 2, 531, 757 shares of common stock through the Issuance Agreement at a weighted-average public offering price of \$ 1. 31 per share and received net proceeds of \$ 3. 2 million. During the year ended December 31, 2022, the Company issued and sold an aggregate of 810, 400 shares of common stock through the Issuance Agreement at a weighted-average public offering price of \$ 2. 84 per share and received net proceeds of \$ 2. 2 million. As of December 31, 2023, an aggregate offering price amount of approximately \$ 44. 4 million remains available to be issued and sold under the Issuance Agreement. Common Stock Reserved for Future Issuance Common stock reserved for future issuance at December 31, 2023 is summarized as follows: December 31, 2023 Warrants to purchase common stock 4, 757, 256 Stock options outstanding 7, 448, 412 Stock options available for future grants 5, 936, 692 Total 18, 142, 360 F-15 The Exercise Notice (Early Exercise) Agreement states that the Company has the option to repurchase all or a portion of the unvested shares in the event of the separation of the holder from service to the Company. The shares continue to vest in accordance with the original vesting schedules of the former option agreements. During the years ended December 31, 2023 and 2022, no shares of common stock were issued upon the early exercise of common stock options. As of December 31, 2023 and 2022, the Company has recorded a repurchase liability for approximately \$ 23, 000 and \$ 136, 000 for 43, 751 and 266, 147 shares that remain unvested, respectively. The weighted average remaining vesting period at December 31, 2023 is less than one year. Note 8—Common Stock Warrants Preferred A Placement Warrants During February 2023, September 2023 and November 2023, the Board approved the amendment of 293, 042 Preferred A Placement Warrants to extend the maturity to April 2024. The Company assessed the accounting treatment of the warrant amendments and determined that the amendments are modifications for accounting purposes. The Company determined the modifications had an insignificant impact on the consolidated financial statements. January and February 2023 Warrants In connection with the sale of common stock during January and February 2023, the Company issued warrants to purchase shares of common stock to common stockholders and to the underwriter for 2, 322, 000 and 348, 300 shares, respectively. The warrants are exercisable upon issuance at \$ 1. 57 per share and have a 5-year term. Beginning with the one-year anniversary of the issuance dates, the Company may redeem the outstanding warrants in whole or in part at \$ 0. 25 per warrant at any time after the date on which (i) the closing price of the Company’s common stock has equaled or exceeded \$ 4. 87 for ten consecutive trading days and (ii) the daily trading volume of the Company’s common stock has exceeded 100, 000 shares on each of ten trading days. A minimum of thirty days prior written notice of redemption is required. F-16 August 2023 Warrants In August 2023, the Company issued warrants to purchase 201, 613 shares of common stock to a third-party professional services firm. The following is a summary of the Company’s warrant activity for the years ended December 31, 2023 and 2022: Warrant Issuance Issuance Exercise Price Outstanding, December 31, 2022 Granted Exercised Canceled/Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2023 Expiration Preferred A Placement Warrants March and April 2018 and August 2019 \$ 1. 40 293, 042 293, 042 April 2024 Preferred A Lead Investor Warrants February 2021 \$ 0. 0125 52, 500 (52, 500) March 2023 Preferred B Placement Warrants April 2019 \$ 2. 10 463, 798 463, 798 April 2024 Convertible Notes Placement Warrants August 2020 \$ 2. 57 171, 830 171, 830 August 2025 Underwriter Warrants March 2021 \$ 6. 00 956, 973 956, 973 March 2026 January 2023 warrants January 2023 \$ 1. 57 2, 322, 000 2, 322, 000 January 2028 February 2023 warrants February 2023 \$ 1. 57 348, 000 348, 000 February 2028 August 2023 warrants August 2023 \$ 1. 24 201, 613 201, 613 August 2028 1, 938, 143 2, 871, 613 (52, 500) 4, 757, 256 Warrant Issuance Issuance Exercise Price Outstanding, December 31, 2021 Granted Exercised Canceled/Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2022 Expiration Preferred A Placement Warrants March and April 2018 and August 2019 \$ 1. 40 293, 042 293, 042 March and April 2023 Preferred A Lead Investor Warrants February 2021 \$ 0. 0125 52, 500 52, 500 March 2023 Preferred B Placement Warrants April 2019 \$ 2. 10 463, 798 463, 798 April 2024 Convertible Notes Placement Warrants August 2020 \$ 2. 57 171, 830 171, 830 August 2025 Underwriter Warrants March 2021 \$ 6. 00 956, 973 956, 973 March 2026 1, 938, 143 1, 938, 143 F-17 Warrants Classified as Equity All of the Company’s outstanding warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance. The warrants are classified as an equity instrument because they are both indexed to the Company’s own stock and classified in stockholders’ equity. The fair value of the warrants was estimated using a Monte Carlo simulation approach. Subsequent changes in fair value are not recognized as long as the warrants continue to be classified in equity. The fair value at the issuance date was calculated utilizing the Monte Carlo univariate pricing model, which simulates a distribution of stock prices for Movano throughout the remaining performance period, based on certain assumptions of stock price behavior. The following major assumptions were used: (1) the stock price of the Company follows a geometric Brownian motion; (2) the daily stock price for the Company is simulated until the termination date using a volatility estimate based on term-match daily stock price returns of peer companies; and (3) the valuation is done under a risk-neutral framework using the term-matched zero-coupon risk-free interest rate. The major inputs were: Issuance Date Dividend yield — % Expected volatility 60. 83 % Risk-free interest rate 3. 54 % Expected life 5. 0 years Valuation date common stock price \$ 1. 39 The fair value of the January and February 2023 warrants at the issuance date is approximately \$ 1. 5 million. The warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance using the Black-Scholes option pricing model with the following assumptions. The amount of the fair value was insignificant. F-18 Note 9—Stock-based Compensation 2019 Equity Incentive Plan Effective as of November 18, 2019, the Company adopted the 2019 Omnibus Incentive Plan (“2019 Plan”) administered by the Board. The 2019 Plan provides for the issuance of incentive stock options, non-statutory stock options, and restricted stock awards, for the purchase of up to a total of 4, 000, 000 shares of the Company’s common stock to employees, directors, and consultants and replaces the previous plan. The Board or a committee of the Board has the authority to determine the amount, type, and terms of each award. The options granted under the 2019 Plan generally have a contractual term of ten years and a vesting term of four years with a one-year cliff. The exercise price for options granted under the 2019 Plan must generally be at least equal to 100 % of the fair value of the Company’s common stock at the date of grant, as determined by the Board. The incentive stock options granted under the 2019 Plan to 10 % or greater stockholders must have an exercise price at least equal to 110 % of the fair value of the Company’s common stock at the date of grant, as determined by the Board, and have a contractual term of ten years. As of March 25, 2021, the 2019 Plan was amended and restated as a result of which the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan was increased from 6, 000, 000

to 7,400,000. On April 15, 2022, the Board approved, subject to stockholder approval, an increase in the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan from 7,400,000 to 13,400,000. On June 21, 2022, the stockholders approved this increase. As of December 31, 2023, the Company had 4,455,442 shares available for future grant under the 2019 Plan. 2021 Employment Inducement Plan On September 15, 2021 the Company's Board adopted the Movano, Inc. 2021 Inducement Award Plan (the "Inducement Plan") without stockholder approval pursuant to Rule 5635 (c) (4) of the Nasdaq Stock Market LLC listing rules ("Rule 5635 (c) (4)"). In accordance with Rule 5635 (c) (4), awards under the Inducement Plan may only be made to a newly hired employee who has not previously been a member of the Company's Board, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee's entering into employment with the Company or its subsidiary. An aggregate of 2,000,000 shares of the Company's common stock have been reserved for issuance under the Inducement Plan. As of December 31, 2023, the Company had 1,481,250 shares available for future grant under the Inducement Plan. Stock Options Stock option activity for the years ended December 31, 2023 and 2022 was as follows (in thousands, except share, per share, and remaining life data):

	Number of Options	Weighted Average Exercise Price	Weighted Average Remaining Life	Intrinsic Value	Outstanding at
December 31, 2021	5,592	\$ 2.29	8.6 years	\$ 9,912	Granted 2,525,000
December 31, 2022	6,919	\$ 2.34	8.2 years	\$ 2,034	Granted 1,610,375
December 31, 2023	7,448	\$ 2.13	7.1 years	\$ 726	Granted 4,760,030

Exercised (77,000) \$ 0.40 Canceled (1,120,243) \$ 3.15 Outstanding at December 31, 2022 6,919,894 \$ 2.34 8.2 years \$ 2,034 Granted 1,610,375 \$ 1.23 Exercised (245,855) \$ 0.44 Canceled (836,002) \$ 2.66 Outstanding at December 31, 2023 7,448,412 \$ 2.13 7.1 years \$ 726 Exercised as of December 31, 2023 4,760,030 \$ 2.02 6.5 years \$ 712 Vested and expected to vest as of December 31, 2023 7,448,412 \$ 2.13 7.1 years \$ 726 F-19 The weighted-average grant date fair value of options granted during the years ended December 31, 2023, and 2022 was \$ 0.74 and \$ 1.48 per share, respectively. During the years ended December 31, 2023 and 2022, 245,855 and 77,000 options were exercised for proceeds of \$ 109,000 and \$ 31,000, respectively. The fair value of the 2,008,712 and 1,707,794 options that vested during the years ended December 31, 2023 and 2022 was approximately \$ 3.1 million and \$ 3.2 million, respectively. On June 21, 2022, the Company granted an award of 100,000 options to the Company's founder at an exercise price of \$ 5.00 per share. The options were to vest in full upon the shipment of 20,000 product units on or before June 30, 2023. For the years ended December 31, 2023 and 2022, the Company has not recognized stock compensation expense of approximately \$ 0.1 million related to this award as the successful achievement of the performance conditions is not yet probable, and the award has been cancelled. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of the stock options was estimated using the following weighted average assumptions for the years ended December 31, 2023 and 2022:

Year Ended	December 31, 2023	2022
Dividend yield	— %	— %
Expected volatility	61.55 %	61.97 %
Risk-free interest rate	3.77 %	2.78 %
Expected life	5.98 years	6.07 years
Dividend Rate	—	—

The expected dividend rate was assumed to be zero, as the Company had not previously paid dividends on common stock and has no current plans to do so. Expected Volatility—The expected volatility was derived from the historical stock volatilities of several public companies within the Company's industry that the Company considers to be comparable to the business over a period equivalent to the expected term of the stock option grants. Risk-Free Interest Rate—The risk-free interest rate is based on the interest yield in effect at the date of grant for zero coupon U.S. Treasury notes with maturities approximately equal to the option's expected term. Expected Term—The expected term represents the period that the Company's stock options are expected to be outstanding. The expected term of option grants that are considered to be "plain vanilla" are determined using the simplified method. The simplified method deems the term to be the average of the time-to-vesting and the contractual life of the options. For other option grants not considered to be "plain vanilla," the Company determined the expected term to be the contractual life of the options. Forfeiture Rate—The Company recognizes forfeitures when they occur. The Company has recorded stock-based compensation expense for the years ended December 31, 2023 and 2022 related to the issuance of stock option awards to employees and nonemployees in the consolidated statement of operations and comprehensive loss as follows:

Year Ended	December 31, 2023	2022
Research and development	\$ 940	\$ 1,169
Sales, general and administrative	\$ 2,040	\$ 1,927
Total	\$ 2,980	\$ 3,096

As of December 31, 2023, unamortized compensation expense related to unvested stock options was approximately \$ 4.0 million, which is expected to be recognized over a weighted average period of 2.0 years. F-20 Note 10—Commitments and Contingencies Operating Leases As of December 31, 2023, the Company had one office lease for the Corporate headquarters and laboratory space. On April 15, 2021, the Company executed a lease agreement for corporate office space. The lease commenced on May 14, 2021 when the improvements were completed by the landlord and the Company had access to the facility. The lease term is 40 months, and the base rent is approximately \$ 14,000 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid a security deposit of approximately \$ 47,000. On April 22, 2022, the Company executed an amendment to its corporate office lease agreement for additional corporate office space. The lease term for the additional space is 36 months from the expansion commencement date of June 23, 2022. The base rent is approximately \$ 5,100 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid an additional security deposit of approximately \$ 5,500. Finance Lease On November 22, 2023, the Company executed a lease agreement for equipment. The lease term is 36 months, and the monthly payment is approximately \$ 1,700. The lease agreement has a bargain purchase option at the end of the lease term. The balances of the lease related accounts as of December 31, 2023 and 2022 are as follows (in thousands):

As of	December 31, 2023	2022
Operating and Finance leases	\$ 203	\$ 212
Right-of-use assets	\$ 247	\$ 389
Operating lease liabilities—Short-term	\$ 203	\$ 212
Operating lease liabilities—Long-term	\$ 15	\$ 214
Finance lease liabilities—Short-term	\$ 14	\$ —
Finance lease liabilities—Long-term	\$ 35	\$ —

Right-of-use assets are included in other assets on the consolidated balance sheets. The short-term lease liabilities and the long-term lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, on the consolidated balance sheets. The components of lease expense and supplemental cash flow information as of and for the years ended December 31, 2023 and 2022 are as follows (in thousands):

Year Ended	December 31, 2023	2022																																																													
Lease Cost	\$ 261	\$ 226																																																													
Operating lease cost	\$ 261	\$ 226																																																													
Other Information: Cash paid for amounts included in the measurement of lease liabilities for the year ended	\$ 243	\$ 209																																																													
Weighted average remaining lease term—operating leases (in years)	0.90	0.97																																																													
Average discount rate—operating leases	10.00 %	10.00 %																																																													
Weighted average remaining lease term—financing leases (in years)	3.00	—																																																													
Average discount rate—financing leases	15.08 %	—																																																													
F-21 Future minimum lease payments are as follows as of December 31, 2023 (in thousands):	2024	224																																																													
2025	48	2026																																																													
18	Total lease payments	290																																																													
Less: Interest	(23)	Total lease liabilities																																																													
\$ 267	From time to time, the Company may become involved in various litigation and administrative proceedings relating to claims arising from its operations in the normal course of business. Management is not currently aware of any matters that may have a material adverse impact on the Company's business, financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. No amounts associated with such indemnifications have been recorded as of December 31, 2023. The Company did not have any non-cancelable contractual commitments as of December 31, 2023. F-22 NOTE 11—INCOME TAXES For the years ended December 31, 2023 and 2022, no U.S. provision or benefit for income taxes was recorded and an insignificant amount of Ireland provision for income taxes for the years ended December 31, 2023 and 2022 was offset by credits. The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal rate as follows: <table border="1"> <thead> <tr> <th>Year Ended</th> <th>December 31, 2023</th> <th>2022</th> </tr> </thead> <tbody> <tr> <td>U.S. federal provision (benefit)</td> <td>21 %</td> <td>21 %</td> </tr> <tr> <td>Valuation allowance</td> <td>(23) %</td> <td>(22) %</td> </tr> <tr> <td>Changes in stock-based compensation</td> <td>(1) %</td> <td>(1) %</td> </tr> <tr> <td>Other</td> <td>3 %</td> <td>1 %</td> </tr> <tr> <td>Effective tax rate</td> <td>—</td> <td>—</td> </tr> </tbody> </table> <p>Significant components of the Company's deferred tax assets and liabilities as of December 31, 2023 and 2022 are as follows (in thousands):</p> <table border="1"> <thead> <tr> <th>2023</th> <th>2022</th> </tr> </thead> <tbody> <tr> <td>Gross deferred tax assets:</td> <td>Net operating loss carryforwards</td> <td>\$ 13,396</td> </tr> <tr> <td>\$ 10,040</td> <td>Research and development credit carryforward</td> <td>2,703</td> </tr> <tr> <td>1,434</td> <td>Capitalized research and development</td> <td>5,964</td> </tr> <tr> <td>3,444</td> <td>Accrued bonus</td> <td>41</td> </tr> <tr> <td>464</td> <td>Stock-based compensation</td> <td>999</td> </tr> <tr> <td>590</td> <td>Lease liabilities</td> <td>56</td> </tr> <tr> <td>90</td> <td>Other</td> <td>12</td> </tr> <tr> <td>53</td> <td>Total gross deferred tax assets</td> <td>23,171</td> </tr> <tr> <td>16,115</td> <td>Less valuation allowance</td> <td>(23,101)</td> </tr> <tr> <td>(16,024)</td> <td>Total net deferred tax assets</td> <td>70</td> </tr> <tr> <td>91</td> <td>Deferred tax liabilities: Property and equipment</td> <td>(18)</td> </tr> <tr> <td>(9)</td> <td>Right-of-use assets</td> <td>(52)</td> </tr> <tr> <td>(82)</td> <td>Total deferred tax liabilities</td> <td>70</td> </tr> <tr> <td>(91)</td> <td>Net deferred tax assets</td> <td>\$ —</td> </tr> </tbody> </table> <p>F-23 During 2023 and 2022, the Company has maintained a valuation allowance against the net deferred tax assets due to the uncertainty surrounding the realization of those assets. The Company periodically evaluates the recoverability of the deferred tax assets and, when it is determined to be more likely than not that the deferred tax assets are realizable, the valuation allowance is reduced. The valuation allowance increased by approximately \$ 7.1 million and \$ 7.0 million during the years ended December 31, 2023 and 2022, respectively. As of December 31, 2023 and 2022, the Company has federal net operating loss carryforwards of approximately \$ 64.8 million and \$ 48.5 million, respectively, all of which do not expire. The net operating loss carryforwards may be available to offset future taxable income for income tax purposes. As of December 31, 2023 and 2022, the Company has federal research and development ("R & D") credit carryforwards of approximately \$ 2.4 million and \$ 1.2 million, respectively. The federal R & D credits begin to expire in 2039. As of December 31, 2023 and 2022, the Company has California R & D credit carryforwards of approximately \$ 1.5 million and \$ 1.1 million, respectively. The California R & D credits do not expire. In accordance with the 2017 Tax Act, research and experimental, or R & E, expenses under IRC Section 174 are required to be capitalized beginning in 2022. R & E expenses are required to be amortized over a period of five years for domestic expenses and 15 years for foreign expenses. The Internal Revenue Code imposes limitations on a corporation's ability to utilize net operating loss ("NOL") and credit carryovers if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over</p>	Year Ended	December 31, 2023	2022	U.S. federal provision (benefit)	21 %	21 %	Valuation allowance	(23) %	(22) %	Changes in stock-based compensation	(1) %	(1) %	Other	3 %	1 %	Effective tax rate	—	—	2023	2022	Gross deferred tax assets:	Net operating loss carryforwards	\$ 13,396	\$ 10,040	Research and development credit carryforward	2,703	1,434	Capitalized research and development	5,964	3,444	Accrued bonus	41	464	Stock-based compensation	999	590	Lease liabilities	56	90	Other	12	53	Total gross deferred tax assets	23,171	16,115	Less valuation allowance	(23,101)	(16,024)	Total net deferred tax assets	70	91	Deferred tax liabilities: Property and equipment	(18)	(9)	Right-of-use assets	(52)	(82)	Total deferred tax liabilities	70	(91)	Net deferred tax assets	\$ —
Year Ended	December 31, 2023	2022																																																													
U.S. federal provision (benefit)	21 %	21 %																																																													
Valuation allowance	(23) %	(22) %																																																													
Changes in stock-based compensation	(1) %	(1) %																																																													
Other	3 %	1 %																																																													
Effective tax rate	—	—																																																													
2023	2022																																																														
Gross deferred tax assets:	Net operating loss carryforwards	\$ 13,396																																																													
\$ 10,040	Research and development credit carryforward	2,703																																																													
1,434	Capitalized research and development	5,964																																																													
3,444	Accrued bonus	41																																																													
464	Stock-based compensation	999																																																													
590	Lease liabilities	56																																																													
90	Other	12																																																													
53	Total gross deferred tax assets	23,171																																																													
16,115	Less valuation allowance	(23,101)																																																													
(16,024)	Total net deferred tax assets	70																																																													
91	Deferred tax liabilities: Property and equipment	(18)																																																													
(9)	Right-of-use assets	(52)																																																													
(82)	Total deferred tax liabilities	70																																																													
(91)	Net deferred tax assets	\$ —																																																													

a three-year period. If an ownership change has occurred, or were to occur, utilization of the Company's NOLs and credit carryovers could be restricted. The Company accounts for uncertainty in income taxes pursuant to the relevant authoritative guidance. The guidance clarified the recognition of tax positions taken, or expected to be taken, on a tax return. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. No liability related to uncertain tax positions is recorded in the financial statements. The Company files income tax returns in the U. S. federal jurisdiction and in various states. For jurisdictions in which tax filings have been filed, all tax years remain open for examination by the federal and various state authorities for three and four years, respectively, from the date of utilization of any net operating losses or credits. Total gross unrecognized tax benefit liabilities as of December 31, 2023 and 2022 were approximately \$ 1.2 million and \$ 0.8 million, respectively, related to Federal and California R & D credits. As of December 31, 2023 and 2022, the Company had no unrecognized tax benefits, which, if recognized would affect the Company's effective tax rate due to the full valuation allowance. The Company's policy is to classify interest and penalties related to unrecognized tax benefits as part of the income tax provision (benefit) in the statements of operations. The Company had no accrued interest and penalties related to unrecognized tax benefits as of December 31, 2023. The following is a rollforward of the total gross unrecognized tax benefits for the years ended December 31, 2023 and 2022 (in thousands):

Year Ended December 31, 2023	2022
Beginning Balance	\$ 811
Gross Increases	\$ 487
Tax Position in Current Period	423
Ending Balance	\$ 1,234

F-24 Note 12 — NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following table computes the computation of the basic and diluted net loss per share attributable to common stockholders during the years ended December 31, 2023 and 2022 is as follows (in thousands, except share and per share data):

Year Ended December 31, 2023	2022
Numerator: Net loss	\$(29,283)
Denominator: Weighted average shares used in computing net loss per share, basic and diluted	46,195
Net loss per share, basic and diluted	\$(0.63)

§ (0.92) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2023 and 2022 because including them would have been antidilutive are as follows: Year Ended December 31, 2023 2022 Shares subject to options to purchase common stock 7,448, 412 6,769, 694 Shares subject to warrants to purchase common stock 4,757, 256 1,938, 143 Total 12,205, 668 8,707, 837 For the year ended December 31, 2022, performance based option awards for 150, 200 shares of common stock, respectively, are not included in the table above or considered in the calculation of diluted earnings per share until the performance conditions of the option award are considered probable by the Company. Note 13 — Subsequent Events On April 2, 2024, the Company entered into a securities purchase agreement for the private placement of an aggregate of 45,252,517 units with each unit consisting of (1) one share of the Company's common stock or at the election of the purchaser a pre-funded warrant, and (2) one warrant to purchase one share of common stock. The purchase price paid for each Unit was \$ 0.533. Certain directors and officers participated and purchased 287,500 of the units at an offering price of \$ 0.565 per share. Pre-funded warrants totaling 3,149,028 shares were issued. Each pre-funded warrant has an exercise price equal to \$ 0.001 per share or calculated pursuant to the cashless exercise provision. The warrants were immediately exercisable on the date of issuance and do not expire. Warrants totaling 45,252,517 shares were issued. Each warrant that was issued to holders other than the Company's officers and directors has an exercise price equal to \$ 0.4071 per share or calculated pursuant to the cashless exercise provision. The warrants issued to the Company's officers and directors have an exercise price equal to \$ 0.44 or calculated pursuant to the cashless exercise provision. The warrants were exercisable immediately and expire on the fifth anniversary of the initial exercise date of the warrant. After April 4, 2025, the warrants may be redeemed in whole or in part at the option of the Company with at least thirty days' notice to the holder of the warrant, which notice may not be given before, but may be given at any time after the date on which (i) the closing price of the Company's common stock has equaled or exceeded \$ 5.00 for ten consecutive trading days and (ii) the daily trading volume of the common stock has exceeded 100,000 shares on each of such ten trading days. The redemption price is \$ 0.025 per share. The gross proceeds were approximately \$ 24.1 million, before deducting offering fees and expenses of approximately \$ 1.4 million. The offering closed on April 5, 2024. Common stock shares of 42,103,489 were issued. F-25 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. None. Item 9A. Controls and Procedures. Evaluation of Disclosure Controls and Procedures As of the end of the period covered by this report, management performed, with the participation of our principal executive and principal financial officers, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15 (e) and 15d-15 (e) of the Exchange Act. Our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC's forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosures. Based on the evaluation, our principal executive and principal financial officers concluded that, as of December 31, 2023, our disclosure controls and procedures were ineffective. As of December 31, 2023, we had a material weakness in our internal control over financial reporting, as described below. A "material weakness" is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the company's annual or interim consolidated financial statements will not be prevented or detected on a timely basis. Management has identified the following material weakness at December 31, 2023: ineffective design and operation of our financial close and reporting controls. Specifically, we did not design and maintain effective controls over certain account reviews and analyses and certain information technology general controls. The material weakness did not result in any identified misstatements to the consolidated financial statements and there were no changes in previously released financial results. Management's Report on Internal Control Over Financial Reporting Our management is responsible for establishing and maintaining effective internal control over financial reporting as defined in Rules 13a-15 (f) and 15d-15 (f) of the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance to the Company's management and board of directors regarding the reliability of our financial reporting for external purposes in accordance with accounting principles generally accepted in the United States of America. Because of its inherent limitations, internal control over financial reporting is not intended to provide absolute assurance that a misstatement of our consolidated financial statements would be prevented or detected. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Therefore, even those systems determined to be effective can only provide reasonable assurance with respect to financial statement preparation and presentation. Management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Management identified the following material weakness as of December 31, 2023: ineffective design and operation of our financial close and reporting controls. Specifically, we did not design and maintain effective controls over certain account reviews and analyses and certain information technology general controls. The material weakness did not result in any identified misstatements to the consolidated financial statements and there were no changes in previously released financial results. Because of this material weakness, management concluded that the Company's internal control over financial reporting was not effective as of December 31, 2023. This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for "emerging growth companies." Changes in Internal Control Over Financial Reporting There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15 (d) under the Exchange Act during the year ended December 31, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Item 9B. Other Information. Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. PART III Item 10. Directors, Executive Officers and Corporate Governance. The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2024 Annual Meeting of Stockholders or an amendment to this Form 10-K within 120 days after the end of the fiscal year ended December 31, 2023. Item 11. Executive Compensation Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters. The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2024 Annual Meeting of Stockholders or an amendment to this Form 10-K within 120 days after the end of the fiscal year ended December 31, 2023. Item 13. Certain Relationships and Related Transactions, and Director Independence The information required by this item is incorporated by reference from our definitive Proxy Statement to be filed with the SEC in connection with our 2024 Annual Meeting of Stockholders or an amendment to this Form 10-K within 120 days after the end of the fiscal year ended December 31, 2023. Item 14. Principal Accountant Fees and Services PART IV Item 15. Exhibits, Financial Statements and Schedules (a) List of documents filed as part of this report: 1. Financial Statements (see "Financial Statements and Supplementary Data" at Item 8 and incorporated herein by reference). 2. Financial Statement Schedules (Schedules to the Financial Statements have been omitted because the information required to be set forth therein is not applicable or is shown in the accompanying Financial Statements or notes thereto) 3. Exhibit Index (The exhibits required to be filed as a part of this Report are listed in the Exhibit Index). Incorporated by Reference Exhibit Number Exhibit Description Filed Herewith Form Exhibit Filing Date SEC File / Registration Number 3-1 Third Amended and Restated Certificate of Incorporation of the Registrant 8-K 3-1 March 25, 2021 001-40254-3-2 Certificate of Amendment to the Third Amended and Restated Certificate of Incorporation of the Registrant 8-K 3-1 June 21, 2023 001-40254-3-3 Amended and Restated Bylaws of the Registrant 8-K 3-2 March 25, 2021 001-40254-4-1 Specimen Certificate representing shares of common stock of the Registrant S-1/A 4-1 March 10, 2021 333-252671-4-2 Form of Underwriter Warrant S-1/A 4-2 March 10, 2021 333-252671-4-3 Form of Amended and Restated Warrant to Purchase Common Stock issued to the placement agent in the Registrant's 2018 private placement offering S-1 4-3 February 2, 2021 333-252671-4-4 Form of Amended and Restated Warrant to Purchase Common

Stock issued to the placement agent in the Registrant's 2019 private placement offering S-1 4. 4 February 2, 2021 333-252671 4. 5 Form of Warrant to Purchase Common Stock issued in 2020 S-1 4. 6 February 2, 2021 333-252671 4. 6 Description of Common Stock of the Registrant Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 10-K 4. 6 March 30, 2022 001-40254 4. 7 Form of Warrant to Purchase Common Stock 8-K 4. 1 January 31, 2023 001-40254 4. 8 Warrant Agent Agreement, dated January 31, 2023, by and between the Company and Pacific Stock Transfer Company 8-K 4. 2 January 31, 2023 001-40254 10. 1 Movano Inc. Amended and Restated 2019 Omnibus Incentive Plan † S-1 / A 10. 1 March 10, 2021 333-252671 10. 2 Form of Stock Option Award Agreement under 2019 Omnibus Incentive Plan † S-1 10. 2 February 2, 2021 333-252671 10. 3 Non-Employee Director Compensation Policy † 10-K 10. 3 March 30, 2022 001-40254 10. 4 Form of Indemnification Agreement by and between the Registrant and each of its directors and executive officers † S-1 10. 4 February 2, 2021 333-252671 10. 5 Offer Letter, dated November 29, 2019, by and between the Registrant and Michael Leabman † S-1 10. 5 February 2, 2021 333-252671 10. 6 Offer Letter, dated November 29, 2019, by and between the Registrant and J. Cogan † S-1 10. 7 February 2, 2021 333-252671 10. 7 Form of 2020 Note Purchase Agreement S-1 10. 16 February 2, 2021 333-252671 10. 8 Amended and Restated Lead Investor Agreement, dated August 27, 2020, between the Registrant and Maestro Venture Partners, LLC S-1 10. 17 February 2, 2021 333-252671 10. 9 Offer Letter, dated February 8, 2021, by and between the Registrant and John Mastrototaro † S-1 / A 10. 17 March 10, 2021 333-252671 10. 10 First Amendment to Employment Letter Agreement, dated February 10, 2021, by and between the Registrant and Michael Leabman † S-1 / A 10. 18 March 10, 2021 333-252671 10. 11 First Amendment to Employment Letter Agreement, dated February 10, 2021, by and between the Registrant and J. Cogan † S-1 / A 10. 20 March 10, 2021 333-252671 10. 12 Amendment No. 1 to Movano Inc. Amended and Restated Omnibus Incentive Plan (incorporated by reference to Exhibit 10.1 to the Company's Current Report on Form 8-K filed on June 22, 2022) † 8-K 10. 1 June 22, 2022 001-40254 10. 13 At the Market Issuance Agreement, dated August 15, 2022 by and between the Company, as issuer, and B. Riley Securities, Inc. as sale agent 10-Q 1. 1 August 15, 2022 001-40254 21. 1 Subsidiaries of the Company x 23. 1 Consent of Moss Adams, LLP x 24. 1 Power of Attorney (included on signature page) x 31. 1 Rule 13 (a)-14 (a) / 15 (d)-14 (a) Certification of Principal Executive Officer x 31. 2 Rule 13 (a)-14 (a) / 15 (d)-14 (a) Certification of Principal Financial and Accounting Officer x 32. 1 Certification Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith) x 97. 1 Incentive-Based Compensation Recovery Policy x 101. INS Inline XBRL Instance Document 101. SCH Inline XBRL Taxonomy Extension Schema Document. 101. CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101. DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101. LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101. PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). † Management contract or compensatory plan or arrangement Item 16. Form 10-K Summary SIGNATURES Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Movano, Inc. Dated: April 16, 2024 By: /s/ John Mastrototaro John Mastrototaro Chief Executive Officer (Principal Executive Officer) POWER OF ATTORNEY AND SIGNATURES We, the undersigned officers and directors of Movano, Inc., hereby severally constitute and appoint John Mastrototaro our true and lawful attorney, with full power to him to sign for us and in our names in the capacities indicated below, any amendments to this Annual Report on Form 10-K, and generally to do all things in our names and on our behalf in such capacities to enable Movano, Inc. to comply with the provisions of the Securities Exchange Act of 1934, as amended, and all the requirements of the Securities Exchange Commission. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Signatures Title Date /s/ John Mastrototaro Chief Executive Officer and Director April 16, 2024 John Mastrototaro (Principal Executive Officer) /s/ J. Cogan Chief Financial Officer April 16, 2024 J. Cogan (Principal Financial and Accounting Officer) /s/ Emily Wang Fairbairn Director April 16, 2024 Emily Wang Fairbairn /s/ Brian Cullinan Director April 16, 2024 Brian Cullinan /s/ Ruben Caballero Director April 16, 2024 Ruben Caballero /s/ Michael Leabman Director April 16, 2024 Michael Leabman /s/ Nan Kirsten Forte Director April 16, 2024 Nan Kirsten Forte 0. 63 0. 924619540346195403 0. 63 0. 92 false FY2023-01-01-2023-12-31 2023-06-30 2024-04-10 2023-12-31 2022-12-31 2022-01-01 2022-12-31 us-gaap: CommonStockMember2021-12-31 us-gaap: AdditionalPaidInCapitalMember2021-12-31 us-gaap: AccumulatedOtherComprehensiveIncomeMember2021-12-31 us-gaap: RetainedEarningsMember2021-12-31 2021-12-31 us-gaap: CommonStockMember2022-01-01 2022-12-31 us-gaap: AdditionalPaidInCapitalMember2022-01-01 2022-12-31 us-gaap: AccumulatedOtherComprehensiveIncomeMember2022-01-01 2022-12-31 us-gaap: RetainedEarningsMember2022-01-01 2022-12-31 us-gaap: CommonStockMember2022-12-31 us-gaap: AdditionalPaidInCapitalMember2022-12-31 us-gaap: AccumulatedOtherComprehensiveIncomeMember2022-12-31 us-gaap: RetainedEarningsMember2022-12-31 2022-12-31 us-gaap: CommonStockMember2023-01-01 2023-12-31 us-gaap: AdditionalPaidInCapitalMember2023-01-01 2023-12-31 us-gaap: AccumulatedOtherComprehensiveIncomeMember2023-01-01 2023-12-31 us-gaap: RetainedEarningsMember2023-01-01 2023-12-31 us-gaap: CommonStockMember2023-12-31 us-gaap: AdditionalPaidInCapitalMember2023-12-31 us-gaap: AccumulatedOtherComprehensiveIncomeMember2023-12-31 us-gaap: RetainedEarningsMember2023-12-31 2023-02-06 2023-02-06 move: WarrantsMember2023-02-06 2023-02-06 us-gaap: CommonStockMember2023-02-06 2023-06-15 2023-06-15 us-gaap: CommonStockMember2023-06-15 2023-11-17 2023-11-01 2023-11-17 us-gaap: CommonStockMember2023-11-17 move: LiquidityAndGoingConcernMember2023-12-31 us-gaap: MoneyMarketFundsMember2023-12-31 us-gaap: FairValueInputsLevel1Member us-gaap: MoneyMarketFundsMember2023-12-31 us-gaap: FairValueInputsLevel2Member us-gaap: MoneyMarketFundsMember2023-12-31 us-gaap: FairValueInputsLevel3Member us-gaap: MoneyMarketFundsMember2023-12-31 us-gaap: FairValueInputsLevel1Member2023-12-31 us-gaap: FairValueInputsLevel2Member2023-12-31 us-gaap: FairValueInputsLevel3Member2023-12-31 us-gaap: MoneyMarketFundsMember2022-12-31 us-gaap: FairValueInputsLevel1Member us-gaap: MoneyMarketFundsMember2022-12-31 us-gaap: FairValueInputsLevel2Member us-gaap: MoneyMarketFundsMember2022-12-31 us-gaap: FairValueInputsLevel3Member us-gaap: MoneyMarketFundsMember2022-12-31 us-gaap: FairValueInputsLevel1Member2022-12-31 us-gaap: FairValueInputsLevel2Member2022-12-31 us-gaap: FairValueInputsLevel3Member2022-12-31 us-gaap: CashMember2023-12-31 us-gaap: CashMember2022-12-31 us-gaap: MoneyMarketFundsMember2023-12-31 us-gaap: MoneyMarketFundsMember2022-12-31 us-gaap: OfficeEquipmentMember2023-12-31 us-gaap: OfficeEquipmentMember2022-12-31 us-gaap: SoftwareDevelopmentMember2023-12-31 us-gaap: SoftwareDevelopmentMember2022-12-31 us-gaap: EquipmentMember2023-12-31 us-gaap: EquipmentMember2022-12-31 us-gaap: WarrantMember2023-02-06 2023-02-06 2023-02-06 srt: MaximumMember2023-02-06 2023-02-06 srt: MinimumMember2023-02-06 2023-02-06 2023-06-15 us-gaap: OverAllotmentOptionMember2023-11-17 2022-08-15 2022-08-15 move: PreferredAPlacementWarrantsMember2019-08-28 move: PreferredAPlacementWarrantsMember2018-03-14 move: PreferredAPlacementWarrantsMember2018-04-23 2019-04-16 move: PreferredBPlacementWarrantsMember2019-04-16 move: PreferredAPlacementWarrantsMember2023-01-01 2023-12-31 move: PreferredAPlacementWarrantsMember2023-12-31 move: PreferredALeadInvestorWarrantsMember2021-02-28 2021-02-28 move: JanuaryAndFebruary2023WarrantsMember2023-01-31 2023-01-31 move: JanuaryAndFebruary2023WarrantsMember2023-02-28 2023-02-28 move: PreferredAPlacementWarrantsMember2023-01-01 2023-12-31 move: PreferredAPlacementWarrantsMember2023-12-31 move: PreferredAPlacementWarrantsMember2022-12-31 move: PreferredALeadInvestorWarrantsMember2023-01-01 2023-12-31 move: PreferredALeadInvestorWarrantsMember2023-12-31 move: PreferredBPlacementWarrantsMember2023-01-01 2023-12-31 move: PreferredBPlacementWarrantsMember2023-12-31 move: PreferredBPlacementWarrantsMember2022-12-31 move: ConvertibleNotesPlacementWarrantsMember2023-01-01 2023-12-31 move: ConvertibleNotesPlacementWarrantsMember2023-12-31 move: UnderwriterWarrantsMember2023-01-01 2023-12-31 move: UnderwriterWarrantsMember2023-12-31 move: UnderwriterWarrantsMember2022-12-31 move: January2023WarrantsMember2023-01-01 2023-12-31 move: January2023WarrantsMember2023-12-31 move: January2023WarrantsMember2022-12-31 move: February2023WarrantsMember2023-01-01 2023-12-31 move: February2023WarrantsMember2023-12-31 move: February2023WarrantsMember2022-12-31 move: August2023WarrantsMember2023-01-01 2023-12-31 move: August2023WarrantsMember2023-12-31 move: August2023WarrantsMember2022-12-31 move: PreferredAPlacementWarrantsMember2022-01-01 2022-12-31 move: PreferredAPlacementWarrantsMember2021-12-31 move: PreferredALeadInvestorWarrantsMember2022-01-01 2022-12-31 move: PreferredALeadInvestorWarrantsMember2021-12-31 move: PreferredBPlacementWarrantsMember2022-01-01 2022-12-31 move: PreferredBPlacementWarrantsMember2021-12-31 move: PreferredBPlacementWarrantsMember2022-01-01 2022-12-31 move: ConvertibleNotesPlacementWarrantsMember2021-12-31 move: UnderwriterWarrantsMember2022-01-01 2022-12-31 move: UnderwriterWarrantsMember2021-12-31 move: EquityIncentivePlanMember2019-11-18 2019-11-18 srt: MinimumMember move: EquityIncentivePlanMember2019-11-18 2019-11-18 srt: MaximumMember2021-03-25 2021-03-25 srt: MinimumMember2022-04-15 2022-04-15 srt: MaximumMember2022-04-15 2022-04-15 move: EquityIncentivePlanMember2023-12-31 move: InducementPlanMember2021-09-15 2021-09-15 move: InducementPlanMember2023-12-31 us-gaap: StockOptionMember2023-01-01 2023-12-31 us-gaap: StockOptionMember2022-01-01 2022-12-31 us-gaap: StockOptionMember2021-12-31 2021-12-31 us-gaap: StockOptionMember2022-01-01 2022-12-31 us-gaap: StockOptionMember2022-12-31 us-gaap: StockOptionMember2023-01-01 2023-12-31 us-gaap: StockOptionMember2023-12-31 us-gaap: ResearchAndDevelopmentExpenseMember2023-01-01 2023-12-31 us-gaap: ResearchAndDevelopmentExpenseMember2022-01-01 2022-12-31 us-gaap: SellingGeneralAndAdministrativeExpensesMember2023-01-01 2023-12-31 us-gaap: SellingGeneralAndAdministrativeExpensesMember2022-01-01 2022-12-31 2021-04-15 2021-04-15 2022-04-22 2022-04-22

2022-04-222023-11-222023-11-222023-11-22srt: ScenarioForecastMember-us-gaap: PrivatePlacementMember2024-04-02srt: ScenarioForecastMember-us-gaap: CommonStockMember2024-04-02srt: ScenarioForecastMember-us-gaap: WarrantMember2024-04-02srt: ScenarioForecastMember-us-gaap: PrivatePlacementMember2024-04-022024-04-02us-gaap: WarrantMember2023-12-31srt: ScenarioForecastMember-srt: DirectorMember2024-04-02srt: ScenarioForecastMember-us-gaap: PrivatePlacementMember2024-04-052024-04-052023-10-012023-12-31iso4217: USDxbrli: sharesxbrli: pureExhibit 21.1 SUBSIDIARIES OF MOVANO INC. Registrant's consolidated subsidiaries are shown below, together with the state or jurisdiction of organization of each subsidiary and the percentage of voting securities that Registrant owns in each subsidiary. Name of Subsidiary Jurisdiction of Incorporation or Organization Percent of Outstanding Voting Securities Owned as of December 31, 2023 Movano Ireland Limited Ireland % Exhibit 23.1 Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-264116) and Form S-8 (No. 333-258938 and No. 333-266876) of Movano Inc. (the "Company"), of our report dated April 16, 2024, relating to the consolidated financial statements of the Company (which report expresses an unqualified opinion and includes an explanatory paragraph relating to a going concern uncertainty) appearing in this Annual Report on Form 10-K of the Company for the year ended December 31, 2023. Exhibit 31.1 CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, John Mastrototaro, certify that: 1. I have reviewed this Annual Report on Form 10-K of Movano Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrant's other certifying officer (s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 (e) and 15d-15 (e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5. The registrant's other certifying officer (s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date: April 16, 2024 /s/ John Mastrototaro Name: John Mastrototaro Title: Chief Executive Officer (Principal Executive Officer) Exhibit 31.2 CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER I, J. Cogan, certify that: /s/ J. Cogan Name: J. Cogan Title: Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Annual Report on Form 10-K of Movano Inc. (the "Company") for the year ended December 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), we, John Mastrototaro, Chief Executive Officer of the Company, and J. Cogan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, to our knowledge that: (1) The Report fully complies with the requirements of section 13 (a) or 15 (d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. A signed original of this written statement required by Section 906 has been provided to Movano Inc. and will be retained by Movano Inc. and furnished to the Securities and Exchange Commission or its staff upon request. /s/ John Mastrototaro /s/ J. Cogan Name: John Mastrototaro Name: J. Cogan Title: Chief Executive Officer Title: Chief Financial Officer (Principal Executive Officer) (Principal Financial Officer and Principal Accounting Officer) Date: April 16, 2024 Date: April 16, 2024 Exhibit 97.1 Incentive-Based Compensation Recovery Policy 1. Policy Purpose. The purpose of this Movano Inc. (the "Company") Incentive-Based Compensation Recovery Policy (this "Policy") is to enable the Company to recover Erroneously Awarded Compensation in the event that the Company is required to prepare an Accounting Restatement. This Policy is intended to comply with the requirements set forth in Listing Rule 5608 of the corporate governance rules of The NASDAQ Stock Market (the "Listing Rule") and shall be construed and interpreted in accordance with such intent. Unless otherwise defined in this Policy, capitalized terms shall have the meaning ascribed to such terms in Section 7. This Policy shall become effective on December 1, 2023. Where the context requires, reference to the Company shall include the Company's subsidiaries and affiliates (as determined by the Committee in its discretion). 2. Policy Administration. This Policy shall be administered by the Compensation Committee of the Board (the "Committee") unless the Board determines to administer this Policy itself. The Committee has full and final authority to make all determinations under this Policy. All determinations and decisions made by the Committee pursuant to the provisions of this Policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and Executive Officers. Any action or inaction by the Committee with respect to an Executive Officer under this Policy in no way limits the Committee's actions or decisions not to act with respect to any other Executive Officer under this Policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Executive Officer other than as set forth in this Policy. 3. Policy Application. This Policy applies to all Incentive-Based Compensation received by a person: (a) on or after October 2, 2023, and beginning service as an Executive Officer; (b) who served as an Executive Officer at any time during the performance period for such Incentive-Based Compensation; (c) while the Company had a class of securities listed on a national securities exchange or a national securities association; and (d) during the three completed fiscal years immediately preceding the Accounting Restatement Date. In addition to such last three completed fiscal years, the immediately preceding clause (d) includes any transition period that results from a change in the Company's fiscal year within or immediately following such three completed fiscal years; provided, however, that a transition period between the last day of the Company's previous fiscal year end and the first day of its new fiscal year that comprises a period of nine to twelve months shall be deemed a completed fiscal year. For purposes of this Section 3, Incentive-Based Compensation is deemed received in the Company's fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of the Incentive-Based Compensation occurs after the end of that period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition. 4. Policy Recovery Requirement. In the event of an Accounting Restatement, the Company must recover, reasonably promptly, Erroneously Awarded Compensation, in amounts determined pursuant to this Policy. The Company's obligation to recover Erroneously Awarded Compensation is not dependent on if or when the Company files restated financial statements. Recovery under this Policy with respect to an Executive Officer shall not require the finding of any misconduct by such Executive Officer or such Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the Company shall satisfy the Company's obligations under this Policy to recover any amount owed from any applicable Executive Officer by exercising its sole and absolute discretion in how to accomplish such recovery. The Company's recovery obligation pursuant to this Section 4 shall not apply to the extent that the Committee, or in the absence of the Committee, a majority of the independent directors serving on the Board, determines that such recovery would be impracticable and: a. The direct expense paid to a third party to assist in enforcing this Policy would exceed the amount to be recovered. Before concluding that it would be impracticable to recover any amount of Erroneously Awarded Compensation based on expense of enforcement, the Company must make a reasonable attempt to recover such Erroneously Awarded Compensation; document such reasonable attempt (s) to recover, and provide that documentation to the Stock Exchange; or b. Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the registrant, to fail to meet the requirements of Section 401 (a) (13) or Section 411 (a) of the Code. 5. Policy Prohibition on Indemnification and Insurance Reimbursement. The Company is prohibited from indemnifying any Executive Officer or former Executive Officer against the loss of Erroneously Awarded Compensation. Further, the Company is prohibited from paying or reimbursing an Executive Officer for purchasing insurance to cover any such loss. 6. Required Policy-Related Filings. The Company shall file all disclosures with respect to this Policy in accordance with the requirements of the Federal securities laws, including disclosures required by U.S. Securities and Exchange Commission filings. 7. Definitions. a. "Accounting Restatement" means an accounting restatement due to the material noncompliance of the Company with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. b. "Accounting Restatement Date" means the earlier to occur of: (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the

Board action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement; and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement. c. "Board" means the board of directors of the Company. d. "Code" means the U. S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation. e. "Erroneously Awarded Compensation" means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes incurred or paid by the relevant Executive Officer; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement: (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received; and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to the Stock Exchange. f. "Executive Officer" means the Company's president, principal financial officer, principal accounting officer (or if there is no such accounting officer, the controller), any vice-president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), any other officer who performs a policy-making function, or any other person who performs similar policy-making functions for the Company. An executive officer of the Company's parent or subsidiary is deemed an "Executive Officer" if the executive officer performs such policy-making functions for the Company. For the avoidance of doubt, "Executive Officer" includes, but is not limited to, any person identified as an executive officer pursuant to Item 401 (b) of Regulation S-K under the U. S. Securities Act of 1933, as amended. g. "Financial Reporting Measure" means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company's financial statements, and any measure that is derived wholly or in part from such measure; provided, however, that a Financial Reporting Measure is not required to be presented within the Company's financial statements or included in a filing with the U. S. Securities and Exchange Commission to qualify as a "Financial Reporting Measure." For purposes of this Policy, "Financial Reporting Measure" includes, but is not limited to, stock price and total stockholder return. h. "Incentive-Based Compensation" means any compensation that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. i. "Stock Exchange" means the national stock exchange on which the Company's common stock is listed. 8. Acknowledgement. Each Executive Officer shall sign and return to the Company, within 30 calendar days following the later of (i) the effective date of this Policy first set forth above or (ii) the date the individual becomes an Executive Officer, the Acknowledgement Form attached hereto as Exhibit A, pursuant to which the Executive Officer agrees to be bound by, and to comply with, the terms and conditions of this Policy. 9. Committee Indemnification. Any members of the Committee, and any other members of the Board who assist in the administration of this Policy, shall not be personally liable for any action, determination or interpretation made with respect to this Policy and shall be fully indemnified by the Company to the fullest extent under applicable law and Company policy with respect to any such action, determination or interpretation. The foregoing sentence shall not limit any other rights to indemnification of the members of the Board under applicable law or Company policy. 10. Severability. The provisions in this Policy are intended to be applied to the fullest extent of the law. To the extent that any provision of this Policy is found to be unenforceable or invalid under any applicable law, such provision shall be applied to the maximum extent permitted, and shall automatically be deemed amended in a manner consistent with its objectives to the extent necessary to conform to any limitations required under applicable law. 11. Amendment; Termination. The Board may amend this Policy from time to time in its sole and absolute discretion and shall amend this Policy as it deems necessary to reflect the Listing Rule. The Board may terminate this Policy at any time. 12. Other Recovery Obligations; General Rights. To the extent that the application of this Policy would provide for recovery of Incentive-Based Compensation that the Company recovers pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, the amount the relevant Executive Officer has already reimbursed the Company will be credited to the required recovery under this Policy. This Policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law. To the maximum extent permitted under the Listing Rule, this Policy shall be administered in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. 13. Successors. This Policy is binding and enforceable against all Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives. 14. Governing Law; Venue. This Policy and all rights and obligations hereunder are governed by and construed in accordance with the internal laws of the State of Delaware, excluding any choice of law rules or principles that may direct the application of the laws of another jurisdiction. All actions arising out of or relating to this Policy shall be heard and determined exclusively in the Court of Chancery of the State of Delaware or, if such court declines to exercise jurisdiction or if subject matter jurisdiction over the matter that is the subject of any such legal action or proceeding is vested exclusively in the U. S. Federal courts, the U. S. District Court for the District of Delaware. EXHIBIT A Acknowledgement Form By signing below, the undersigned acknowledges and confirms that the undersigned has received and reviewed a copy of the Movano Inc. (the "Company") Incentive-Based Compensation Recovery Policy (the "Policy"). By signing this Acknowledgement Form, the undersigned acknowledges and agrees that the undersigned is and will continue to be subject to the Policy and that the Policy will apply both during and after the undersigned's employment with the Company. Further, by signing below, the undersigned agrees to abide by the terms of the Policy; including, without limitation, by returning any Erroneously Awarded Compensation (as defined in the Policy) to the Company to the extent required by, and in a manner consistent with, the Policy. Further, by signing below, the undersigned agrees that the terms of the Policy shall govern in the event of any inconsistency between the Policy and the terms of any employment agreement to which the undersigned is a party, or the terms of any compensation plan, program or agreement under which any compensation has been granted, awarded, earned or paid. EXECUTIVE OFFICER Signature Print Name Date v3. 24. 1. u1Cover USD (\$) 12 Months Ended Dec. 31, 2023 Apr. 10, 2024 Jun. 30, 2023 Document Information [Line Items] Document Type 10-K Document Annual Report true Document Transition Report false Document Financial Statement Error Correction [Flag] false Entity Interactive Data Current Yes ICFR Auditor Attestation Flag false Amendment Flag false Document Period End Date Dec. 31, 2023 Document Fiscal Year Focus Document Fiscal Period Focus FY Documents Incorporated by Reference [Text Block] The registrant intends to file a definitive proxy statement pursuant to Regulation 14A or an amendment to this Form 10-K within 120 days after the end of the fiscal year ended December 31, 2023. Portions of such proxy statement or amendment to this Form 10-K are incorporated by reference into Part III of this Form 10-K. Entity Information [Line Items] Entity Registrant Name MOVANO INC. Entity Central Index Key Entity File Number 001-40254 Entity Tax Identification Number 82-4233771 Entity Incorporation, State or Country Code DE Current Fiscal Year End Date -12-31 Entity Well-known Seasoned Issuer No Entity Voluntary Filers No Entity Current Reporting Status Yes Entity Shell Company false Entity Filer Category Non-accelerated Filer Entity Small Business true Entity Emerging Growth Company true Entity Ex-Transition Period false Entity Public Float \$ 52,910,782 Entity Contact Personnel [Line Items] Entity Address, Address Line One 6800 Koll Center Parkway Entity Address, City or Town Pleasanton Entity Address, State or Province CA Entity Address, Postal Zip Code Entity Phone Fax Numbers [Line Items] City Area Code (415) Local Phone Number 651-3172 Entity Listings [Line Items] Title of 12 (b) Security Common Stock, par value \$ 0.0001 per share Trading Symbol MOVE Security Exchange Name NASDAQ Entity Common Stock, Shares Outstanding 98,225,068 X-Definition Boolean flag that is true when the XBRL content amends previously-filed or accepted submission. References No definition available. Details Name: dei_AmendmentFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-Definition Area code of city References No definition available. Details Name: dei_CityAreaCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-Definition End date of current fiscal year in the format-MM-DD. References No definition available. Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: durationX-Definition Boolean flag that is true only for a form used as an annual report. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310 Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f Details Name: dei_DocumentAnnualReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-Definition Indicates whether any of the financial statement period in the filing include a restatement due to error correction. References Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 402-Subsection w Reference 2: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 10-K-Number 249-Section 310 Reference 3: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 20-F-Number 249-Section 220-Subsection f Reference 4: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Form 40-F-Number 249-Section 240-Subsection f Details Name: dei_DocumentFinStmtErrorCorrectionFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-Definition Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. References No definition available. Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: durationX-Definition This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. References No definition available. Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_Data Type: xbrli:gYearItemType Balance Type: na Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References No definition available.

Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. ReferencesNo definition available. Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_Data Type: xbrli:dateItemType Balance Type: na Period Type: durationX-DefinitionBoolean flag that is true only for a form used as a transition report. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForms10-K,10-Q,20-F-Number240-Section13-Subsectiona-1> Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other". ReferencesNo definition available. Details Name: dei_DocumentType Namespace Prefix: dei_Data Type: dei:submissionTypeItemType Balance Type: na Period Type: durationX-DefinitionDocuments incorporated by reference. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-23> Details Name: dei_DocumentsIncorporatedByReferenceTextBlock Namespace Prefix: dei_Data Type: dtr:types:textBlockItemType Balance Type: na Period Type: durationX-DefinitionAddress Line 1 such as Attn, Building Name, Street Name ReferencesNo definition available. Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionName of the City or Town ReferencesNo definition available. Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionCode for the postal or zip code ReferencesNo definition available. Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionName of the state or province. ReferencesNo definition available. Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: durationX-DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_Data Type: dei:centerIndexKeyItemType Balance Type: na Period Type: durationX-DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. ReferencesNo definition available. Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityContactPersonnelLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesNo definition available. Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-DefinitionIndicate if registrant meets the emerging growth company criteria. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionIndicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameSecuritiesAct-Number7A-SectionB-Subsection2> Details Name: dei_EntityExTransitionPeriod Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. ReferencesNo definition available. Details Name: dei_EntityFileNumber Namespace Prefix: dei_Data Type: dei:fileNumberItemType Balance Type: na Period Type: durationX-DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityFilerCategory Namespace Prefix: dei_Data Type: dei:filerCategoryItemType Balance Type: na Period Type: durationX-DefinitionTwo-character EDGAR code representing the state or country of incorporation. ReferencesNo definition available. Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: durationX-DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityInformationLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameRegulationS-T-Number232-Section405-DetailsName> dei_EntityInteractiveDataCurrent Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityListingsLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: dei_EntityPhoneFaxNumbersLineItems Namespace Prefix: dei_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter. ReferencesNo definition available. Details Name: dei_EntityPublicFloat Namespace Prefix: dei_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityRegistrantName Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityShellCompany Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionIndicates that the company is a Smaller Reporting Company (SRC). ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_Data Type: dei:employerIdItemType Balance Type: na Period Type: durationX-DefinitionIndicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15 (d) of the Act. ReferencesNo definition available. Details Name: dei_EntityVoluntaryFilers Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-DefinitionIndicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameSecuritiesAct-Number230-Section405> Details Name: dei_EntityWellKnownSeasonedIssuer Namespace Prefix: dei_Data Type: dei:yesNoItemType Balance Type: na Period Type: durationX-ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm10-K-Number249-Section310> Reference 2: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm20-F-Number249-Section220-Subsectionf> Reference 3: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameForm40-F-Number249-Section240-Subsectionf> Details Name: dei_IefrAuditorAttestationFlag Namespace Prefix: dei_Data Type: xbrli:booleanItemType Balance Type: na Period Type: durationX-DefinitionLocal phone number for entity. ReferencesNo definition available. Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: durationX-DefinitionTitle of a 12 (b) registered security. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectionb-2> Details Name: dei_Security12bTitle Namespace Prefix: dei_Data Type: dei:securityTitleItemType Balance Type: na Period Type: durationX-DefinitionName of the Exchange on which a security is registered. ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-PublisherSEC-NameExchangeAct-Number240-Section12-Subsectiond1-1> Details Name: dei_SecurityExchangeName Namespace Prefix: dei_Data Type: dei:

edgarExchangeCodeItem Type: Balance Type: na Period Type: durationX- DefinitionTrading symbol of an instrument as listed on an exchange. ReferencesNo definition available. Details Name: dei_TradingSymbol Namespace Prefix: dei_Data Type: dei_tradingSymbolItem Type: Balance Type: na Period Type: durationAudit Information 12 Months Ended Dec. 31, 2023 Auditor [Table] Auditor Name Moss Adams LLP Auditor Firm ID Auditor Location San Francisco, California X- Definition PCAOB issued Audit Firm Identifier ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-10-K-Number-249-Section-310Reference-2>: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-20-F-Number-249-Section-220-Subsection-fReference-3>: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-40-F-Number-249-Section-240-Subsection-fDetailsName>: dei_AuditorFirmId Namespace Prefix: dei_Data Type: dei_nonemptySequenceNumberItem Type: Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-10-K-Number-249-Section-310Reference-2>: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-20-F-Number-249-Section-220-Subsection-fReference-3>: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-40-F-Number-249-Section-240-Subsection-fDetailsName>: dei_AuditorLocation Namespace Prefix: dei_Data Type: dei_internationalNameItem Type: Balance Type: na Period Type: durationX- ReferencesReference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-10-K-Number-249-Section-310Reference-2>: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-20-F-Number-249-Section-220-Subsection-fReference-3>: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-40-F-Number-249-Section-240-Subsection-fDetailsName>: dei_AuditorTable Namespace Prefix: dei_Data Type: xbrli:stringItem Type: Balance Type: na Period Type: durationConsolidated Balance Sheets-USD (\$) \$ in Thousands Dec. 31, 2023 Dec. 31, 2022Current assets: Cash and cash equivalents \$ 6, 118 \$ 10, 759Payroll tax credit, current portionVendor depositsInventory 1, 114Prepaid expenses and other current assetsTotal current assets 8, 523 11, 646Property and equipment, netPayroll tax credit, noncurrent portionOther assetsTotal assets 9, 421 13, 243Current liabilities: Accounts payable 3, 118Deferred revenue 1, 252 Other current liabilities 1, 529 4, 421Total current liabilities 5, 899 4, 978Noncurrent liabilities: Early exercised stock option liabilityOther noncurrent liabilitiesTotal noncurrent liabilitiesTotal liabilities 5, 972 5, 328Commitments and contingencies (Note 10) Stockholders' equity: Preferred stock, \$ 0.0001 par value, 5, 000, 000 shares authorized at December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022 Common stock, \$ 0.0001 par value, 150, 000, 000 shares authorized at December 31, 2023 and 75, 000, 000 at December 31, 2022; 55, 848, 272 and 33, 659, 466 shares issued and outstanding at December 31, 2023 and 2022, respectivelyAdditional paid-in capital 127, 823 103, 009Accumulated deficit (124, 380) (95, 097) Total stockholders' equity 3, 449 7, 915Total liabilities and stockholders' equity \$ 9, 421 \$ 13, 243X- DefinitionEarly exercised stock option liability. ReferencesNo definition available. Details Name: move_EarlyExercisedStockOptionLiability Namespace Prefix: move_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: instantX- DefinitionThe amount of payroll tax credit current portion. ReferencesNo definition available. Details Name: move_PayrollTaxCreditCurrentPortion Namespace Prefix: move_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: instantX- DefinitionPayroll tax credit, noncurrent portion. ReferencesNo definition available. Details Name: move_PayrollTaxCreditNoncurrentPortion Namespace Prefix: move_Data Type: xbrli:monetaryItem Type: Balance Type: debit Period Type: instantX- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference-2>: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-19\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-19(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: instantX- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference-2>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-04\(18\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-04(18))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1) Reference 3: [http://www.xbrl.org/2003/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02\(30\)\(a\)\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02(30)(a)(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type: Balance Type: credit Period Type: instantX- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(bb\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(bb)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference-2): [http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-25-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference-3): [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-4-08\(g\)\(1\)\(iii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-4-08(g)(1)(iii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference-5](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference-5): [http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference-6](http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference-6): <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference-7>: <http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-930-Name-Accounting-Standards-Codification-Section-55-Paragraph-12-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480167/946-830-55-12Reference-8>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-03\(a\)\(12\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-03(a)(12))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479440/944-210-S99-1) Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference-10>: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-6-04\(8\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-04(8))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479617/946-210-S99-1) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02\(18\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02(18))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01\(a\)\(4\)\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 13: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01\(a\)\(4\)\(ii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(ii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 14: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01\(a\)\(4\)\(iii\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(iii))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(iii)(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01\(a\)\(4\)\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-\(SX-210-13-01\(a\)\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02\(a\)\(4\)\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(iii)(A))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(iii)(B))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02\(a\)\(4\)\(iv\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(iv))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-\(SX-210-13-02\(a\)\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480097/470-10-S99-1) Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-\(a\)-Publisher-FASB-URI-https://](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(a)-Publisher-FASB-URI-https://)

asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24:

valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-5-02 \(6\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-5-02 (6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap-InventoryNet Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit-Period Type: instantX-DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-4-08 \(g\) \(1\) \(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-4-08 (g) (1) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-12>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-6-04 \(14\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-6-04 (14))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479617/946-210-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(iii\) \(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (iii) (A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(ii\) \(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (ii) (A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(iii\) \(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (iii) (B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 19: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)Reference 21: [http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 22: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210-5-02 \(19-26\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210-5-02 (19-26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap-Liabilities Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit-Period Type: instantX-DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-7-03 \(a\) \(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-7-03 (a) (25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1)Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-4-08 \(g\) \(1\) \(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-4-08 (g) (1) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-9-03 \(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-9-03 (23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479853/942-210-S99-1)Reference 7: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 910-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-5-02 \(32\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.fasb.org/us-gaap/role/ref/legacyRef-Topic 910-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-5-02 (32))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap-LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit-Period Type: instantX-DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-4-08 \(g\) \(1\) \(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-4-08 (g) (1) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 7: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-5>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(iii\) \(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (iii) (A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)Reference 13: <http://www.xbrl.org/2003/role/>

disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02-21)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Details Name: us-gaap-LiabilitiesCurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-ReferencesNo definition available. Details Name: us-gaap-LiabilitiesCurrentAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of obligation due after one year or beyond the normal operating cycle, if longer. ReferencesReference 1: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))-SubTopic 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08 (g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 20: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 21: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 22: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 201.5-02(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 23: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 201.5-02(26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Details Name: us-gaap-LiabilitiesNonecurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-ReferencesNo definition available. Details Name: us-gaap-LiabilitiesNonecurrentAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of noncurrent assets classified as other. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(17))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Details Name: us-gaap-OtherAssetsNonecurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02-20)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Details Name: us-gaap-OtherLiabilitiesCurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. ReferencesReference 1: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02.24)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Details Name: us-gaap-OtherLiabilitiesNonecurrentNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(21))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479440/944-210-S99-1Reference 3: http://asc.fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Details Name: us-gaap-PreferredStockValueNamespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. ReferencesReference 1: http://www.xbrl.org/2009

fasb.org//1943274/2147483443/250-10-50-1Reference-7: http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference-8: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference-9: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference-10: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference-11: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference-12: http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference-13: http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference-14: http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference-15: http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-1-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference-16: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference-17: http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-1-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference-18: http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210-6-09-(1)-(d))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference-19: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(i))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference-20: http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(ii))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference-21: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iii)-(A))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference-22: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(4)-(iv))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference-23: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01-(a)-(5))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference-24: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(i))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference-25: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(ii)-(A))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference-26: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iii)-(B))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference-27: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(4)-(iv))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference-28: http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02-(a)-(5))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference-29: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference-30: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference-31: http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(a)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference-32: http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference-33: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference-34: http://www.xbrl.org/2003/role/disclosureRef-Topic-205-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference-35: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-28-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference-36: http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-(a)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference-37: http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-(a)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference-38: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-(20))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference-39: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-04-(22))-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Details-Name: us-gaap_NetIncomeLoss-namespace-Prefix: us-gaap_Data-Type: xbrli:monetaryItemType-Balance-Type: credit-Period-Type: durationX-DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-7)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Details-Name: us-gaap_NonoperatingIncomeExpense-namespace-Prefix: us-gaap_Data-Type: xbrli:monetaryItemType-Balance-Type: credit-Period-Type: durationX-ReferencesNo definition available. Details-Name: us-gaap_NonoperatingIncomeExpense-namespace-Prefix: us-gaap_Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. ReferencesNo definition available. Details-Name: us-gaap_OperatingExpenses-namespace-Prefix: us-gaap_Data-Type: xbrli:monetaryItemType-Balance-Type: debit-Period-Type: durationX-ReferencesNo definition available. Details-Name: us-gaap_OperatingExpenses-namespace-Prefix: us-gaap_Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionThe net result for the period of deducting operating expenses from operating revenues. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference-2: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference-3: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference-4: http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference-5: http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c)-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Details-Name: us-gaap_OperatingIncomeLoss-namespace-Prefix: us-gaap_Data-Type: xbrli:monetaryItemType-Balance-Type: credit-Period-Type: durationX-DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-730-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference-2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic

912-SubTopic 730-Name Accounting Standards Codification-Section 25-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 985-SubTopic 20-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1Details Name: us-gaap-ResearchAndDevelopmentExpense-namespace-Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: debit-Period Type: durationX-Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Details Name: us-gaap-WeightedAverageNumberOfSharesOutstanding-Basic-namespace-Prefix: us-gaap-Data Type: xbrli:sharesItemType-Balance Type: na-Period Type: durationConsolidated Statements of Operations and Comprehensive Loss (Parent/Child) - \$ / shares 12-Months Ended Dec. 31, 2023-Dec. 31, 2022Income Statement [Abstract] Net loss per share, diluted \$ (0.63) \$ (0.92) Weighted average shares used in computing net loss per share, diluted 46,195,403.33, 025,721X-Definition The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (c)-(4)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03 (25))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04 (27))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04 (23))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7Details Name: us-gaap-EarningsPerShareDiluted-namespace-Prefix: us-gaap-Data Type: dtr-types:perShareItemType-Balance Type: na-Period Type: durationX-Definition The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. References Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 16-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-16Details Name: us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding-namespace-Prefix: us-gaap-Data Type: xbrli:sharesItemType-Balance Type: na-Period Type: durationConsolidated Statements of Stockholders' Equity-USD (\$) \$ in Thousands Common Stock-Additional Paid-In Capital-Accumulated Other Comprehensive Loss-Accumulated Deficit Total Balance at Dec. 31, 2021 \$ 3,975,506 \$ (11) \$ (64,768) \$ 32,730 Balance (in Shares) at Dec. 31, 2021 32,772,060 Stock-based compensation 3,096.3, 096 Issuance of common stock 2,231.2, 231 Issuance of common stock (in Shares) 810,400 Issuance of common stock upon exercise of options 3,211 Issuance of common stock upon exercise of options (in Shares) 77,000 31,000 Vesting of early exercised stock options \$ 145 Other comprehensive loss Net loss (30,329) (30,329) Balance at Dec. 31, 2022 \$ 3,103,009 (95,097) 7,915 Balance (in Shares) at Dec. 31, 2022 33,659,460 Stock-based compensation 2,980.2, 980 Issuance of common stock upon February 2023 public offering, net of issuance costs \$ 1.5, 179.5, 180 Issuance of common stock upon February 2023 public offering, net of issuance costs (in Shares) 5,340,600 Issuance of warrants upon February 2023 public offering 1,473.1, 473 Issuance of common stock upon June 2023 public offering, net of issuance costs \$ 1.8, 065.8, 066 Issuance of common stock upon June 2023 public offering, net of issuance costs (in Shares) 9,200,000 Issuance of common stock upon November 2023 public offering, net of issuance costs \$ 1.3, 568.3, 569 Issuance of common stock upon November 2023 public offering, net of issuance costs (in Shares) 4,870,600 Issuance of common stock 3,203.3, 203 Issuance of common stock (in Shares) 2,531,757 Issuance of common stock upon exercise of options \$ 109 Issuance of common stock upon exercise of options (in Shares) 245,855,000 Issuance of common stock warrant \$ 124 Vesting of early exercised stock options Net loss (29,283) (29,283) Balance at Dec. 31, 2022 \$ 6,127,823 \$ (124,380) \$ 3,449 Balance (in Shares) at Dec. 31, 2022 55,848,272 X-Definition Issuance of warrants upon public offering. References No definition available. Details Name: move-AdjustmentsToAdditionalPaidInCapitalIssuanceOfWarrantsUponPublicOffering-namespace-Prefix: move-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. References No definition available. Details Name: move-IssuanceOfCommonStockPublicOfferingNetOfIssuanceCosts-namespace-Prefix: move-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition Number of new stock issued during the period. References No definition available. Details Name: move-IssuanceOfCommonStockSharesPublicOfferingNetOfIssuanceCosts-namespace-Prefix: move-Data Type: xbrli:sharesItemType-Balance Type: na-Period Type: durationX-Definition Value of vesting exercised stock option. References No definition available. Details Name: move-StockIssuedDuringPeriodValueVestingOfEarlyExercisedStockOptions-namespace-Prefix: move-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition Amount of increase to additional paid-in capital (APIC) for recognition of cost-for-option-under-share-based payment arrangement. References No definition available. Details Name: us-gaap-AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition-namespace-Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition Amount of increase in additional paid-in capital (APIC) resulting from issuance costs from a share-lending arrangement entered into, in contemplation of a convertible debt offering or other financing. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 470-SubTopic 20-Section 25-Paragraph 20A-Publisher FASB-URI https://asc.fasb.org//1943274/2147481284/470-20-25-20ADetails Name: us-gaap-AdjustmentsToAdditionalPaidInCapitalStockIssuedOwnshareLendingArrangementIssuanceCosts-namespace-Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition Amount of increase in additional paid-in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 470-SubTopic 20-Section 25-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147481284/470-20-25-2Details Name: us-gaap-AdjustmentsToAdditionalPaidInCapitalWarrantIssued-namespace-Prefix: us-gaap-Data Type: xbrli:monetaryItemType-Balance Type: credit-Period Type: durationX-Definition The portion of profit or loss for the period,

net of income taxes, which is attributable to the parent. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210-4-08 \(g\) \(1\) \(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210-4-08 (g) (1) (ii))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480678/235-10-599-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3> Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\) \(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1) Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9> Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11) Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4> Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147480167/946-830-55-10> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483581/946-220-45-7> Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210-7-04 \(18\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210-7-04 (18))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483586/944-220-599-1> Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22> Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210-6-07 \(9\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210-6-07 (9))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483575/946-220-599-1> Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph \(SX 210-6-09 \(1\) \(d\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph (SX 210-6-09 (1) (d))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483575/946-220-599-3> Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (i))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1A> Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (ii))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1A> Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(iii\) \(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (iii) (A))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1A> Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(4\) \(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (4) (iv))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1A> Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210-13-01 \(a\) \(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210-13-01 (a) (5))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1A> Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (i))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1B> Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(iii\) \(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (iii) (A))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1B> Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(iii\) \(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (iii) (B))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1B> Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(4\) \(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (4) (iv))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1B> Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210-13-02 \(a\) \(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210-13-02 (a) (5))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147480097/470-10-599-1B> Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B) Reference 31: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31> Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32) Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7> Reference 34: [http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/220-10-45-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 23-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/220-10-45-28) Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A) Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B) Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210-5-03 \(20\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210-5-03 (20))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483621/220-10-599-2> Reference 38: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210-7-04 \(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210-7-04 (19))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483589/942-220-599-1> Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount of tax expense (benefit) allocated to other comprehensive income (loss). ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 12-SubTopic 10-Topic 220-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-12> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-4> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 17-Publisher FASB-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17> Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 20-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 20-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210-7-04 \(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210-7-04 (19))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483586/944-220-599-1> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10> Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-11) Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210-5-03 \(21\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210-5-03 (21))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483621/220-10-599-2> Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210-7-04 \(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210-7-04 (19))) Publisher FASB-URI <https://asc.fasb.org/1943274/2147483589/942-220-599-1>

210.9-04(23)) Publisher FASB URI <https://asc.fasb.org//1943274/2147483589/942-220-S99-1> Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482659/740-20-45-2) Details Name: us-gaap-OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Number of shares issued which are neither cancelled nor held in the treasury. References No definition available. Details Name: us-gaap-SharesOutstanding Namespace Prefix: us-gaap-Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. References No definition available. Details Name: us-gaap-StockIssuedDuringPeriodSharesIssuedForServices Namespace Prefix: us-gaap-Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Number of new stock issued during the period. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3) Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1) Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Details Name: us-gaap-StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap-Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Number of shares of stock issued attributable to transactions classified as other. References No definition available. Details Name: us-gaap-StockIssuedDuringPeriodSharesOther Namespace Prefix: us-gaap-Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Number of share options (or share units) exercised during the current period. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1) Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Details Name: us-gaap-StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap-Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders. References No definition available. Details Name: us-gaap-StockIssuedDuringPeriodValueIssuedForServices Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480767/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480767/946-205-45-4) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481004/946-505-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3) Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1) Reference 8: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Details Name: us-gaap-StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Value of stock issued as a result of the exercise of stock options. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph \(SX 210.5-02-29-31\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph (SX 210.5-02-29-31)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Details Name: us-gaap-StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. References Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10> Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2) Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3) Reference 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1) Reference 9: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3) Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28) Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Reference 12: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Reference 13: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Reference 14: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/310-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/310-10-S99-2)

<https://asc.fasb.org/1943274/2147480418/310-10-S99-2> Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant Consolidated Statements of Cash Flows-USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss \$(29,283) \$(20,329) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Stock-based compensation 2,980 3,096 Noncash lease expense (13) Accretion of discount on short-term investments Loss on disposal of property and equipment Changes in operating assets and liabilities: Payroll tax credit (250) Inventory (1,114) Prepaid expenses, vendor deposits and other current assets (209) Other assets (41) (50) Accounts payable 2,555 Deferred revenue 1,252 Other current and noncurrent liabilities (3,139) 1,316 Net cash used in operating activities (26,177) (24,902) CASH FLOWS FROM INVESTING ACTIVITIES: Purchases of property and equipment (64) (105) Maturities of short-term investments 15,829 Net cash provided by (used in) investing activities (64) 15,724 CASH FLOWS FROM FINANCING ACTIVITIES: Issuance of common stock and warrants upon February 2023 public offering, net of issuance costs 6,653 Issuance of common stock upon June 2023 public offering, net of issuance costs 8,066 Issuance of common stock upon November 2023 public offering, net of issuance costs 3,569 Issuance of common stock, net of issuance costs 3,203 2,23 Issuance of common stock upon exercise of stock options Net cash provided by financing activities 21,600 2,262 Net decrease in cash and cash equivalents (4,641) (6,916) Cash and cash equivalents at beginning of period 10,759 17,675 Cash and cash equivalents at end of period 6,118 10,759 NONCASH INVESTING AND FINANCING ACTIVITIES: Vesting of common stock issued upon early exercise Warrants issued upon February 2023 public offering 1,473 Issuance of common stock warrant Property and equipment purchases in other current liabilities \$ 19 Right of use asset recorded for equipment finance lease \$ 50 X- Definition Payroll tax credit. References No definition available. Details Name: move_IncreaseDecreasesInPayrollTaxCredit Namespace Prefix: move Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Issuance of common stock upon June 2023 public offering, net of issuance costs. References No definition available. Details Name: move_IssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts Namespace Prefix: move Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Issuance of common stock upon November 2023 public offering, net of issuance costs. References No definition available. Details Name: move_IssuanceOfCommonStockUponPublicOfferingNetOfIssuanceCosts Namespace Prefix: move Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition The amount of issuance of warrants upon public offering. References No definition available. Details Name: move_IssuanceOfWarrantsUponPublicOffering Namespace Prefix: move Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Property and equipment purchase in accounts payable. References No definition available. Details Name: move_PropertyAndEquipmentPurchaseInAccountsPayableValue Namespace Prefix: move Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Vesting of common stock issued upon early exercise. References No definition available. Details Name: move_VestingOfCommonStockIssuedUponEarlyExercise Namespace Prefix: move Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Details Name: us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- References No definition available. Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482913/230-10-50-8> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph24-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-24> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic230-SubTopic10-Section45-Paragraph4-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-4> Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX- Definition Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph24-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147482740/230-10-45-24> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph1-SubTopic230-Topic830-PublisherFASB-URI> <https://asc.fasb.org/1943274/2147481877/830-230-45-1> Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- References No definition available. Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-Subparagraph\(e\)-PublisherFASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-Subparagraph(e)-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482810/280-10-50-22> Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(b\)-SubTopic10-Topic230-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(b)-SubTopic10-Topic230-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Details Name: us-gaap_GainLossOnSaleOfPropertyPlantEquipment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URI](http://www.xbrl.org/2003/role/exampleRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Details Name: us-gaap_IncreaseDecreaseInDeferredRevenue Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- References No definition available. Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Amount of increase (decrease) in operating assets classified as other. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Details Name: us-gaap_IncreaseDecreaseInOtherOperatingAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX- Definition Amount of increase (decrease) in operating liabilities classified as other. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URI](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URI) <https://asc.fasb.org/1943274/2147482740/230-10-45-28> Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX- Definition Amount of increase (decrease) in prepaid expenses, and assets

classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph\(a\)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section45-Paragraph28-Subparagraph(a)-SubTopic10-Topic230-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482740/230-10-45-28) Details Name: us-gaap-IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph24-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482740/230-10-45-24> Details Name: us-gaap-NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap-NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph24-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482740/230-10-45-24> Details Name: us-gaap-NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap-NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482740/230-10-45-28> Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph24-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482740/230-10-45-24> Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph25-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482740/230-10-45-25> Details Name: us-gaap-NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap-NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.4.08\(g\)\(1\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic235-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.4.08(g)(1)(ii))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480678/235-10-S99-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph\(e\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic323-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-Subparagraph(e)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147481687/323-10-50-3) Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic825-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph28-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482907/825-10-50-28) Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482765/220-10-50-6> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph3-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-3> Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(b\)\(2\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(b)(2)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-1) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic815-SubTopic40-NameAccountingStandardsCodification-Section65-Paragraph1-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480175/815-40-65-1) Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph8-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-8> Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-9> Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-11) Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph11-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-11) Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic250-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483443/250-10-50-4> Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic946-SubTopic830-NameAccountingStandardsCodification-Section55-Paragraph10-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480167/946-830-55-10> Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-Section45-Paragraph7-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483581/946-220-45-7> Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.7.04\(18\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic944-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.7.04(18))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483586/944-220-S99-1) Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph22-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-22> Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph\(SX210.6.07\(9\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph1-Subparagraph(SX210.6.07(9))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-1) Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph\(SX210.6.09\(1\)\(d\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic220-NameAccountingStandardsCodification-SectionS99-Paragraph3-Subparagraph(SX210.6.09(1)(d))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483575/946-220-S99-3) Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1) Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(ii\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(ii))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A) Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A) Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A) Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph\(SX210.13-01\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1A-Subparagraph(SX210.13-01(a)(5))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1A) Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(i\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(i))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B) Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(A\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(A))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B) Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iii\)\(B\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iii)(B))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B) Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(4\)\(iv\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(4)(iv))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B) Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph\(SX210.13-02\(a\)\(5\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic470-SubTopic10-NameAccountingStandardsCodification-SectionS99-Paragraph1B-Subparagraph(SX210.13-02(a)(5))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480097/470-10-S99-1B) Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph30-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-30) Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(f\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(f)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32) Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph60B-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic260-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph60B-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482689/260-10-45-60B) Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph31-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-31> Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic280-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph32-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482810/280-10-50-32) Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Topic205-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph7-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483499/205-20-50-7> Reference 35: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic230-SubTopic10-NameAccountingStandards>

Codification-Section 45-Paragraph 28-Publisher FASB-URI <https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B)Reference 38: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210-5-03 \(20\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210-5-03 (20))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2)Reference 39: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-9-04 \(22\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-9-04 (22))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1) Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28> Details Name: us-gaap_OtherNonecashIncomeExpense Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 13-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 13-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13) Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-Definition The cash inflow from the additional capital contribution to the entity. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14) Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt). ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14) Details Name: us-gaap_ProceedsFromIssuanceOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 12-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-12> Details Name: us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Amount of cash inflow from exercise of option under share-based payment arrangement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2A-Subparagraph \(a\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2A-Subparagraph (a)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A) Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Amount of increase in right-of-use asset obtained in exchange for finance lease liability. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB-URI https://asc.fasb.org//1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(g\) \(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g) (2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147478964/842-20-50-4) Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Amount of nonecash expense for share-based payment arrangement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28) Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition The fair value of stock issued in noneash financing activities. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org//1943274/2147482913/230-10-50-5> Details Name: us-gaap_StockIssuedI Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationBusiness Organization, Nature of Operations-12 Months Ended Dec. 31, 2023 Business Organization, Nature of Operations [Abstract] BUSINESS ORGANIZATION, NATURE OF OPERATIONS Note 1 - Business Organization, Nature of Operations Movano Inc., dba Movano Health (the "Company", "Movano", "Movano Health", "we", "us" or "our"), was incorporated in Delaware on January 30, 2018 as Maestro Sensors Inc. and changed its name to Movano Inc. on August 3, 2018. The Company is in the development stage and is developing a platform to deliver purpose-driven healthcare solutions at the intersection of medical and consumer devices. Movano is on a mission to make medical grade data more accessible and actionable for all. The Company's solutions are being developed to provide vital health information, including heart rate, heart rate variability ("HRV"), sleep, respiration rate, temperature, SpO2, steps, and calories as well as glucose and blood pressure data, in a variety of form factors to meet individual style needs and give users actionable feedback to improve their quality of life. On April 28, 2021, the Company established Movano Ireland Limited, organized under the laws of Ireland, as a wholly owned subsidiary of the Company. Operations and activity at the wholly owned subsidiary were not significant for the years ended December 31, 2022 and 2022, respectively. Since inception, the Company has engaged in only limited research and development of product candidates and underlying technology and the commercialization of the Company's first proposed commercial product, the Evic Ring. As of December 31, 2023, the Company had not yet completed the development of its product and had not yet recorded any revenues. On February 6, 2023, the Company completed a \$ 7.5 million underwritten public offering of 5,340,600 shares of its common stock and warrants to purchase up to 2,670,300 shares of common stock, including the full exercise of the underwriter's overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of \$ 1.57. The public offering price per share, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant was \$ 1.40. The net proceeds from the offering were approximately \$ 6.7 million (See Note 7). On June 15, 2023, the Company completed a \$ 9.2 million underwritten public offering of 9,200,000 shares of its common stock, including the full exercise of the underwriter's overallotment option. The public offering price per share, before the underwriters' discount and commissions, for each share of common stock was \$ 1.00. The net proceeds from the offering were approximately \$ 8.1 million (See Note 7). On November 17, 2023, the Company completed a \$ 4.1 million underwritten public offering of 4,870,600 shares of its common stock, including the full exercise of the underwriter's overallotment option. The public offering price per share, before the underwriters' discount and commissions, for each share of common stock was \$ 0.85. The net proceeds from the offering were approximately \$ 3.6 million. (See Note 7). The Company has incurred losses from operations and has generated negative cash flows from operating activities since inception. The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology. The Company's ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Through December 31, 2023, the Company has relied primarily on the proceeds from equity offerings to finance its operations. Through December 31, 2023, the Company has received gross proceeds of approximately \$ 5.6 million from an at-the-market issuance program, and an aggregate offering price amount of approximately \$ 44.4 million remains available to be issued. (See Note 7.) The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products. The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has an accumulated deficit of \$ 124.4 million as of December 31, 2023. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. The Company's existence is dependent upon management's ability to obtain additional funding sources. These circumstances raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its product or any commercialization efforts. There can be no assurance that the Company's efforts

will result in the resolution of the Company's liquidity needs. The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern. X-DefinitionThe entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward. ReferencesReference 1:

the Company's repurchase right lapses. Leases The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition, and if the lease is classified as an operating lease or finance lease in accordance with Accounting Standards Codification 842, Leases ("ASC 842"). Operating and finance leases are included in right-of-use ("ROU") assets and lease liabilities in the Company's consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. For leases which do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considers relevant banking rates and the Company's costs incurred for underwriting discounts and financing costs in its previous equity financings. The ROU assets also include any lease payments made and exclude lease incentives. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately. Short-term leases of twelve months or less, if any, are expensed as incurred which approximates the straight-line basis due to the short-term nature of the leases. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the years ended December 31, 2023 and 2022. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company's tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share since the effects of potentially dilutive securities are antidilutive. Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being recognized separately from their host contracts. The pronouncement also revises the derivatives scope exception for contracts in an entity's own equity and improves the consistency of earnings per share calculations as that relates to convertible instruments. The Company has early-adopted this pronouncement as of January 1, 2023 using the modified retrospective method of transition. The adoption did not have any impact on the Company's consolidated financials. Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2024. Adoption of the provisions should be on a prospective basis. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption. X-ReferencesNo definition available. Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 235-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/235-10-50-1tableOfContent Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationFair Value Measurements 12 Months Ended Dec. 31, 2023 Fair Value Measurements [Abstract] FAIR VALUE MEASUREMENTS Note 3—FAIR VALUE MEASUREMENTS Financial assets and liabilities are recorded at fair value. The Company uses a three-level hierarchy, which prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those financial instruments. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3—Significant unobservable inputs that cannot be corroborated by market data. The asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company's Level 1 financial assets are money market funds whose fair values are based on quoted market prices. The carrying amounts of prepaid expenses and other current assets, payroll tax credit, vendor deposits, inventory, accounts payable, deferred revenue, and other current liabilities approximate fair value due to the short-term nature of these instruments. The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in thousands): December 31, 2023 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds \$ 4,393 \$ 4,393 \$ — Total cash equivalents \$ 4,393 \$ 4,393 \$ — December 31, 2022 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds \$ 8,171 \$ 8,171 \$ — Total cash equivalents \$ 8,171 \$ 8,171 \$ — X-ReferencesNo definition available. Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationCash and Cash Equivalents 12 Months Ended Dec. 31, 2023 Cash and Cash Equivalents [Abstract] CASH AND CASH EQUIVALENTS Note 4—CASH AND CASH EQUIVALENTS Cash and cash equivalents consist of the following (in thousands): December 31, 2023 2022 Cash and cash equivalents: Cash \$ 1,725 \$ 2,588 Money market funds 4,393 8,171 Total cash and cash equivalents \$ 6,118 \$ 10,759 X-ReferencesNo definition available. Details Name: us-gaap_CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-5-02 (1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-7-03 (a) (2))-Publisher FASB-URI https://asc-

fasb.org//1943274/2147479440/944-210-S99-1-Details-Name: us-gaap-CashAndCashEquivalentsDisclosureTextBlock-Namespace-Prefix: us-gaap-Data-Type: dtr-types: textBlockItemType-Balance-Type: na-Period-Type: durationProperty-and-Equipment-12-Months-Ended-Dec-31, 2023-Property-and-Equipment-Abstract-PROPERTY-AND-EQUIPMENT-Note-5-Property-and-Equipment-Property-and-equipment, net, as of December 31, 2023 and 2022, consisted of the following (in thousands): December 31, 2023 2022 Office equipment and furniture \$ 266 \$ 263 Software 144 131 Test equipment 310 277 Total property and equipment 720 671 Less: accumulated depreciation (378) (228) Total property and equipment, net \$ 342 \$ 443 Total depreciation and amortization expense related to property and equipment for the years ended December 31, 2023 and 2022 was approximately \$ 158,000 and \$ 147,000, respectively. X-ReferencesNo definition available. Details Name: us-gaap-PropertyPlantAndEquipmentAbstract-Namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 6-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org//1943274/2147480321/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org//1943274/2147480321/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 7-SubTopic 360-Topic 958-Publisher FASB-URI https://asc.fasb.org//1943274/2147480321/958-360-50-7-Details-Name: us-gaap-PropertyPlantAndEquipmentDisclosureTextBlock-Namespace-Prefix: us-gaap-Data-Type: dtr-types: textBlockItemType-Balance-Type: na-Period-Type: durationOther Current Liabilities-12-Months-Ended-Dec-31, 2023-Other Current Liabilities-Abstract-OTHER CURRENT LIABILITIES-Note 6-Other Current Liabilities-Other current liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands): December 31, 2023 2022 Accrued compensation \$ 299 \$ 2,708 Accrued research and development 461 536 Accrued vacation 246 243 Accrued severance payment 5 517 Lease liabilities, current portion 217 212 Other 301 205 Total other current liabilities \$ 1,529 \$ 4,421 X-ReferencesNo definition available. Details Name: us-gaap-OtherLiabilitiesCurrentAbstract-Namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionThe entire disclosure for other liabilities. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210-5-02, 20, 24)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1-Details-Name: us-gaap-OtherLiabilitiesDisclosureTextBlock-Namespace-Prefix: us-gaap-Data-Type: dtr-types: textBlockItemType-Balance-Type: na-Period-Type: durationCommon Stock-12-Months-Ended-Dec-31, 2023-Common Stock-Abstract-COMMON STOCK-Note 7-Common Stock-As of December 31, 2023 and 2022, the Company was authorized to issue 150,000,000 and 75,000,000 shares of common stock, respectively, with a par value of \$ 0.0001 per share. As of December 31, 2023 and 2022, 55,848,272 and 33,659,460 shares were outstanding, respectively. January and February 2023 Issuance of Common Stock On February 6, 2023, the Company completed a \$ 7.5 million underwritten public offering of 5,340,600 shares of its common stock and warrants to purchase up to 2,670,300 shares of common stock, including the full exercise of the underwriter's overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of \$ 1.57 (See Note 8). The public offering price per share, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant was \$ 1.40. The Company used the relative fair value method to allocate the gross proceeds of approximately \$ 7.5 million between the common stock and the warrants. The net proceeds from the offering were approximately \$ 6.7 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately \$ 0.8 million. The Company recorded the fair value of the warrants of \$ 1.5 million as additional costs of issuance, thus reducing the net proceeds of \$ 6.7 million to \$ 5.2 million as presented in the accompanying consolidated statements of stockholders' equity. June 2023 Issuance of Common Stock On June 15, 2023, the Company completed a \$ 9.2 million underwritten public offering of 9,200,000 shares of its common stock, including the full exercise of the underwriter's overallotment option. The public offering price per share, before the underwriters' discount and commissions, for each share of common stock was \$ 1.00. The net proceeds from the offering were approximately \$ 8.1 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately \$ 1.1 million. November 2023 Issuance of Common Stock On November 17, 2023, the Company completed a \$ 4.1 million underwritten public offering of 4,870,600 shares of its common stock, including the full exercise of the underwriter's overallotment option. The public offering price per share, before the underwriters' discount and commissions, for each share of common stock was \$ 0.85. The net proceeds from the offering were approximately \$ 3.6 million after the deduction of underwriting discounts, commissions and other offering expenses that were approximately \$ 0.5 million. At the Market Issuance of Common Stock On August 15, 2022, the Company entered into an At the Market Issuance Agreement (the "Issuance Agreement") with B. Riley Securities, Inc. (the "Sales Agent"). Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company's common stock having an aggregate offering price of up to \$ 50,000,000 (the "Shares"). Sales of Shares, if any, may be made by means of transactions that are deemed to be "at the market" offerings as defined in Rule 415 under the Securities Act, including block trades, ordinary brokers' transactions on the Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices or by any other method permitted by law. Under the terms of the Issuance Agreement, the Company may also sell Shares to the Sales Agent as principal for its own accounts at a price to be agreed upon at the time of sale. Any sale of Shares to the Sales Agent as principal would be pursuant to the terms of a separate terms agreement between the Company and the Sales Agent. The Company has no obligation to sell any of the Shares under the Issuance Agreement and may at any time suspend solicitation and offers under the Issuance Agreement. During the year ended December 31, 2023, the Company issued and sold an aggregate of 2,531,757 shares of common stock through the Issuance Agreement at a weighted-average public offering price of \$ 1.31 per share and received net proceeds of \$ 3.2 million. During the year ended December 31, 2022, the Company issued and sold an aggregate of 810,400 shares of common stock through the Issuance Agreement at a weighted-average public offering price of \$ 2.84 per share and received net proceeds of \$ 2.2 million. As of December 31, 2023, an aggregate offering price amount of approximately \$ 44.4 million remains available to be issued and sold under the Issuance Agreement. Common Stock Reserved for Future Issuance Common stock reserved for future issuance at December 31, 2023 is summarized as follows: December 31, 2023 Warrants to purchase common stock 4,757,256 Stock options outstanding 7,448,412 Stock options available for future grants 5,936,692 Total 18,142,360 Early Exercised Stock Option Liability The Exercise Notice (Early Exercise) Agreement states that the Company has the option to repurchase all or a portion of the unvested shares in the event of the separation of the holder from service to the Company. The shares continue to vest in accordance with the original vesting schedules of the former option agreements. During the years ended December 31, 2023 and 2022, no shares of common stock were issued upon the early exercise of common stock options. As of December 31, 2023 and 2022, the Company has recorded a repurchase liability for approximately \$ 23,000 and \$ 136,000 for 43,751 and 266,147 shares that remain unvested, respectively. The weighted average remaining vesting period at December 31, 2023 is less than one year. X-ReferencesNo definition available. Details Name: us-gaap-CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract-Namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType-Balance-Type: na-Period-Type: durationX-DefinitionThe entire disclosure for equity. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 235-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 50-Paragraph 6-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-4-08 (c) (1))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org//505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/

505-10-50-13Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 16-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18)Details Name: us-gaap-StockholdersEquityNoteDisclosureTextBlock-namespace: Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na-Period Type: durationCommon Stock Warrants 12 Months Ended Dec. 31, 2023 Common Stock Warrants [Abstract] COMMON STOCK WARRANTS Note 8-Common Stock Warrants Preferred A Placement Warrants During February 2023, September 2023 and November 2023, the Board approved the amendment of 293,042 Preferred A Placement Warrants to extend the maturity to April 2024. The Company assessed the accounting treatment of the warrant amendments and determined that the amendments are modifications for accounting purposes. The Company determined the modifications had an insignificant impact on the consolidated financial statements. January and February 2023 Warrants In connection with the sale of common stock during January and February 2023, the Company issued warrants to purchase shares of common stock to common stockholders and to the underwriter for 2,322,000 and 348,300 shares, respectively. The warrants are exercisable upon issuance at \$ 1.57 per share and have a 5-year term. Beginning with the one-year anniversary of the issuance dates, the Company may redeem the outstanding warrants in whole or in part at \$ 0.25 per warrant at any time after the date on which (i) the closing price of the Company's common stock has equaled or exceeded \$ 4.87 for ten consecutive trading days and (ii) the daily trading volume of the Company's common stock has exceeded 100,000 shares on each of ten trading days. A minimum of thirty days prior written notice of redemption is required. August 2023 Warrants In August 2023, the Company issued warrants to purchase 201,613 shares of common stock to a third-party professional services firm. The following is a summary of the Company's warrant activity for the years ended December 31, 2023 and 2022: Warrant Issuance Exercise Price Outstanding, December 31, 2022 Granted Exercised Canceled/Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2023 Expiration Preferred A Placement Warrants March and April 2018 and August 2019 \$ 1.40 293,042 293,042 April 2024 Preferred A Lead Investor Warrants February 2021 \$ 0.0125 52,500 (52,500) March 2023 Preferred B Placement Warrants April 2019 \$ 2.10 463,798 463,798 April 2024 Convertible Notes Placement Warrants August 2020 \$ 2.57 171,830 171,830 August 2025 Underwriter Warrants March 2021 \$ 6.00 956,973 956,973 March 2026 January 2023 Warrants January 2023 \$ 1.57 2,322,000 2,322,000 January 2028 February 2023 warrants February 2023 \$ 1.57 348,000 348,000 February 2028 August 2023 warrants August 2023 \$ 1.24 201,613 201,613 August 2028 1,938,143 2,871,613 (52,500) 4,757,256 Warrant Issuance Exercise Price Outstanding, December 31, 2021 Granted Exercised Canceled/Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2021 Expiration Preferred A Placement Warrants March and April 2018 and August 2019 \$ 1.40 293,042 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 \$ 0.0125 52,500 52,500 March 2023 Preferred B Placement Warrants April 2019 \$ 2.10 463,798 463,798 April 2024 Convertible Notes Placement Warrants August 2020 \$ 2.57 171,830 171,830 August 2025 Underwriter Warrants March 2021 \$ 6.00 956,973 956,973 March 2026 1,938,143 1,938,143 Warrants Classified as Equity All of the Company's outstanding warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance. January and February 2023 Warrants The warrants are classified as an equity instrument because they are both indexed to the Company's own stock and classified in stockholders' equity. The fair value of the warrants was estimated using a Monte Carlo simulation approach. Subsequent changes in fair value are not recognized as long as the warrants continue to be classified in equity. The fair value at the issuance date was calculated utilizing the Monte Carlo univariate pricing model, which simulates a distribution of stock prices for Movano throughout the remaining performance period, based on certain assumptions of stock price behavior. The following major assumptions were used: (1) the stock price of the Company follows a geometric Brownian motion; (2) the daily stock price for the Company is simulated until the termination date using a volatility estimate based on term-match daily stock price returns of peer companies; and (3) the valuation is done under a risk-neutral framework using the term-matched zero-coupon risk-free interest rate. The major inputs were: Issuance Date Dividend yield — % Expected volatility 60.83 % Risk-free interest rate 3.54 % Expected life 5.0 years Valuation date common stock price \$ 1.39 The fair value of the January and February 2023 warrants at the issuance date is approximately \$ 1.5 million. August 2023 Warrants The warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance using the Black-Scholes option pricing model with the following assumptions. The amount of the fair value was insignificant. X-References No definition available. Details Name: move-CommonStockWarrantsAbstract Namespace Prefix: move-Data Type: xbrli:stringItemType Balance Type: na-Period Type: durationX-References No definition available. Details Name: move-CommonStockWarrantsTextBlock-namespace: Prefix: move-Data Type: dtr-textBlockItemType Balance Type: na-Period Type: durationStock-Based Compensation 12 Months Ended Dec. 31, 2023 Stock-Based Compensation [Abstract] STOCK-BASED COMPENSATION Note 9-Stock-based Compensation 2019 Equity Incentive Plan Effective as of November 18, 2019, the Company adopted the 2019 Omnibus Incentive Plan ("2019 Plan") administered by the Board. The 2019 Plan provides for the issuance of incentive stock options, non-statutory stock options, and restricted stock awards, for the purchase of up to a total of 4,000,000 shares of the Company's common stock to employees, directors, and consultants and replaces the previous plan. The Board or a committee of the Board has the authority to determine the amount, type, and terms of each award. The options granted under the 2019 Plan generally have a contractual term of ten years and a vesting term of four years with a one-year cliff. The exercise price for options granted under the 2019 Plan must generally be at least equal to 100% of the fair value of the Company's common stock at the date of grant, as determined by the Board. The incentive stock options granted under the 2019 Plan to 10% or greater stockholders must have an exercise price at least equal to 110% of the fair value of the Company's common stock at the date of grant, as determined by the Board, and have a contractual term of ten years. As of March 25, 2021, the 2019 Plan was amended and restated as a result of which the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan was increased from 6,000,000 to 7,400,000. On April 15, 2022, the Board approved, subject to stockholder approval, an increase in the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan from 7,400,000 to 13,400,000. On June 21, 2022, the stockholders approved this increase. As of December 31, 2023, the Company had 4,455,442 shares available for future grant under the 2019 Plan. 2021 Employment Inducement Plan On September 15, 2021 the Company's Board adopted the Movano, Inc. 2021 Inducement Award Plan (the "Inducement Plan") without stockholder approval pursuant to Rule 5635 (e) (4) of the Nasdaq Stock Market LLC listing rules ("Rule 5635 (e) (4)"). In accordance with Rule 5635 (e) (4), awards under the Inducement Plan may only be made to a newly hired employee who has not previously been a member of the Company's Board, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee's entering into employment with the Company or its subsidiary. An aggregate of 2,000,000 shares of the Company's common stock have been reserved for issuance under the Inducement Plan. As of December 31, 2023, the Company had 1,481,250 shares available for future grant under the Inducement Plan. Stock Options Stock option activity for the years ended December 31, 2023 and 2022 was as follows (in thousands, except share, per share, and remaining life data): Number of Options Weighted Average Exercise Price Weighted Average Remaining Life Intrinsic Value Outstanding at December 31, 2021 5,592,137 \$ 2.29 8.6 years \$ 9,912 Granted 2,525,000 \$ 2.77 Exercised (77,000) \$ 0.40 Cancelled (1,120,243) \$ 3.15 Outstanding at December 31, 2022 6,919,894 \$ 2.34 8.2 years \$ 2,034 Granted 1,610,375 \$ 1.23 Exercised (245,855) \$ 0.44 Cancelled (836,002) \$ 2.66 Outstanding at December 31, 2023 7,448,412 \$ 2.13 7.1 years \$ 726 Exercisable as of December 31, 2023 4,760,030 \$ 2.02 6.5 years \$ 712 Vested and expected to vest as of December 31, 2023 7,448,412 \$ 2.13 7.1 years \$ 726 The weighted average grant date fair value of options granted during the years ended December 31, 2023, and 2022 was \$ 0.74 and \$ 1.48 per share, respectively. During the years ended December 31, 2023 and 2022, 245,855 and 77,000 options were exercised for proceeds of \$ 109,000 and \$ 31,000, respectively. The fair value of the 2,008,712 and 1,707,794 options that vested during the years ended December 31, 2023 and 2022 was approximately \$ 3.1 million and \$ 3.2 million, respectively. On June 21, 2022, the Company granted an award of 100,000 options to the Company's founder at an exercise price of \$ 5.00 per share. The options were to vest in full upon the shipment of 20,000 product units on or before June 30, 2023. For the years ended December 31, 2023 and 2022, the Company has not recognized stock compensation expense of approximately \$ 0.1 million related to this award as the successful achievement of the performance conditions is not yet probable, and the award has been cancelled. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of the stock options was estimated using the following weighted average assumptions for the years ended December 31, 2023 and 2022: Year Ended December 31, 2023 2022 Dividend yield — % — % Expected volatility 61.55 % 61.97 % Risk-free interest rate 3.77 % 2.78 % Expected life 5.98 years 6.07 years Dividend Rate — The expected dividend rate was assumed to be zero, as the Company had not previously paid dividends on common stock and has no current plans to do so. Expected Volatility — The expected volatility was derived from the historical stock volatilities of several public companies within the Company's industry that the Company considers to be comparable to the business over a period equivalent to the expected term of the stock option grants. Risk-Free Interest Rate — The risk-free interest rate is based on the interest yield in effect at the date of grant for zero coupon

U. S. Treasury notes with maturities approximately equal to the option's expected term. Expected Term — The expected term represents the period that the Company's stock options are expected to be outstanding. The expected term of option grants that are considered to be "plain vanilla" are determined using the simplified method. The simplified method deems the term to be the average of the time to vesting and the contractual life of the options. For other option grants not considered to be "plain vanilla," the Company determined the expected term to be the contractual life of the options. Forfeiture Rate — The Company recognizes forfeitures when they occur. The Company has recorded stock-based compensation expense for the years ended December 31, 2023 and 2022 related to the issuance of stock option awards to employees and nonemployees in the consolidated statement of operations and comprehensive loss as follows: Year Ended December 31, 2023 2022 Research and development \$ 940 \$ 1,169 Sales, general and administrative 2,040 1,927 \$ 2,980 \$ 3,096 As of December 31, 2023, unamortized compensation expense related to unvested stock options was approximately \$ 4.0 million, which is expected to be recognized over a weighted average period of 2.0 years. X- Definition The entire disclosure for share-based payment arrangement. References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)(1)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//718/tableOfContentReference3: http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//718/tableOfContentReference3: http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(h\)\(2\)\(i\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(h)(2)(i)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(h\)\(2\)\(i\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(h)(2)(i)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(i\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic718-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(i)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationX- References No definition available. Details Name: us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: duration Commitments and Contingencies 12 Months Ended Dec. 31, 2023 Commitments and Contingencies [Abstract] COMMITMENTS AND CONTINGENCIES Note 10 — Commitments and Contingencies Operating Leases As of December 31, 2023, the Company had one office lease for the Corporate headquarters and laboratory space. On April 15, 2021, the Company executed a lease agreement for corporate office space. The lease commenced on May 14, 2021 when the improvements were completed by the landlord and the Company had access to the facility. The lease term is 40 months, and the base rent is approximately \$ 14,000 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid a security deposit of approximately \$ 47,000. On April 22, 2022, the Company executed an amendment to its corporate office lease agreement for additional corporate office space. The lease term for the additional space is 36 months from the expansion commencement date of June 23, 2022. The base rent is approximately \$ 5,100 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid an additional security deposit of approximately \$ 5,500. Finance Lease On November 22, 2023, the Company executed a lease agreement for equipment. The lease term is 36 months, and the monthly payment is approximately \$ 1,700. The lease agreement has a bargain purchase option at the end of the lease term. The balances of the lease related accounts as of December 31, 2023 and 2022 are as follows (in thousands): As of December 31, Operating and Finance leases 2023 2022 Right-of-use assets \$ 247 \$ 389 Operating lease liabilities—Short-term \$ 203 \$ 212 Operating lease liabilities—Long-term \$ 15 \$ 214 Finance lease liabilities—Short-term \$ 14 \$ — Finance lease liabilities—Long-term \$ 35 \$ — Right-of-use assets are included in other assets on the consolidated balance sheets. The short-term lease liabilities and the long-term lease liabilities are included in other current liabilities and other noncurrent liabilities, respectively, on the consolidated balance sheets. The components of lease expense and supplemental cash flow information as of and for the years ended December 31, 2023 and 2022 are as follows (in thousands): Year Ended December 31, 2023 2022 Lease Cost: Operating lease cost \$ 261 \$ 226 Other Information: Cash paid for amounts included in the measurement of lease liabilities for the year ended \$ 243 \$ 209 Weighted average remaining lease term—operating leases (in years) 0.90 1.97 Average discount rate—operating leases 10.00% 10.00% Weighted average remaining lease term—financing leases (in years) 3.00 — Average discount rate—financing leases 15.08% — Future minimum lease payments are as follows as of December 31, 2023 (in thousands): 2024 2025 48 2026 18 Total lease payments 290 Less: Interest (23) Total lease liabilities \$ 267 Litigation From time to time, the Company may become involved in various litigation and administrative proceedings relating to claims arising from its operations in the normal course of business. Management is not currently aware of any matters that may have a material adverse impact on the Company's business, financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. No amounts associated with such indemnifications have been recorded as of December 31, 2023. Non-cancelable Obligations The Company did not have any non-cancelable contractual commitments as of December 31, 2023. X- References No definition available. Details Name: us-gaap-CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The entire disclosure for commitments and contingencies. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic440-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic440-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482648/440-10-50-4) Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic450-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//450/tableOfContentReference3: http://www.xbrl.org/2003/role/disclosureRef-Topic954-SubTopic440-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(a\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480327/954-440-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic450-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//450/tableOfContentReference3: http://www.xbrl.org/2003/role/disclosureRef-Topic954-SubTopic440-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(a)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480327/954-440-50-1) Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic440-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic440-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph4-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482648/440-10-50-4) Reference 5:

6Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\) \(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b) (2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4>Reference 13: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210. 7-04 \(18\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 7-04 (18))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483586/944-220-599-1)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210. 6-07 \(9\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 6-07 (9))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-599-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph \(SX 210. 6-09 \(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-599-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph (SX 210. 6-09 (1)(d))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483575/946-220-599-3)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iii\) \(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iii) (A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(4\) \(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210. 13-01 \(a\) \(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210. 13-01 (a) (5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iii\) \(A\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iii) (A))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iii\) \(B\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iii) (B))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(4\) \(iv\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (4) (iv))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210. 13-02 \(a\) \(5\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210. 13-02 (a) (5))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480097/470-10-599-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B)Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32)Reference 34: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7>Reference 35: <http://www.xbrl.org/2003/role/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B)Reference 38: [http://www.xbrl.org/2003/role/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210. 5-03 \(20\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-599-2](http://www.xbrl.org/2003/role/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210. 5-03 (20))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-599-2)Reference 39: [http://www.xbrl.org/2003/role/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210. 9-04 \(22\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-599-1](http://www.xbrl.org/2003/role/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210. 9-04 (22))-Publisher FASB-URI https://asc.fasb.org//1943274/2147483589/942-220-599-1)Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration Insider Trading Arrangements 3 Months Ended Dec. 31, 2023 Trading Arrangements, by Individual Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X-References Reference 1:

three months or less to be cash equivalents. As of December 31, 2023 and 2022, the Company did not hold any short-term investments. Concentrations of Credit Risk and Off-Balance Sheet Risk Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. Substantially all cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts and institutional money market funds. The amounts deposited in the money market accounts exceed federally insured limits. Further, the Company has amounts in excess of federally insured limits as of December 31, 2023 at one financial institution that totaled approximately \$ 2.5 million. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials. The Company has no financial instruments with off-balance sheet risk of loss. Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were primarily comprised of prepaid expenses and other current receivables. Inventory Inventory Inventory, which consists of raw materials, is stated at the lower of cost or net realizable value. Cost comprises purchase price and incidental expenses incurred in bringing the inventory to its present location and condition. Cost is computed using the weighted-average cost method. The Company writes down its inventory for estimated obsolescence or unmarketable inventory equal to the difference between the cost of inventory and the estimate net realized value based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by management, additional inventory write-downs may be required. Software Development Costs Software Development Costs Costs related to software development are included in research and development expense until the point that technological feasibility is reached, which, for the Company's product, will be shortly before the product is released to manufacturing. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated lives of the product. During the years ended December 31, 2023 and 2022, no development costs were capitalized. Impairment of Long-Lived Assets Impairment of Long-Lived Assets The Company reviews the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. Revenue Revenue The Company generates revenue from the sale of Evic Rings, portable chargers and charging cables, ring sizers, and mobile applications. As part of the purchase, customers also receive customer support and future unspecified software updates. These items are collectively referred to as the Evic Ring Elements. During the year ended December 31, 2023 the Company began taking pre-orders for the Evic Ring Elements but did not deliver any Evic Rings as of December 31, 2023. The Company recognizes revenue when control is transferred to the customer in an amount that reflects the net consideration to which the Company expects to be entitled. In determining how revenue should be recognized, a five-step process is used which includes identifying the contract, identifying the distinct performance obligations, determining the transaction price, allocating the transaction price to each distinct performance obligation, and determining the timing of revenue recognition for each distinct performance obligation. For each contract, the Company considers the obligation to transfer the Evic Ring Elements, each of which are distinct, to be separate performance obligations. Transaction price for the Evic Ring Elements reflects the net consideration to which the Company expects to be entitled. Transaction price is based on the sales price. The Company includes an estimate of variable consideration in the calculation of the transaction price at the time of sale. Variable consideration primarily includes product return provisions. The Company classifies the product return provisions as liabilities in the consolidated balance sheet. The adequacy of the estimates for the variable consideration is reviewed at each reporting date. If the actual amount of consideration differs from the estimates, the Company would adjust the estimates, impacting revenue in the period that such variances become known. If any of the judgments were to change, this change could cause a material increase or decrease in the amount of revenue reported in a particular period. The Company allocates the transaction price to each performance obligation using the relative standalone selling price ("SSP") for each distinct good or service in the contract. The Company offers limited rights of return for a 30-day right of return, whereby customers may return the Evic Ring Elements. The Company records revenue from the sales of the Evic Ring Elements upon transfer of control of the distinct Evic Ring Elements to the customer. The Company typically determines transfer of control for the Evic Ring Elements based on when the product is delivered, or when our customer has obtained the significant risks and reward of ownership. The future unspecified software updates and customer support that the Company offers are separate performance obligations, and revenue is recognized over time on a ratable basis. The sales of the Evic Ring Elements include an assurance warranty. Contract balances represent amounts presented in the consolidated balance sheets when the Company has transferred goods or services to the customer, or the customer has paid consideration to the Company under the contract. Payment is made by the customer upon the purchase of the Evic Ring Elements, and the Company has no accounts receivable at December 31, 2023, 2022, or 2021, respectively. The Company records deferred revenue when cash payments from customers are received prior to the transfer of control or satisfaction of the related performance obligations. A contract asset is recorded when inventory has shipped but control has not yet transferred to the customer. Deferred revenue at December 31, 2023 was \$ 1.3 million and is included in current liabilities on the consolidated balance sheets. There was no deferred revenue at December 31, 2022 or 2021, respectively. There were no contract assets at December 31, 2023, 2022, or 2021, respectively. The Company collects sales taxes at the point of sale and remits the taxes to the proper state authorities. Sales tax is excluded from the measurement of the transaction price. Shipping and handling costs are incurred as part of fulfillment activities with customers and are included as a component of cost of revenue. Determining the Timing of Satisfaction of Performance Obligations In determining how revenue should be recognized, a five-step process is used which includes identifying the contract, identifying the distinct performance obligations, determining the transaction price, allocating the transaction price to each distinct performance obligation, and determining the timing Advertising Costs Advertising Costs The Company expenses advertising costs as they are incurred. Advertising expenses were \$ 1.35 million for the year ending December 31, 2023 and were not significant for the year ended December 31, 2022. These costs are included in "Sales, general and administrative expenses" in the accompanying consolidated statements of operations and comprehensive loss. Research and Development Research and Development Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities on the Company's behalf. Stock-Based Compensation Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company's common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur. Common Stock Warrants Common Stock Warrants The Company assesses each warrant to determine if it meets the characteristics of a liability or a derivative, and if the warrant does meet the characteristics of a liability or a derivative, the warrant is measured at fair value. The derivative liabilities are remeasured at each period end, on a recurring basis, to the estimated fair value with the changes in fair value reflected as current period income or loss until the warrant is exercised, extinguished, or expires. If the warrant does not meet the characteristics of a liability or a derivative, the warrant is classified as equity and recorded at its fair value on the date of issuance. The fair value of warrants is estimated using appropriate pricing models based on the nature and characteristics of the underlying warrants. Early Exercised Stock Option Liability Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of invested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company's repurchase right lapses. Leases Leases The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition, and if the lease is classified as an operating lease or finance lease in accordance with Accounting Standards Codification 842, Leases ("ASC 842"). Operating and finance leases are included in right-of-use ("ROU") assets and lease liabilities in the Company's consolidated balance sheets. ROU assets represent the Company's right to use an underlying asset for the lease term. Lease liabilities represent the Company's obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at commencement date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. For leases which do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considers relevant banking rates and the Company's costs incurred for underwriting discounts and financing costs in its previous equity financings. The ROU assets also include any lease payments made and exclude lease incentives. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately. Short-term leases of twelve months or less, if any, are expensed as incurred which approximates the straight-line basis due to the short-term nature of the leases. Income Taxes Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the years ended December 31, 2023 and 2022. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income

tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company's tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Net Loss Per Share Net Loss Per Share Basic net loss per share is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is the same as basic net loss per share since the effects of potentially dilutive securities are antidilutive. Recently Adopted Accounting Pronouncements Recently Adopted Accounting Pronouncements In August 2020, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity. The amendments in this update reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being recognized separately from their host contracts. The pronouncement also revises the derivatives scope exception for contracts in an entity's own equity and improves the consistency of earnings per share calculations as that relates to convertible instruments. The Company has early-adopted this pronouncement as of January 1, 2023 using the modified retrospective method of transition. The adoption did not have any impact on the Company's consolidated financials. Recently Issued Accounting Pronouncements Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures, which amends the guidance in ASC 740, Income Taxes. The ASU is intended to improve the transparency of income tax disclosures by requiring (1) consistent categories and greater disaggregation of information in the rate reconciliation and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. The ASU's amendments are effective for public business entities for annual periods beginning after December 15, 2024. Adoption of the provisions should be on a prospective basis. The Company is currently evaluating the impact of the ASU but does not expect any material impacts upon adoption. X-Definition Disclosure of accounting policy for common stock warrants. References No definition available. Details Name: move_CommonStockWarrantsPolicyTextBlock Namespace Prefix: move_Data Type: dtr: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for Determining the Timing of Satisfaction of Performance Obligations Policy Text Block. References No definition available. Details Name: move_DeterminingTheTimingOfSatisfactionOfPerformanceObligationsPolicyTextBlock Namespace Prefix: move_Data Type: dtr: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for early-exercised stock option liability. References No definition available. Details Name: move_EarlyExercisedStockOptionLiabilityPolicyTextBlock Namespace Prefix: move_Data Type: dtr: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of prepaid expenses and other current assets. References No definition available. Details Name: move_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock Namespace Prefix: move_Data Type: dtr: textBlockItem Type Balance Type: na Period Type: durationX-Definition Recently issued accounting pronouncements. References No definition available. Details Name: move_RecentlyIssuedAccountingPronouncementsPolicyTextBlock Namespace Prefix: move_Data Type: dtr: textBlockItem Type Balance Type: na Period Type: durationX-References No definition available. Details Name: us_gaap_AccountingPoliciesAbstract Namespace Prefix: us_gaap_Data Type: xbrli: stringItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for advertising cost. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(a\)-SubTopic35-Topic720-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483406/720-35-50-1](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(a)-SubTopic35-Topic720-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483406/720-35-50-1) Details Name: us_gaap_AdvertisingCostsPolicyTextBlock Namespace Prefix: us_gaap_Data Type: dtr: types: textBlockItem Type Balance Type: na Period Type: durationX-Definition The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic235-NameAccountingStandardsCodification-PublisherFASB-URIhttps://asc.fasb.org//235/tableOfContent> Details Name: us_gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us_gaap_Data Type: dtr: types: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic230-SubTopic10-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482913/230-10-50-1> Details Name: us_gaap_CashAndCashEquivalentsPolicyTextBlock Namespace Prefix: us_gaap_Data Type: dtr: types: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for credit risk. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic942-SubTopic825-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480981/942-825-50-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph\(d\)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-NameAccountingStandardsCodification-Section50-Paragraph1-Subparagraph(d)-SubTopic10-Topic275-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482861/275-10-50-1) Details Name: us_gaap_ConcentrationRiskCreditRisk Namespace Prefix: us_gaap_Data Type: dtr: types: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260-10-50-1) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph2-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482662/260-10-50-2> Details Name: us_gaap_EarningsPerSharePolicyTextBlock Namespace Prefix: us_gaap_Data Type: dtr: types: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic360-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph2-Subparagraph\(SABTopic5-CC\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480091/360-10-599-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic360-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph2-Subparagraph(SABTopic5-CC)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147480091/360-10-599-2) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section05-Paragraph4-SubTopic10-Topic360-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482338/360-10-05-4> Details Name: us_gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock Namespace Prefix: us_gaap_Data Type: dtr: types: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph3-Subparagraph\(SX210-6-03\(h\)\(1\)\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479886/946-10-599-3](http://www.xbrl.org/2003/role/disclosureRef-Topic946-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph3-Subparagraph(SX210-6-03(h)(1))-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147479886/946-10-599-3) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph17-Subparagraph\(b\)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-10-50-17](http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph17-Subparagraph(b)-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-10-50-17) Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph9-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-10-50-9> Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph25-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482525/740-10-45-25> Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section45-Paragraph28-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482525/740-10-45-28> Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph19-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-10-50-19> Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic220-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482525/220-10-50-1> Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph20-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147482685/740-10-50-20> Details Name: us_gaap_IncomeTaxPolicyTextBlock Namespace Prefix: us_gaap_Data Type: dtr: types: textBlockItem Type Balance Type: na Period Type: durationX-Definition Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost. References Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph1-PublisherFASB-URIhttps://asc.fasb.org//1943274/2147483489/210-10-50-1> Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic210-SubTopic10-NameAccountingStandardsCodification-Section599-Paragraph>

1-Subparagraph (SX 210.5-02 (6) (b)) - Publisher FASB - URI <https://asc.fasb.org//1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483426/235-10-50-4)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-912-SubTopic-330-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482105/912-330-50-1>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-330-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483080/330-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-330-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org//330/tableOfContentReference-6-https://www.xbrl.org/2003/role/disclosureRef-Topic-330-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483080/330-10-50-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic-330-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483080/330-10-50-4>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-6-Subparagraph-\(a\)-SubTopic-10-Topic-270-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482989/270-10-45-6](http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-6-Subparagraph-(a)-SubTopic-10-Topic-270-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482989/270-10-45-6)Details Name: us-gaap-InventoryPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147478964/842-20-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147478964/842-20-50-1)Details Name: us-gaap-LesseeLeasesPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. ReferencesNo definition available. Details Name: us-gaap-NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-730-SubTopic-10-Name-Accounting-Standards-Codification-Section-05-Paragraph-1-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483044/730-10-05-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-730-SubTopic-10-Name-Accounting-Standards-Codification-Section-05-Paragraph-1-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483044/730-10-05-1)Details Name: us-gaap-ResearchAndDevelopmentExpensePolicy Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-985-SubTopic-20-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147481283/985-20-50-1>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-25-Paragraph-4-SubTopic-50-Topic-350-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482610/350-50-25-4>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-30-Paragraph-1-SubTopic-40-Topic-350-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482633/350-40-30-1>Details Name: us-gaap-ResearchDevelopmentAndComputerSoftwarePolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-07\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483575/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-07(1))-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483575/946-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483426/235-10-50-4)Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(e\)-SubTopic-10-Topic-235-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483426/235-10-50-4](http://www.xbrl.org/2003/role/exampleRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(e)-SubTopic-10-Topic-235-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147483426/235-10-50-4)Details Name: us-gaap-RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for segment reporting. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-47-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482785/280-10-55-47](http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-47-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482785/280-10-55-47)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-41-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-41-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-41)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-\(e\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-29-Subparagraph-(e)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482810/280-10-50-29)Details Name: us-gaap-SegmentReportingPolicyPolicyTextBlock Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)-\(2\)-\(i\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)-(2)-(i)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)-\(2\)-\(ii\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)-(2)-(ii)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)-\(2\)-\(v\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)-(2)-(v)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-14.C-Q3\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-14.C-Q3)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-14.D.1-Q5\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-14.D.1-Q5)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-14.D.3-Q2\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-14.D.3-Q2)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-14.D.2-Q6\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-14.D.2-Q6)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147479830/718-10-S99-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org//718/tableOfContentReference-9-https://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)-\(1\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)-(1)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)-\(2\)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)-(2)-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap-ShareBasedCompensationOptionAndIncentivePlansPolicy Namespace Prefix: us-gaap_Data Type: dtr-types: textBlockItemType Balance Type: na Period Type: durationX-DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-50-Paragraph-9-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/275-10-50-9>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-275-SubTopic-10-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/275-10-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(b\)-SubTopic-10-Topic-275-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(b)-SubTopic-10-Topic-275-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/275-10-50-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(c\)-SubTopic-10-Topic-275-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/275-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(c)-SubTopic-10-Topic-275-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/275-10-50-1)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-SubTopic-10-Topic-275-Publisher-FASB-URI-https://asc.fasb.org//1943274/2147482861/275-10-50-11>Reference 6: <http://www.xbrl.org/>

2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 12-SubTopic 10-Topic 275-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 275-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 Details Name: us-gaap-UseOfEstimates Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationFair Value Measurements (Tables) 12 Months Ended Dec. 31, 2023 Fair Value Measurements [Abstract] Schedule of Assets and Liabilities that are Measured at Fair Value The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2023 and 2022 (in thousands). December 31, 2023 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds \$ 4,393 \$ 4,393 \$ — Total cash equivalents \$ 4,393 \$ 4,393 \$ — December 31, 2022 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds \$ 8,171 \$ 8,171 \$ — Total cash equivalents \$ 8,171 \$ 8,171 \$ — X-ReferencesNo definition available. Details Name: us-gaap-FairValueDisclosuresAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Details Name: us-gaap-ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationCash and Cash Equivalents (Tables) 12 Months Ended Dec. 31, 2023 Cash and Cash Equivalents [Abstract] Schedule of Cash and Cash Equivalents Cash and cash equivalents consist of the following (in thousands): December 31, 2023 2022 Cash and cash equivalents: Cash \$ 1,725 \$ 2,588 Money market funds 4,393 8,171 Total cash and cash equivalents \$ 6,118 \$ 10,759 X-ReferencesNo definition available. Details Name: us-gaap-CashAndCashEquivalentsAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of the components of cash and cash equivalents. ReferencesNo definition available. Details Name: us-gaap-ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationProperty and Equipment (Tables) 12 Months Ended Dec. 31, 2023 Property and Equipment [Abstract] Schedule of Property and Equipment Property and equipment, net, as of December 31, 2023 and 2022, consisted of the following (in thousands): December 31, 2023 2022 Office equipment and furniture \$ 266 \$ 263 Software 144 131 Test equipment 310 277 Total property and equipment 720 671 Less: accumulated depreciation (378) (228) Total property and equipment, net \$ 342 \$ 443 X-ReferencesNo definition available. Details Name: us-gaap-PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 Details Name: us-gaap-PropertyPlantAndEquipmentTableTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationOther Current Liabilities (Tables) 12 Months Ended Dec. 31, 2023 Other Current Liabilities [Abstract] Schedule of Other Current Liabilities Other current liabilities as of December 31, 2023 and 2022 consisted of the following (in thousands): December 31, 2023 2022 Accrued compensation \$ 299 \$ 2,708 Accrued research and development 461 536 Accrued vacation 246 243 Accrued severance payment 5 517 Lease liabilities, current portion 217 212 Other 301 205 Total other current liabilities \$ 1,529 \$ 4,421 X-Definition Tabular disclosure of other current liabilities. ReferencesNo definition available. Details Name: us-gaap-OtherCurrentLiabilitiesTableTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap-OtherLiabilitiesCurrentAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationCommon Stock (Tables) 12 Months Ended Dec. 31, 2023 Common Stock [Abstract] Schedule of Common Stock Reserved for Future Issuance Common stock reserved for future issuance at December 31, 2023 is summarized as follows: December 31, 2023 Warrants to purchase common stock 4,757,256 Stock options outstanding 7,448,412 Stock options available for future grants 5,936,692 Total 18,142,360 X-ReferencesNo definition available. Details Name: move-ScheduleOfCommonStockReservedForFutureIssuanceTableTextBlock Namespace Prefix: move-Data Type: dtr-textBlockItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap-CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationCommon Stock Warrants (Tables) 12 Months Ended Dec. 31, 2023 Common Stock Warrants [Abstract] Schedule of Company's Warrant Activity The following is a summary of the Company's warrant activity for the years ended December 31, 2023 and 2022: Warrant Issuance Issuance Price Outstanding, December 31, 2022 Granted Exercised Canceled / Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2023 Expiration Preferred A Placement Warrants March and April 2018 and August 2019 \$ 1.40 293,042 293,042 April 2024 Preferred A Lead Investor Warrants February 2021 \$ 0.0125 52,500 (52,500) March 2023 Preferred B Placement Warrants April 2019 \$ 2.10 463,798 463,798 April 2024 Convertible Notes Placement Warrants August 2020 \$ 2.57 171,830 171,830 August 2025 Underwriter Warrants March 2021 \$ 6.00 956,973 956,973 March 2026 January 2023 warrants January 2023 \$ 1.57 2,322,000 2,322,000 January 2028 February 2023 warrants February 2023 \$ 1.57 348,000 348,000 February 2028 August 2023 warrants August 2023 \$ 1.24 201,613 201,613 August 2028 1,938,143 2,871,613 (52,500) 4,757,256 Warrant Issuance Issuance Exercise Price Outstanding, December 31, 2021 Granted Exercised Canceled / Expired Variable Settlement Provision Adjustment Outstanding, December 31, 2022 Expiration Preferred A Placement Warrants March and April 2018 and August 2019 \$ 1.40 293,042 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 \$ 0.0125 52,500 52,500 March 2023 Preferred B Placement Warrants April 2019 \$ 2.10 463,798 463,798 April 2024 Convertible Notes Placement Warrants August 2020 \$ 2.57 171,830 171,830 August 2025 Underwriter Warrants March 2021 \$ 6.00 956,973 956,973 March 2026 1,938,143 1,938,143 Schedule of Major Inputs The major inputs were: Issuance Date Dividend yield — % Expected volatility 60.83 % Risk-free interest rate 3.54 % Expected life 5.0 years Valuation date common stock price \$ 1.39 X-ReferencesNo definition available. Details Name: move-CommonStockWarrantsAbstract Namespace Prefix: move-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (bbb)-SubTopic 10-Topic 820-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Details Name: us-gaap-FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationX-Definition Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 Details Name: us-gaap-ScheduleOfStockholdersEquityNoteWarrantsOrRightsTableTextBlock Namespace Prefix: us-gaap-Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: durationStock-Based Compensation (Tables) 12 Months Ended Dec. 31, 2023 Stock-Based Compensation [Abstract] Schedule of Stock Option Activity Stock option activity for the years ended December 31, 2023 and 2022 was as follows (in thousands, except share, per share, and remaining life data): Number of Options Weighted Average Exercise Price Weighted Average Remaining Life Intrinsic Value Outstanding at December 31, 2021 5,592,137 \$ 2.29 8.6 years \$ 9,912 Granted 2,525,000 \$ 2.77 Exercised (77,000) \$ 0.40 Cancelled (1,120,243) \$ 3.15 Outstanding at December 31, 2022 6,919,894 \$ 2.34 8.2 years \$ 2,034 Granted 1,610,375 \$ 1.23 Exercised (245,855) \$ 0.44 Cancelled (836,002) \$ 2.66 Outstanding at December 31, 2023 7,448,412 \$ 2.13 7.1 years \$ 726 Exercisable as of December 31, 2023 4,760,030 \$ 2.02 6.5 years \$ 712 Vested and expected to vest as of December 31, 2023 7,448,412 \$ 2.13 7.1 years \$ 726 Schedule of Weighted Average Assumptions for Fair Value of Options Estimated The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of the stock options was estimated using the following weighted average assumptions for the years ended December 31, 2023 and 2022: Year Ended December 31, 2023 2022 Dividend yield — % Expected volatility 61.55 % 61.97 % Risk-free interest rate 3.77 % 2.78 % Expected life 5.98 years 6.07 years Schedule of Stock-Based Compensation Expense to Employees and Non-Employees The Company has recorded stock-based compensation expense for the years

ended December 31, 2023 and 2022 related to the issuance of stock option awards to employees and nonemployees in the consolidated statement of operations and comprehensive loss as follows: Year Ended December 31, 2023-2022 Research and development \$ 940 \$ 1,169 Sales, general and administrative 2,040 1,927 \$ 2,980 \$ 3,096 X-ReferencesNo definition available. Details Name: us-gaap-DisclosureOfCompensationRelatedCostsShareBasedPaymentsAbstract Namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph\(h\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Details](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph(h)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Details) Name: us-gaap-ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)\(1\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Reference2](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic718-SubTopic10-Section50-Paragraph2-Subparagraph(c)(1)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Reference2): [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Reference3](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(c)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Reference3): [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph\(c\)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Details](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Section50-Paragraph2-Subparagraph(c)-SubTopic10-Topic718-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Details) Name: us-gaap-ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate (s), and (e) discount for post-vesting restrictions. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-Subparagraph\(f\)\(2\)-NameAccountingStandardsCodification-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Details](http://fasb.org/us-gaap/role/ref/legacyRef-Topic718-SubTopic10-Subparagraph(f)(2)-NameAccountingStandardsCodification-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147480429/718-10-50-2-Details) Name: us-gaap-ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationCommitments and Contingencies (Tables) 12 Months Ended Dec. 31, 2023 Commitments and Contingencies [Abstract] Schedule of Operating Lease Related Accounts The balances of the lease related accounts as of December 31, 2023 and 2022 are as follows (in thousands): As of December 31, Operating and Finance leases 2023-2022 Right-of-use assets \$ 247 \$ 389 Operating lease liabilities-Short-term \$ 203 \$ 212 Operating lease liabilities-Long-term \$ 15 \$ 214 Finance lease liabilities-Short-term \$ 14 \$ — Finance lease liabilities-Long-term \$ 35 \$ — Schedule of Lease Expense and Supplemental Cash Flow The components of lease expense and supplemental cash flow information as of and for the years ended December 31, 2023 and 2022 are as follows (in thousands): Year Ended December 31, 2023-2022 Lease Cost: Operating lease cost \$ 261 \$ 226 Other Information: Cash paid for amounts included in the measurement of lease liabilities for the year ended \$ 243 \$ 209 Weighted average remaining lease term- operating leases (in years) 0.90 1.97 Average discount rate- operating leases 10.00 % 10.00 % Weighted average remaining lease term- financing leases (in years) 3.00 — Average discount rate- financing leases 15.08 % — Schedule of Future Minimum Lease Payments Future minimum lease payments are as follows as of December 31, 2023 (in thousands): 2024 224 2025 48 2026 18 Total lease payments 290 Less: Interest (23) Total lease liabilities \$ 267 X-ReferencesNo definition available. Details Name: us-gaap-CommitmentsAndContingenciesDisclosureAbstract Namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic842-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph4-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478964/842-20-50-4-Details> Name: us-gaap-LeaseCostTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic842-SubTopic20-NameAccountingStandardsCodification-Section50-Paragraph6-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147478964/842-20-50-6-Details> Name: us-gaap-LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of supplemental cash flow information for the periods presented. ReferencesNo definition available. Details Name: us-gaap-ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationIncome Taxes (Tables) 12 Months Ended Dec. 31, 2023 Income Taxes [Abstract] Schedule of Effective Tax Rate of the Company's Provision (Benefit) for Income Taxes The effective tax rate of the Company's provision (benefit) for income taxes differs from the federal rate as follows: Year Ended December 31, 2023-2022 U.S. federal provision (benefit): At statutory rate 21 % 21 % Valuation allowance (23) % (22) % Changes in stock-based compensation (1) % (1) % Other 3 % 1 % Effective tax rate — Schedule of Deferred Tax Assets and Liabilities Significant components of the Company's deferred tax assets and liabilities as of December 31, 2023 and 2022 are as follows (in thousands): 2023-2022 Gross deferred tax assets: Net operating loss carryforwards \$ 13,396 \$ 10,040 Research and development credit carryforward 2,703 1,434 Capitalized research and development 5,964 3,444 Accrued bonus 41,464 Stock-based compensation 999 590 Lease liabilities 56 90 Other 12 53 Total gross deferred tax assets 23,171 16,115 Less valuation allowance (23,101) (16,024) Total net deferred tax assets 70 91 Deferred tax liabilities: Property and equipment (18) (9) Right-of-use assets (52) (82) Total deferred tax liabilities 70 (91) Net deferred tax assets \$ — Schedule of Total Gross Unrecognized Tax Benefits The following is a rollforward of the total gross unrecognized tax benefits for the years ended December 31, 2023 and 2022 (in thousands): Year Ended December 31, 2023-2022 Beginning Balance \$ 811 \$ 487 Gross Increases- Tax Position in Prior Periods — 1 Gross Increases- Tax Position in Current Period 423 323 Ending Balance \$ 1,234 \$ 811 X-ReferencesNo definition available. Details Name: us-gaap-IncomeTaxesPaidNetAbstract Namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Paragraph2-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-2-Details> Name: us-gaap-ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Paragraph12-Section50-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-12-Details> Name: us-gaap-ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of the change in unrecognized tax benefits. ReferencesReference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section55-Paragraph217-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482663/740-10-55-217-Reference2>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic740-SubTopic10-NameAccountingStandardsCodification-Section50-Paragraph15A-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482685/740-10-50-15A-Details> Name: us-gaap-ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:textBlockItemType Balance-Type: na Period-Type: durationNet Loss Per Share Attributable to Common Stockholders (Tables) 12 Months Ended Dec. 31, 2023 Earnings Per Share [Abstract] Schedule of Basic and Diluted Net Loss Per Share The following table computes the computation of the basic and diluted net loss per share attributable to common stockholders during the years ended December 31, 2023 and 2022 as follows (in thousands, except share and per share data): Year Ended December 31, 2023-2022 Numerator: Net loss \$ (29,283) \$ (30,329) Denominator: Weighted average shares used in computing net loss per share, basic and diluted 46,195,403 33,025,721 Net loss per share, basic and diluted \$ (0.63) \$ (0.92) Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2023 and 2022 because including them would have been antidilutive are as follows: Year Ended December 31, 2023-2022 Shares subject to options to purchase common stock 7,448,412 6,769,694 Shares subject to warrants to purchase common stock 4,757,256 1,938,143 Total 12,205,668 8,707,837 X-ReferencesNo definition available. Details Name: us-gaap-EarningsPerShareAbstract Namespace-Prefix: us-gaap-Data-Type: xbrli:stringItemType Balance-Type: na Period-Type: durationX-DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph\(c\)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-50-1-Details](http://fasb.org/us-gaap/role/ref/legacyRef-NameAccountingStandardsCodification-Topic260-SubTopic10-Section50-Paragraph1-Subparagraph(c)-PublisherFASB-URIhttps://asc.fasb.org/1943274/2147482662/260-10-50-1-Details) Name: us-gaap-ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace-Prefix: us-gaap-Data-Type: dtr-types:

textBlockItemType-Balance-Type: na-Period-Type: durationX-DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. ReferencesReference 1:

revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. ReferencesReference 1:

Balance-Type: debit Period-Type: instantX-Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_OfficeEquipmentMember Namespace Prefix: Data-Type: na Balance-Type: Period-Type: X-Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_SoftwareDevelopmentMember Namespace Prefix: Data-Type: na Balance-Type: Period-Type: X-Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis = us-gaap_EquipmentMember Namespace Prefix: Data-Type: na Balance-Type: Period-Type: Other Current Liabilities (Details) Schedule of Other Current Liabilities-USD (\$) \$ in Thousands Dec. 31, 2023 Dec. 31, 2022 Schedule of Other Current Liabilities [Abstract] Accrued compensation \$ 299 \$ 2, 708 Accrued research and development Accrued vacation Accrued severance payment Lease liabilities, current portion Other Total other current liabilities \$ 1, 529 \$ 4, 421 X-Definition Accrued severance payment. References No definition available. Details Name: move_AccruedSeverancePayment Namespace Prefix: move_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instantX-Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-20\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-20)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instantX-Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-942-SubTopic-210-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-03-15-5\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-942-SubTopic-210-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-03-15-5)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479853/942-210-S99-1) Details Name: us-gaap_AccruedLiabilitiesCurrentAndNoncurrent Namespace Prefix: us-gaap_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instantX-Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References No definition available. Details Name: us-gaap_AccruedMarketingCostsCurrent Namespace Prefix: us-gaap_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instantX-Definition Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-20\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-20)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-710-SubTopic-10-Section-25-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483070/710-10-25-3> Details Name: us-gaap_AccruedVacationCurrent Namespace Prefix: us-gaap_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instantX-Definition Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-20\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-210-SubTopic-10-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-20)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instantX-References No definition available. Details Name: us-gaap_OtherLiabilitiesAbstract Namespace Prefix: us-gaap_Data-Type: xbrli: stringItem Type Balance-Type: na Period-Type: durationX-Definition Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-20\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-20)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-03-15-5\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479853/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-03-15-5)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479853/942-210-S99-1) Details Name: us-gaap_WorkersCompensationLiabilityCurrentAndNoncurrent Namespace Prefix: us-gaap_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instant Common Stock (Details) USD (\$) 1 Months Ended 12 Months Ended Jun. 15, 2023 Aug. 15, 2023 Jun. 15, 2022 Nov. 17, 2023 Dec. 31, 2023 Dec. 31, 2022 Common Stock [Line Items] Common stock, shares authorized (in Shares) 150,000,000 75,000,000 000,000 Common stock, par value (in Dollars per share) \$ 1 \$ 0.85 \$ 0.0001 \$ 0.0001 Common stock, outstanding (in Shares) 55,848,272 33,659,460 Underwritten public offering \$ 7,500,000 \$ 4,100,000 Underwritten shares of common stock (in Shares) 9,200,000 5,340,600 Exercisable at a price per share (in Dollars per share) \$ 1.57 \$ 0.001 Warrant per share (in Dollars per share) \$ 1.4 Gross proceeds \$ 7,500,000 Net proceeds \$ 8,100,000 6,700,000 Other offering expenses 1,400,000 800,000 500,000 Fair value of the warrants 1,500,000 Underwritten public offering \$ 9,200,000 7,500,000 Common stock, shares issued (in Shares) 55,848,272 33,659,460 Net proceeds \$ 3,600,000 \$ 3,200,000 \$ 2,200,000 Aggregate offering price \$ 50,000,000 \$ 44,400,000 Aggregate shares of common stock (in Shares) 2,531,757 810,400 Weighted average public offering price (in Dollars per share) \$ 1.31 \$ 2.84 Repurchase liability \$ 23,000 \$ 136,000 Unvested shares (in Shares) 43,751 266,147 Weighted average vesting period 1 year Over-Allotment Option [Member] Common Stock [Line Items] Common stock, shares issued (in Shares) 4,870,600 Maximum [Member] Common Stock [Line Items] Net proceeds 6,700,000 Minimum [Member] Common Stock [Line Items] Net proceeds \$ 5,200,000 Warrant [Member] Common Stock [Line Items] Underwritten shares of common stock (in Shares) 2,670,300 Exercisable at a price per share (in Dollars per share) \$ 0.4071 X-Definition Value of aggregate offering price. References No definition available. Details Name: move_AggregateOfferingPrice Namespace Prefix: move_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: durationX-Definition Gross proceeds. References No definition available. Details Name: move_GrossProceeds Namespace Prefix: move_Data-Type: xbrli: monetaryItem Type Balance-Type: debit Period-Type: durationX-Definition Amount of net proceeds. References No definition available. Details Name: move_NetProceeds Namespace Prefix: move_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: durationX-Definition Amount of underwritten public offering. References No definition available. Details Name: move_UnderwrittenPublicOffering Namespace Prefix: move_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: durationX-Definition Amount of underwritten public offering. References No definition available. Details Name: move_UnderwrittenSharesOfCommonStock Namespace Prefix: move_Data-Type: xbrli: sharesItem Type Balance-Type: na Period-Type: durationX-Definition Weighted average public offering price. References No definition available. Details Name: move_WeightedAveragePublicOfferingPrice Namespace Prefix: move_Data-Type: dtr: perShareItem Type Balance-Type: na Period-Type: durationX-Definition Amount to be repaid to the counterparty to the repurchase agreement when the carrying amount (or market value, if higher than the carrying amount) of securities or other assets sold under the repurchase agreement exceeds 10 percent of total assets. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-4-08\(m\)\(1\)\(i\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-4-08(m)(1)(i))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Details Name: us-gaap_AssetsSoldUnderAgreementsToRepurchaseRepurchaseLiability Namespace Prefix: us-gaap_Data-Type: xbrli: monetaryItem Type Balance-Type: credit Period-Type: instantX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/exampleRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13) Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic-272-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483014/272-10-45-3> Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic-272-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482987/272-10-50-1> Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-4-08\(d\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-4-08(d))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13) Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13) Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)

Paragraph 13-Subparagraph (h)-Publisher FASB-URI <https://asc.fasb.org//1943274/2147481112/505-10-50-13>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(27\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(27)(b))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(i))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(2\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(ii))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3)Details Name: us-gaap-ClassOfStockLineItems Namespace Prefix: us-gaap_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionExercise price per share or per unit of warrants or rights outstanding. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3>Details Name: us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX-DefinitionFace amount or stated value per share of common stock. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap-CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: instantX-DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap-CommonStockSharesAuthorized Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap-CommonStockSharesIssued Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionNumber of shares of excess stock held by shareholders. ReferencesNo definition available. Details Name: us-gaap-ExcessStockSharesOutstanding Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28)Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 25-Paragraph 13-SubTopic 10-Topic 480-Publisher FASB-URI https://asc.fasb.org//1943274/2147481766/480-10-25-13>Details Name: us-gaap-FairValueAdjustmentOfWarrants Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount of expense classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03.4,6\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03.4,6)-Publisher FASB-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2)Details Name: us-gaap-OtherExpenses Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14)Details Name: us-gaap-ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionAmount of cash inflow from the issuance of equity classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14)Details Name: us-gaap-ProceedsFromOtherEquity Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-DefinitionThe number of shares issued or sold by the subsidiary or equity method investee per stock transaction. ReferencesNo definition available. Details Name: us-gaap-SaleOfStockNumberOfSharesIssuedInTransaction Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition. In 'PnYnMnDnFnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. ReferencesReference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardVestingPeriod1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItemType Balance Type: na Period Type: durationX-DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(2)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(2)(ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2)Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionPer share increase in exercise price of warrant. Excludes change due to standard antidilution provision. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3>Details Name: us-gaap-WarrantExercisePriceIncrease Namespace Prefix: us-gaap_Data Type: dtr-types: perShareItemType Balance Type: na Period Type: durationX-Details Name: us-gaap-SubsidiarySaleOfStockAxis = us-gaap-OverAllotmentOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt-RangeAxis = srt-MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt-RangeAxis = srt-MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap-ClassOfWarrantOrRightAxis = us-gaap-WarrantMember Namespace Prefix: Data Type: na Balance Type: Period Type: Common Stock (Details)-Schedule of Common Stock Reserved for Future Issuance Dec. 31, 2023 sharesSchedule of Common Stock Reserved for Future Issuance [Abstract]-Warrants to purchase common stock 4,757,256Stock options outstanding 7,448,412Stock options available for future grants 5,936,692Total 18,142,360X-ReferencesNo definition available. Details Name: move-ScheduleOfCommonStockReservedForFutureIssuanceAbstract Namespace Prefix: move_Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionWarrants to purchase common stock. ReferencesNo definition available. Details Name: move-ShareBasedCompensationArrangementBySharesBasedPaymentAwardWarrantsToPurchaseCommonStock Namespace Prefix: move_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-DefinitionAggregate number of common shares reserved for future issuance. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1)Details Name: us-gaap-CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap_Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-

February 2028 August 2023 warrants [Member] Class of Warrant or Right [Line Items] Warrant Issuance, Issuance August 2023 Warrant Issuance, Exercise Price (in Dollars per share) (in Dollars per share) \$ 1.24 Warrant Issuance, Outstanding beginning Warrant Issuance, Granted 201, 613 Warrant Issuance, Exercised Warrant Issuance, Canceled / Expired Warrant Issuance, Variable Settlement Provision Adjustment Warrant Issuance, Outstanding ending 201, 613 Warrant Issuance, Expiration August 2028 X- Definition Warrant issuance, expiration. ReferencesNo definition available. Details Name: move_WarrantIssuanceExpiration Namespace Prefix: move_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Warrant issuance variable settlement provision adjustment. ReferencesNo definition available. Details Name: move_WarrantIssuanceVariableSettlementProvisionAdjustment Namespace Prefix: move_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- Definition Exercise price per share or per unit of warrants or rights outstanding. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3-Details Name: us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instantX- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. ReferencesNo definition available. Details Name: us-gaap_ClassOfWarrantOrRightLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Number of warrants or rights outstanding. ReferencesNo definition available. Details Name: us-gaap_ClassOfWarrantOrRightOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX- Definition Description of reason for issuing warrant or right. ReferencesNo definition available. Details Name: us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition Number of non-option equity instruments exercised by participants. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (2)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- Definition Net number of non-option equity instruments granted to participants. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (1)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- Definition Other increase (decrease) in number of shares reserved for issuance under non-option equity instrument agreements that is not separately disclosed. ReferencesNo definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_PreferredAPlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_PreferredALeadInvestorWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_PreferredBPlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_ConvertibleNotesPlacementWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_UnderwriterWarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_January2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_February2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X- Details Name: us-gaap_ClassOfWarrantOrRightAxis = move_August2023WarrantsMember Namespace Prefix: Data Type: na Balance Type: Period Type: Common Stock Warrants (Details) - Schedule of Major Inputs 12 Months Ended Dec. 31, 2023 \$ / shares Schedule of Major Inputs [Abstract] Dividend yield Expected volatility 60.83 % Risk-free interest rate 3.54 % Expected life 5 years Valuation date common stock price (in Dollars per share) \$ 1.39X- ReferencesNo definition available. Details Name: move_ScheduleOfMajorInputsAbstract Namespace Prefix: move_ Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX- Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (iii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX- Definition The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (ii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX- Definition The risk-free interest rate assumption that is used in valuing an option on its own shares. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (iv)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: durationX- Definition The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d) (1)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: durationX- Definition Expected term of award under share-based payment arrangement, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: durationStock-Based Compensation (Details) \$ / shares in Units, \$ in Millions 12 Months Ended Jun. 21, 2022 \$ / shares shares Apr. 15, 2022 shares Sep. 15, 2021 shares Mar. 25, 2021 shares Nov. 18, 2019 shares Dec. 31, 2022 USD (\$) \$ / shares shares Dec. 31, 2022 USD (\$) \$ / shares shares Stock-Based Compensation [Line Items] Aggregate shares issued 150,200 Future grant shares 18,142,360 Stock options exercised 245,855-77,000 Option exercised, shares 109,000 31,000 Fair value option 2,008,712-1,707,794 Fair value option vested (in Dollars) | \$ 3.1 \$ 3.2 Granted award options shares 100,000 Product units 20,000 Stock compensation expense (in Dollars) | \$ 0.1 \$ 0.1 Unamortized compensation expense (in Dollars) | \$ 4.0 Recognized over a weighted average period 2 years Founder [Member] Stock-Based Compensation [Line Items] Exercise price per share (in Dollars per share) | \$ / shares \$ 5-2019 Equity Incentive Plan [Member] Stock-Based Compensation [Line Items] Restricted stock awards shares 4,000,000 Contractual term 10 years Vesting term 4 years Exercise price percentage 10.00 % Future grant shares 4,455,442 2021 Employment Inducement Plan [Member] Stock-Based Compensation [Line Items] Aggregate shares issued 2,000,000 Future grant shares 1,481,250 Minimum [Member] Stock-Based Compensation [Line Items] Aggregate shares issued 7,400,000 6,000,000 Minimum [Member] | 2019 Equity Incentive Plan [Member] Stock-Based Compensation [Line Items] Fair value percentage 100.00 % Maximum [Member] | Stock-Based Compensation [Line Items] Aggregate shares issued 13,400,000 7,400,000 Maximum [Member] | 2019 Equity Incentive Plan [Member] Stock-Based Compensation [Line Items] Fair value percentage 110.00 % Equity Option [Member] Stock-Based Compensation [Line Items] Fair value per share (in Dollars per share) | \$ / shares \$ 0.74 \$ 1.48X- Definition Number of vested products ReferencesNo definition available. Details Name: move_NumberOfProducts Namespace Prefix: move_ Data Type: xbrli:integerItemType Balance Type: na Period Type: durationX- Definition Stock option exercise percentage. ReferencesNo definition available. Details Name: move_StockOptionExercisePercentage Namespace Prefix: move_ Data Type: dtr:percentItemType Balance Type: na Period Type: durationX- Definition Stock options exercised ReferencesNo definition available. Details Name: move_StockOptionsExercised Namespace Prefix: move_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX- Definition Aggregate number of common shares reserved for future issuance. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 210-SubTopic 10-Section S99-Paragraph 1-Subparagraph (SX 210-5-02-29)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1-Details Name: us-

gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-Definition Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1) Namespace Prefix: us-gaap Data Type: xbrli:durationItemType Balance Type: na Period Type: durationX-Definition Amount of cost to be recognized for option under share-based payment arrangement. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions) Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition The amount of plan compensation cost recognized during the period. References Reference 1: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 40-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480489/718-40-50-1-Details Name: us-gaap-EmployeeStockOwnershipPlanESOPCompensationExpense](http://www.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 40-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480489/718-40-50-1-Details Name: us-gaap-EmployeeStockOwnershipPlanESOPCompensationExpense) Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: durationX-Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\) \(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a) (3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (1) (iv) (04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c) (2) (iii) (03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f) (2) (v)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems) Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Net number of share options (or share units) granted during the period. References Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(1\) \(iv\) \(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (1) (iv) (01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod) Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationX-Definition Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber) Namespace Prefix: us-gaap Data Type: xbrli:sharesItemType Balance Type: na Period Type: instantX-Definition The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range. References Reference 1: [http://www.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit](http://www.fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap-ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit) Namespace Prefix: us-gaap Data Type: dtr:types:perShareItemType Balance Type: na Period Type: durationX-Definition Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDtHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\) \(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e) (2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details)

Name: us-

gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm Namespace- Prefix: us-gaap Data Type: xbrli: durationItem Type: Balance Type: na Period Type: durationX-Definition Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodFairValue1 Namespace- Prefix: us-gaap Data Type: xbrli: monetaryItem Type: Balance Type: credit Period Type: durationX-Definition Number of options vested. References No definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares Namespace- Prefix: us-gaap Data Type: xbrli: sharesItem Type: Balance Type: na Period Type: durationX-Definition Weighted average grant date fair value of options vested. References No definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Namespace- Prefix: us-gaap Data Type: dtr-types: perShareItem Type: Balance Type: na Period Type: durationX-Definition Purchase price of common stock expressed as a percentage of its fair value. References No definition available. Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercent Namespace- Prefix: us-gaap Data Type: dtr-types: percentItem Type: Balance Type: na Period Type: durationX-Definition Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDtnInMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph \(e\)\(1\)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph (e)(1)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 Namespace- Prefix: us-gaap Data Type: xbrli: durationItem Type: Balance Type: na Period Type: durationX-Definition Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2> Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1) Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross Namespace- Prefix: us-gaap Data Type: xbrli: sharesItem Type: Balance Type: na Period Type: durationX-Definition Number of share options (or share units) exercised during the current period. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1) Reference 5: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1) Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace- Prefix: us-gaap Data Type: xbrli: sharesItem Type: Balance Type: na Period Type: durationX-Details Name: us-gaap_SubsiidiarySaleOfStockAxis = move_FounderMember Namespace- Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_PlanNameAxis = move_EquityIncentivePlanMember Namespace- Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_PlanNameAxis = move_InducementPlanMember Namespace- Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MinimumMember Namespace- Prefix: Data Type: na Balance Type: Period Type: X-Details Name: srt_RangeAxis = srt_MaximumMember Namespace- Prefix: Data Type: na Balance Type: Period Type: X-Details Name: us-gaap_DerivativeInstrumentRiskAxis = us-gaap_StockOptionMember Namespace- Prefix: Data Type: na Balance Type: Period Type: Stock-Based Compensation (Details)-Schedule of Stock Option Activity-Stock Option [Member]-USD (\$) \$ / shares in Units, \$ in Thousands 12 Months Ended Dec. 31, 2021-Dec. 31, 2023-Dec. 31, 2022 Stock-Based Compensation (Details)-Schedule of Stock Option Activity [Line Items] Number of Options, Outstanding Beginning 5,592, 137.6, 919, 894 Weighted Average Exercise Price, Outstanding Beginning \$ 2.29 \$ 2.34 Weighted Average Remaining Life, Outstanding Beginning 8 years 7 months 6 days Intrinsic Value, Outstanding Beginning \$ 9,912 \$ 2,034 Number of Options, Outstanding Granted 1,610, 375.2, 525,000 Weighted Average Exercise Price Granted \$ 1.23 \$ 2.77 Number of Options, Outstanding Exercisable 4,760, 030 Weighted Average Exercise Price, Outstanding Exercisable \$ 2.02 Weighted Average Remaining Life, Outstanding Exercisable 6 years 6 months Intrinsic Value, Outstanding Exercisable \$ 712 Number of Options, Outstanding Vested and expected to vest 7,448, 412 Weighted Average Exercise Price, Outstanding Vested and expected to vest \$ 2.13 Weighted Average Remaining Life, Outstanding Vested and expected to vest 7 years 1 month 6 days Intrinsic Value, Outstanding Vested and expected to vest \$ 726 Number of Options, Outstanding Exercised (245,855) (77,000) Weighted Average Exercise Price Exercised \$ 0.44 \$ 0.4 Number of Options, Outstanding Cancelled (836,002) (1,120,243) Weighted Average Exercise Price Cancelled \$ 2.66 \$ 3.15 Number of Options, Outstanding Ending 7,448, 412.6, 919, 894 Weighted Average Exercise Price, Outstanding Ending \$ 2.13 \$ 2.34 Weighted Average Remaining Life, Outstanding Ending 7 years 1 month 6 days 8 years 2 months 12 days Intrinsic Value, Outstanding Ending \$ 726 \$ 2,034X-Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtnInMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. References No definition available. Details Name: move_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm Namespace- Prefix: move Data Type: xbrli: durationItem Type: Balance Type: na Period Type: durationX-References No definition available. Details Name: move_StockBasedCompensationDetailsScheduleofStockOptionActivityLineItems Namespace- Prefix: move Data Type: xbrli: stringItem Type: Balance Type: na Period Type: durationX-Definition The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace- Prefix: us-gaap Data Type: xbrli: sharesItem Type: Balance Type: na Period Type: instantX-Definition The weighted average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iii)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace- Prefix: us-gaap Data Type: dtr-types: perShareItem Type: Balance Type: na Period Type: instantX-Definition The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)\(iv\)\(03\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Namespace- Prefix: us-gaap Data Type: xbrli: sharesItem Type: Balance Type: na Period Type: durationX-Definition Gross number of share options (or share units) granted during the period. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)\(iv\)\(01\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace- Prefix: us-gaap Data Type: xbrli: sharesItem Type: Balance Type: na Period Type: durationX-Definition Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding. References Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2> Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Namespace- Prefix: us-gaap Data Type: xbrli: monetaryItem Type: Balance Type: debit Period Type: instantX-Definition Number of options outstanding, including both vested and non-vested options. References Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(i)-Publisher FASB-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2) Reference 2: <http://www.xbrl.org/2003/role/>

disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX-Definition Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX-Definition Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instantX-Definition Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: instantX-Definition Weighted average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: instantX-Definition Weighted average price at which option holders acquired shares when converting their stock options into shares. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: durationX-Definition Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: durationX-Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_Data Type: dtr-types:perShareItem Type Balance Type: na Period Type: durationX-Definition Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1 Namespace Prefix: us-gaap_Data Type: xbrli:monetaryItem Type Balance Type: debit Period Type: instantX-Definition Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: durationX-Definition Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph (e)(1)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: durationX-Definition Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDtnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 Namespace Prefix: us-gaap_Data Type: xbrli:durationItem Type Balance Type: na Period Type: durationX-Definition Number of share options (or share units) exercised during the current period. ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1-Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_Data Type: xbrli:sharesItem Type Balance Type: na Period Type: durationX-Details Name: us-gaap_AwardTypeAxis us-gaap_StockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: Stock-Based Compensation (Details)-Schedule of Weighted Average Assumptions for Fair Value of Options Estimated-Stock Options [Member]-12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Schedule of Weighted Average Assumptions for Fair Value of Options Estimated [Line Items]-Dividend yield-Expected volatility 61.55% 61.97% Risk-free interest rate 3.77% 2.78% Expected life 5 years 11 months 23 days 6 years 25 days X-Definition The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term. ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2-Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Namespace Prefix: us-gaap_Data Type: dtr-types:percentItem Type Balance Type: na Period Type: durationX-Definition The estimated measure of the percentage by which a share price is expected to fluctuate

during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period. ReferencesReference 1:

format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. ReferencesReference 1:

gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap Data Type: dtr-types: percentItemType Balance Type: na Period Type: durationX-Definition Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 6.1.Fact. 4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 6.1.Fact. 4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments Namespace Prefix: us-gaap Data Type: dtr-types: percentItemType Balance Type: na Period Type: durationX-Definition Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 2: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 2-SubTopic 740-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480887/718-740-35-2>Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Namespace Prefix: us-gaap Data Type: dtr-types: percentItemType Balance Type: na Period Type: durationIncome Taxes (Details)-Schedule of Deferred Tax Assets and Liabilities-USD (\$) \$ in Thousands Dec. 31, 2023 Dec. 31, 2022 Gross deferred tax assets: Net operating loss carryforwards \$ 13,396 \$ 10,040 Research and development credit carryforward 2,703 1,434 Capitalized research and development 5,964 3,444 Accrued bonus Stock-based compensation Lease liabilities Other Total gross deferred tax assets 23,171 16,115 Less valuation allowance (23,101) (16,024) Total net deferred tax assets Deferred tax liabilities: Property and equipment (18) (9) Right-of-use assets (52) (82) Total deferred tax liabilities (91) Net deferred tax assets X-References No definition available. Details Name: move_GrossDeferredTaxAssetsAbstract Namespace Prefix: move Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting. References No definition available. Details Name: move_TotalDeferredTaxLiabilities Namespace Prefix: move Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxAssetsCapitalLossCarryforwards Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2)Details Name: us-gaap_DeferredTaxAssetsGross Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2>Details Name: us-gaap_DeferredTaxAssetsLiabilitiesNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2>Details Name: us-gaap_DeferredTaxAssetsNet Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxAssetsOperatingLossCarryforwards Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxAssetsOther Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from employee bonuses. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBonuses Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from provisions, reserves, allowances, and accruals, classified as other. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxAssetsTaxDeferredExpenseOther Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instantX-Definition Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-2)Details Name: us-gaap_DeferredTaxAssetsValuationAllowance Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-References No definition available. Details Name: us-gaap_DeferredTaxLiabilitiesAbstract Namespace Prefix: us-gaap Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-Definition Amount of deferred tax liability attributable to taxable temporary differences classified as other. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap_DeferredTaxLiabilitiesOther Namespace Prefix: us-gaap Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-Definition Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment. ReferencesReference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 740-SubTopic 10-Name Accounting Standards>

Codification-Section 50-Paragraph 6-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482685/740-10-50-6>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 740-SubTopic 10-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-8>Details Name: us-gaap-DeferredTaxLiabilitiesPropertyPlantAndEquipment Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantIncome Taxes (Details)-Schedule of Total Gross Unrecognized Tax Benefits-USD (\$) \$ in Thousands 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Schedule of Total Gross Unrecognized Tax Benefits [Abstract] Beginning Balance \$ 811 \$ 487 Gross Increases-Tax Position in Prior Periods Gross Increases-Tax Position in Current Period Ending Balance \$ 1,234 \$ 811X-ReferencesNo definition available. Details Name: move-ScheduleOfTotalGrossUnrecognizedTaxBenefitsAbstract Namespace Prefix: move-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount of unrecognized tax benefits. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10B-Publisher FASB-URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B>Details Name: us-gaap-UnrecognizedTaxBenefits Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instantX-DefinitionAmount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15A-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15A-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A)Details Name: us-gaap-UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionAmount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15A-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 15A-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A)Details Name: us-gaap-UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationNet Loss Per Share Attributable to Common Stockholders (Details) 12 Months Ended Dec. 31, 2022 Shares Earnings Per Share [Abstract] Aggregate shares issued 150,200X-ReferencesNo definition available. Details Name: us-gaap-EarningsPerShareAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionNumber of options vested. ReferencesNo definition available. Details Name: us-gaap-ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedNumberOfShares Namespace Prefix: us-gaap-Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationNet Loss Per Share Attributable to Common Stockholders (Details)-Schedule of Basic and Diluted Net Loss Per Share-USD (\$) \$ /shares in Units, \$ in Thousands 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Numerator: Net loss \$ (29,283) \$ (30,329) Denominator: Weighted average shares used in computing net loss per share, Basic 46,195,403 33,025,721 Net loss per share, Basic \$ (0.63) \$ (0.92)X-ReferencesNo definition available. Details Name: move-DenominatorAbstract Namespace Prefix: move-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-ReferencesNo definition available. Details Name: move-NumeratorAbstract Namespace Prefix: move-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(24\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(26\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 220-SubTopic 10-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-5>Details Name: us-gaap-ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: durationX-DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 16: <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 17: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7>Details Name: us-gaap-EarningsPerShareBasic Namespace Prefix: us-gaap-Data Type: dt-types:perShareItemType Balance Type: na Period Type: durationX-DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>Details Name: us-gaap-WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap-Data Type: xbrli:sharesItemType Balance Type: na Period Type: durationNet Loss Per Share Attributable to Common Stockholders (Details)-Schedule of Basic and Diluted Net Loss Per Share (Parentheticals)-\$/shares 12 Months Ended Dec. 31, 2023 Dec. 31, 2022 Schedule of Basic and Diluted Net Loss Per Share [Abstract] Weighted average shares used in computing net loss per share, Diluted 46,195,403 33,025,721 Net loss per share, Diluted \$ (0.63) \$ (0.92)X-ReferencesNo definition available. Details Name: move-ScheduleOfBasicAndDilutedNetLossPerShareAbstract Namespace Prefix: move-Data Type: xbrli:stringItemType Balance Type: na Period Type: durationX-DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the

reporting period. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-15-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(c\)-\(4\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(c)-(4)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210-5-03-\(25\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-(25))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-9-04-\(27\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483589/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-04-(27))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483589/942-220-S99-1)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-04-\(23\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-04-(23))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483586/944-220-S99-1)Reference 15: <http://www.xbrl.org/2003/role/exampleRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-52-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-7>Details Name: us-gaap-EarningsPerShareDilutedNamespace Prefix: us-gaap-Data Type: dt:types:perShareItem Type: durationX-DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. ReferencesReference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-16-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-16>Details Name: us-gaap-WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: durationX-DefinitionThe schedule of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders - shares 12 Months Ended Dec. 31, 2023 Dec. 31, 2022Schedule of Diluted Net Loss Per Share Attributable to Common Stockholders [Abstract] Shares subject to options to purchase common stock 7, 448, 412 6, 769, 694Shares subject to warrants to purchase common stock 4, 757, 256 1, 938, 143Total 12, 205, 668 8, 707, 837X-DefinitionShares subject to options to purchase common stock. ReferencesNo definition available. Details Name: move-SharesSubjectToOptionsToPurchaseCommonStock Namespace Prefix: move-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: durationX-DefinitionShares subject to warrants to purchase common stock. ReferencesNo definition available. Details Name: move-SharesSubjectToWarrantsToPurchaseCommonStock Namespace Prefix: move-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: durationX-DefinitionPotential shares of common stock. ReferencesNo definition available. Details Name: move-PotentialSharesOfCommonStock Namespace Prefix: move-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: durationX-ReferencesNo definition available. Details Name: us-gaap-NetIncomeLossAbstract Namespace Prefix: us-gaap-Data Type: xbrli:stringItem Type Balance Type: na-Period Type: durationX-Subsequent Events (Details) USD (\$) \$ / shares in Units, \$ in Millions 1 Months Ended 12 Months Ended Apr. 05, 2024 Apr. 02, 2024 Jun. 15, 2023 Feb. 06, 2023 Nov. 17, 2023 Dec. 31, 2022Subsequent Event [LineItems] Shares issued 45, 252, 517 Shares of common stock 100, 000 Exercise price per share (in Dollars per share) \$ 1.57 \$ 0.001 Common stock exceeded (in Dollars per share) Redemption price per share (in Dollars per share) \$ 0.025 Offering fees and expenses (in Dollars) \$ 1.1 \$ 0.8 \$ 0.5 Common stock, shares issued 55, 848, 272 33, 659, 460 Common Stock [Member] Subsequent Event [LineItems] Shares issued 3, 149, 028 Common stock, shares issued 42, 103, 489 Warrant [Member] Subsequent Event [LineItems] Exercise price per share (in Dollars per share) \$ 0.4071 Forecast [Member] Private Placement [Member] Subsequent Event [LineItems] Shares issued 45, 252, 517 Purchase price per share (in Dollars per share) \$ 0.533 Purchase of private placement units 287, 500 Offering price per share (in Dollars per share) \$ 0.565 Gross proceeds (in Dollars) \$ 24.1 Offering fees and expenses (in Dollars) \$ 1.4 Forecast [Member] Warrant [Member] Subsequent Event [LineItems] Shares of common stock Warrant shares Forecast [Member] Common Stock [Member] Subsequent Event [LineItems] Shares of common stock Forecast [Member] Officers and Directors [Member] Subsequent Event [LineItems] Exercise price per share (in Dollars per share) \$ 0.44 X-DefinitionThe cash outflow associated with the repurchase of shares received from entity's raising of capital via private rather than public placement. ReferencesNo definition available. Details Name: move-RepurchaseOfPrivatePlacementShares Namespace Prefix: move-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: durationX-DefinitionExercise price per share or per unit of warrants or rights outstanding. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-3>Details Name: us-gaap-ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap-Data Type: dt:types:perShareItem Type Balance Type: na-Period Type: instantX-DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500, 000 warrants may be converted into 1, 000, 000 shares. ReferencesReference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-3>Details Name: us-gaap-ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights Namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: instantX-DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02-\(29\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02-(29))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Details Name: us-gaap-CommonStockSharesIssued Namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: instantX-DefinitionNumber of excess stock shares of an entity that have been sold or granted to shareholders. ReferencesNo definition available. Details Name: us-gaap-ExcessStockSharesIssued Namespace Prefix: us-gaap-Data Type: xbrli:sharesItem Type Balance Type: na-Period Type: instantX-DefinitionAmount of expense classified as other. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210-5-03-4-6\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210-5-03-4-6)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Details Name: us-gaap-OtherExpenses Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type Balance Type: debit-Period Type: durationX-DefinitionThe price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer. ReferencesReference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-10-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-3>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-10-Section-50-Paragraph-5-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-5](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-10-Section-50-Paragraph-5-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-5)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-505-SubTopic-10-Section-50-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-11>Details Name: us-gaap-PreferredStockRedemptionPricePerShare Namespace Prefix: us-gaap-Data Type: dt:types:perShareItem Type Balance Type: na-Period Type: instantX-DefinitionThe cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. ReferencesReference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-\(a\)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-14-Subparagraph-(a)-SubTopic-10-Topic-230-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-14)Details Name: us-gaap-ProceedsFromIssuanceOfPrivatePlacement Namespace Prefix: us-gaap-Data Type: xbrli:monetaryItem Type Balance Type: debit-Period Type: durationX-DefinitionPrice of a single share of a number of saleable stocks of a

